

Risk Ratio, odds ratio, risk difference... Which causal measure is easier to generalize?

Bénédicte Colnet^{*} Julie Josse[†] Gaël Varoquaux[‡] Erwan Scornet[§]

April 2, 2024

Abstract

There are many measures to report so-called treatment or causal effects: absolute difference, ratio, odds ratio, number needed to treat, and so on. The choice of a measure, *eg* absolute versus relative, is often debated because it leads to different impressions of the benefit or risk of a treatment. Besides, different causal measures may lead to various treatment effect heterogeneity: some input variables may have an influence on some causal measures and no effect at all on others. In addition some measures – but not all – have appealing properties such as collapsibility, matching the intuition of a population summary. In this paper, we first review common causal measures and their pros and cons typically brought forward. Doing so, we clarify the notions of collapsibility and treatment effect heterogeneity, unifying existing definitions. Then, we show that for any causal measures there exists a generative model such that the conditional average treatment effect (CATE) captures the treatment effect. However, only the risk difference can disentangle the treatment effect from the baseline at both population and strata levels, regardless of the outcome type (continuous or binary). As our primary goal is the generalization of causal measures, we show that different sets of covariates are needed to generalize an effect to a target population depending on *(i)* the causal measure of interest, and *(ii)* the identification method chosen, that is generalizing either conditional outcome or local effects.

Keywords: Standardization; Transportability; Collapsibility; Treatment effect modifier; Clinical trials.

1 The age-old question of how to report effects

From the physician to the patient, the term *effect* of a drug on an outcome usually appears very spontaneously, within a casual discussion or in scientific documents. Overall, everyone agrees that for a binary treatment an effect is a comparison between two states: treated or not. But there are various ways to report the average effect of a treatment. For example, the scale on which we choose to quantify the effect of a treatment may be absolute (e.g. the number of migraine days per month is expected to diminishes by 0.8 taking Rimegepant, see [Edvinsson, 2021](#)) or relative (e.g. the probability of having a thrombosis is expected to be multiplied by 3.8 when taking oral contraceptives ([Vandenbroucke et al., 1994](#))). Choosing one measure or

^{*}Soda project-team, Premedical project-team, INRIA (email: benedicte.colnet@inria.fr).

[†]Premedical project team, INRIA Sophia-Antipolis, Montpellier, France.

[‡]Soda project-team, INRIA Saclay, France.

[§]LPSM and SCAI, Sorbonne Université, Paris, France (email: erwan.scornet@polytechnique.edu).

the other has several consequences. First, it conveys a different impression of the same data to an external reader. [Naylor et al. \(1992\)](#); [Forrow et al. \(1992\)](#) both showed that physicians’s likelihood to treat patient – following their impression of therapeutic effect – is impacted by the scale chosen to report clinical effect. Such subjective impressions may be even more prominent in newspapers, where most effects are presented in relative rather than absolute terms, creating a heightened sense of sensationalism ([Moynihan et al., 2000](#)). Second, the heterogeneity of the treatment effect – i.e. how the treatment effect changes from one sub-population to another – depends on the chosen causal measure (see p.199 in [Rothman, 2011](#)). The choice of the measure to report an effect is still actively discussed ([Spiegelman and VanderWeele, 2017](#); [Spiegelman et al., 2017](#); [Baker and Jackson, 2018](#); [Feng et al., 2019](#); [Doi et al., 2020, 2022](#); [Xiao et al., 2021, 2022](#); [Huitfeldt et al., 2021](#); [Lapointe-Shaw et al., 2022](#); [Liu et al., 2022](#)). Publications on the topic come with many diverging opinions and guidelines (see Appendix F for quotes). Yet, the question of the measure (or metric) of interest is not new. For example, as [Sheps \(1958\)](#) wrote in the *New England Journal of Medicine* (see also [Huitfeldt et al., 2021](#)):

“ We wish to decide whether we shall count the failures or the successes and whether we shall make relative or absolute comparisons ”.

Beyond conveyed impressions and captured heterogeneity, different causal measures lead to different generalization properties towards populations ([Huitfeldt et al., 2018](#)). The problem of generalizability (or portability) encompasses a range of different scenarios, and refers to the ability of carrying over findings to a broader population, beyond the study sample. Generalizability of trials’ findings is crucial as, most often, clinicians use causal effects from published trials to estimate the expected response to treatments for a specific patient based on his/her baseline risks, and therefore to choose the best treatment. In this work, we show that some effect measures are less sensitive than others to population’s differences between the study sample and the target population.

Section 2 starts with a didactic clinical example to introduce the questions, the concepts, the notations, and our main results. Our four contributions are detailed in Section 2 and summarized below. In Section 3, we review, clarify, and demonstrate typical properties of causal measures, such as treatment effect homogeneity, heterogeneity, and collapsibility. In Section 4, we show that for any causal measures there exists a generative model such that the conditional average treatment effect captures the treatment effect. We also show that among collapsible measures, only the Risk Difference can disentangle these effects at both the conditional and unconditional level, for a variety of settings. This result also holds for bounded outcome as binary ones, but only for some values of the baseline risk. We exhibit specific settings in which some causal measures are able to disentangle the treatment effect from the baseline. More precisely, we study a model for binary outcome inspired by the example of the Russian Roulette, in which the Risk Difference depends on the baseline, but the Survival Ratio is constant. Section 5 presents the consequences on the generalizability of causal measures. We show that the Risk Difference is easier to generalize, in the sense that it requires adjustment only on the shifted treatment effect modulators introduced in Section 4, and not on all shifted prognostic covariates, i.e. variables both predictive of the outcome and with a different distribution between sources. Other causal measures can be generalized in some very specific settings (e.g., homogeneous treatment effect). Section 6 illustrates the takeaways through simulations.

As this paper builds on a prolific and diverse literature, we differentiate our original contributions from previously-known results. For this purpose, all definitions, assumptions, and lemmas from prior work contain an explicit reference in their title, while those without are original contributions.

2 Problem setting and key results

2.1 Causal effects in the potential outcomes framework

Among the various frameworks for causal reasoning such as Pearl (2000), Dawid (2000), or Hernàn and Robins (2020), we use the *potential outcome* framework to characterize treatment (or causal) effects. This framework has been proposed by Neyman in 1923 (English translation in Splawa-Neyman et al., 1990), and popularized by Donald Rubin in the 70s (Imbens and Rubin, 2015; Hernàn and Robins, 2020). It formalizes the concept of an intervention by studying two possible values $Y_i^{(1)}$ and $Y_i^{(0)}$ for the outcome of interest (say the pain level of headache) for the two different situations where the individual i has been exposed to the treatment ($A_i = 1$) or not ($A_i = 0$). We will only consider binary exposure. The treatment has a causal effect if the potential outcomes are different, that is testing the assumption:

$$Y_i^{(1)} \stackrel{?}{=} Y_i^{(0)}. \quad (1)$$

Unfortunately, one cannot observe the two worlds for a single individual. Statistically, it can still be possible to compare the *expected* values of each potential outcome $Y^{(a)}$ but it requires a population-level approach, broadening from a specific individual. The paradigmatic example is a randomized experiment (called Randomized Controlled Trial –RCT– in clinical research or A/B test in marketing): randomly assigning the treatment to half of the individuals enables the average comparison of the two situations. Doing so, the previous question of interest amounts to *comparing* or *contrasting* two expectations:

$$\mathbb{E} [Y^{(1)}] \stackrel{?}{=} \mathbb{E} [Y^{(0)}], \quad (2)$$

where $\mathbb{E}[Y^{(a)}]$ is the expected counterfactual outcome had all individuals in the *population* received the treatment level a . This quantity is defined with respect to a population: statistically, the expectation is taken on a distribution, which we denote P_s (reflecting the source or study sample from which evidence comes, for example a RCT). Many methodological efforts have focused on estimating the two expectations (namely $\hat{\mathbb{E}} [Y^{(1)}]$ and $\hat{\mathbb{E}} [Y^{(0)}]$). Our focus is different: we propose theoretical guidance for choosing among different real-valued measures that allow us to compare those two expectations at the population level, e.g. ratio, difference, or odds. What are the properties of these measures? How do they impact the conclusions of a study?

2.2 Comparing two averaged situations: different treatment effect measures

We focus on two types of outcomes: continuous (e.g. headache pain level) and binary (e.g. death). Binary outcomes are frequent in medical questions, often related to the occurrence of an event.

Continuous outcome For continuous outcomes, a common measure is the absolute difference, which corresponds to the difference of means (for homogeneity of notations with the binary outcome, we denote it as the the Risk Difference - RD):

$$\tau_{\text{RD}} := \mathbb{E} [Y^{(1)}] - \mathbb{E} [Y^{(0)}].$$

A null effect corresponds to $\tau_{\text{RD}} = 0$. If the outcomes are of constant sign and different from 0, one can also consider relative measures¹ such as the ratio of means (also called Risk Ratio -

¹Allowing situations where the outcomes can be null or change sign is at risk of having undefined ratio due to $\mathbb{E} [Y^{(0)}] = 0$. This is why, when considering relative measure we assume that the continuous outcome is of

RR), or relative difference of means (also called Excess Risk Ratio - ERR):

$$\tau_{\text{RR}} := \frac{\mathbb{E}[Y^{(1)}]}{\mathbb{E}[Y^{(0)}]}, \quad \tau_{\text{ERR}} := \frac{\mathbb{E}[Y^{(1)}] - \mathbb{E}[Y^{(0)}]}{\mathbb{E}[Y^{(0)}]} = \tau_{\text{RR}} - 1.$$

Contrary to the difference of means which equals the mean of the differences, the ratio of means τ_{RR} is not equal to the mean of the ratios. A null effect now corresponds to $\tau_{\text{RR}} = 1$ or $\tau_{\text{ERR}} = 0$. Note that the ranges of the three metrics are different, e.g. if $\mathbb{E}[Y^{(1)}] = 200$ and $\mathbb{E}[Y^{(0)}] = 100$, then $\tau_{\text{RD}} = 100$, while $\tau_{\text{RR}} = 2$ and $\tau_{\text{ERR}} = 1$.

Binary outcome Due to the binary nature of the outcome, the two expectations of eq.2 can now also be understood as the probability of the event to occur $\mathbb{E}[Y^{(a)}] = \mathbb{P}[Y^{(a)} = 1]$. As long as the phenomenon is non-deterministic in the sense that $\mathbb{P}[Y^{(0)} = 1] \neq 0$, previous relative measures τ_{RR} and τ_{ERR} can be used for binary outcomes. Other measures, such as the Survival Ratio (SR) can be considered if $\mathbb{P}[Y^{(1)} = 1] \neq 1$: SR is nothing but a *reversed* Risk Ratio (RR) where null events are counted instead of positive events. Doing so, one could also define a reversed Excess Risk Ratio (ERR), which we denote Risk Susceptibility. The Odds Ratio (OR) is another very common measure, as it serves as a link between follow-up studies and case-control studies (Greenland, 1987; King and Zeng, 2002). Another measure called the Number Needed to Treat (NNT) has been proposed more recently (Laupacis et al., 1988): it helps the interpretation of the Risk Difference by counting how many individuals should be treated to observe one individual answering positively to the treatment. Depending on the direction of the effect, NNT can also be called Number Needed to Harm (NNH) when the events are side effects or Number of Prevented Events (NPE) when it comes to prevention. One unappealing aspect of NNT, NNH and NPE is that the null effect corresponds to an infinite value of these measures which implies that when the difference between the two treatments is not statistically significant, the confidence interval for the number needed to treat is difficult to describe (Altman, 1998). For simplicity of the exposition, in this work, we only consider NNT. The exact expression of the above measures are given here:

$$\tau_{\text{SR}} := \frac{\mathbb{P}[Y^{(1)} = 0]}{\mathbb{P}[Y^{(0)} = 0]}, \quad \tau_{\text{OR}} := \frac{\mathbb{P}[Y^{(1)} = 1]}{\mathbb{P}[Y^{(1)} = 0]} \bigg/ \left(\frac{\mathbb{P}[Y^{(0)} = 1]}{\mathbb{P}[Y^{(0)} = 0]} \right), \quad \tau_{\text{NNT}} := \tau_{\text{RD}}^{-1}.$$

Other measures can be found in the literature, such as the log Odds Ratio (log-OR). We recall each measure in Appendix A, where Figure 7 illustrates the differences between measures, for different values of the expected outcomes of controls and treated. We also compute all these measures on a clinical example in Section 2.3.

Treatment effects on subgroups Treatment effects can also be reported within subgroups of a population (i.e. stratified risks) to show how sub-populations react to the treatment. Therefore, one could also define each of the previously introduced measures on sub-populations. For the rest of the work, we denote by X a set of covariates². We denote by $\tau(x)$ the treatment effect on the subpopulation $X = x$ for any causal measure. For example $\tau_{\text{RD}}(x)$ denotes the Risk Difference on the subgroup for which $X = x$. The quantity $\tau(x)$ is often referred to as the Conditional Average Treatment Effect (CATE).

constant sign. Note that this is often the case in medicine. For example with blood glucose level, systolic blood pressure, etc.

²Those covariates are baseline or pre-treatment covariates. See VanderWeele and Robins (2007) for a detailed explanation.

Assumptions Throughout this paper, and for the Average Treatment Effect and the Conditional Average Treatment Effect to be well-defined, we assume that $\mathbb{E}[|Y^{(0)}|], \mathbb{E}[|Y^{(1)}|] < \infty$ and $\mathbb{E}[|Y^{(0)}||X], \mathbb{E}[|Y^{(1)}||X] < \infty$. Such assumptions are satisfied as soon as the response variable is bounded.

2.3 Key messages: from effect measures to generalization

2.3.1 An illustrative example

We consider clinical data assessing the benefit of antihypertensive therapy (A) against stroke (Y) (MacMahon et al., 1990; Cook and Sackett, 1995). We denote by $Y = 1$ a stroke, and $Y = 0$ no stroke. Individuals can be categorized into two groups depending on their diastolic blood pressure: either $X = 0$ corresponding to a mild baseline risk of stroke or $X = 1$ corresponding to a moderate baseline risk of stroke: $\mathbb{P}[Y^{(0)} = 1 | X = 0] \leq \mathbb{P}[Y^{(0)} = 1 | X = 1]$. In this example, $X = 1$ (resp. $X = 0$) corresponds to a baseline risk of 2 events for 10 individuals (resp. 15 events for 1,000 individuals). All the measures previously introduced are computed from values reported in the original articles and presented in Table 1.

Table 1: Different treatment measures give different impressions of the phenomenon:

The outcome is stroke in 5 years ($Y = 1$ denoting stroke and $Y = 0$ no stroke) and stratification is done along a binary covariate X (moderate $X = 1$ or mild $X = 0$). Each measure are computed from aggregated data taken from MacMahon et al. (1990); Cook and Sackett (1995). No confidence intervals are represented as our focus is the interpretation of the measure and not statistical significance.

	τ_{RD}	τ_{RR}	τ_{SR}	τ_{NNT}	τ_{OR}	τ_{ERR}
All (P_s)	-0.045	0.6	1.05	22	0.57	-0.4
X = 0	-0.006	0.6	1.01	167	0.60	-0.4
X = 1	-0.080	0.6	1.10	13	0.55	-0.4

A Risk Ratio below 1 means that there is an inverse association, that is a decreased risk of stroke in the treated group compared with the treated group. More precisely, the treated group has 0.6 times the risk of having a stroke outcome when compared with the non-treated group. On this example, one can also recover that the Odds Ratio approximates the Risk Ratio in a stratum where prevalence of the outcome is low ($X = 0$), but not if the prevalence is higher ($X = 1$) (derivations recalled in Appendix A). The survival ratio of 1.05 captures that there is an increased chance of not having a stroke when treated compared to the control by a factor 1.05. Note that the Survival Ratio takes really different values than the Risk Ratio: it corresponds to the Risk Ratio where labels Y are swapped for occurrences and non-occurrences, illustrating that Risk Ratio is not symmetric to the choice of outcome 0 and 1 –e.g. counting the living or the dead (Sheps, 1958). This lack of symmetry is usually considered as a drawback of the survival ratio and Risk Ratio compared to the odds ratio. Indeed, the odds ratio is robust to a change of labels: swapping labels leads to changing the odds ratio τ_{OR} by its inverse τ_{OR}^{-1} (see Appendix A).

Finally, the Risk Difference translates the effect on a absolute scale: treatment reduces by 0.045 the probability to suffer from a stroke when treated³. The NNT is the number of patients you

³When it comes to binary outcomes, such absolute effects are rather presented as reducing by 45 events over 1,000 individuals.

need to treat to prevent one additional bad outcome. Here the NNT is 22, meaning that on average, one has to treat 22 people with the drug to prevent one additional stroke. NNT may seem simpler to interpret than a difference in probability and it enables us to quickly assess the cost (e.g., in terms of money) of a positive outcome.

2.3.2 Contributions: how to choose a causal measure?

This section intends to present key results in an intuitive manner. Complete mathematical definitions are given in Sections 3, 4 and 5.

Contribution 1: Properties of causal measures [Sections 3] Different causal measures can have different properties (homogeneous/heterogeneous treatment, logic-respecting, collapsibility), which may in turn impact their interpretation. We give precise definitions of all these properties and establish relations between them. For instance, to understand the importance of collapsibility, let us dive into the following example. If we were only provided with subgroup effects, and not the population effect (P_s or **All** on Figure 1), an intuitive procedure to obtain the population effect from local effects would be to average subgroups effects. More explicitly,

$$\text{(Collapsibility)} \quad \tau_{\text{RD}} = \underbrace{p_s(X = 1)}_{\% \text{ individuals with } X = 1 \text{ in } P_s} \cdot \tau_{\text{RD}}(X = 1) + \underbrace{p_s(X = 0)}_{\% \text{ individuals with } X = 0 \text{ in } P_s} \cdot \tau_{\text{RD}}(X = 0), \quad (3)$$

where P_s is the source population from which the study was sampled, and $p_s(X = x)$ is the proportion of individual with $X = x$ in this population. In our example study above, $p_s(X = 0) = 0.53$ (Cook and Sackett, 1995), thus for the risk difference, the formula retrieves the population effect from the sub-group effects:

$$-0.47 \cdot 0.08 - 0.53 \cdot 0.006 = 0.0452 = \tau_{\text{RD}}.$$

When a population-effect measure can be written as a weighted average of subgroup effects with positive weights and summing to 1, it is said to be *collapsible* (Definition 5, based on Huitfeldt et al., 2019), or *directly collapsible* (Definition 4, based on Greenland et al., 1999; Pearl, 2000) if the weights are simply equal to the population’s proportions. While the Risk Difference is directly collapsible, this is not true for all measures (e.g. the Number Needed to Treat is such that $0.47 \cdot 167 + 0.53 \cdot 13 = 85 \neq 22$). We precisely define collapsibility and which measures are collapsible (or not) in Section 3.2, and summarized the results in Table 3.

Contribution 2: A measure can disentangle treatment effect from baseline risk [Section 4] Table 1 shows that the choice of the measure gives different impressions of the heterogeneity of the effect, i.e. how much the effects measures change on different subgroups. Such differences can be due to different baseline risks. For example, it seems that a higher number needed to treat on the subgroup with low prevalence ($X = 0$) is expected as, even without the treatment, individuals already have a low risk of stroke. Is it possible to disentangle the baseline variation with the treatment effect in itself? Surprisingly, in this example, one measure is constant (or *homogeneous*) over the strata X : the Risk Ratio. We will show that among collapsible measures, only the Risk Difference can disentangle in all generality the baseline risk with the treatment effect at both the levels of strata and population. Other causal measures are able to do so only in specific settings (e.g., homogeneous treatment effect). This is the case in the example given in Table 1 for the Risk Ratio. For binary outcomes, we exhibit a specific model (inspired from the Russian Roulette) in which natural causal measures to consider are (i) the Conditional Risk Ratio when the effect is beneficial or (ii) the Conditional Survival Ratio when the effect is detrimental.

Contribution 3: There exist two generalization strategies, via potential outcomes or local effects [Section 5.1] Collapsibility may come into play when one is interested in the population effect on a target population P_T different from the original source population P_S , *e.g.* with a different proportion of individuals with diastolic pressure ($\forall x \in \{0, 1\}, p_S(x) \neq p_T(x)$). In Section 5, we provide two different strategies to generalize causal measures via the generalization of conditional outcomes or local effects. The first approach is valid for any causal measures, whereas the second one may require fewer variables, but can be applied to collapsible measures only (see Contribution 4 below). The second strategy works as follows. Considering the Risk Difference, the average treatment effect τ_{RD}^T on the target population is given by

$$\tau_{RD}^{P_T} = \underbrace{p_T(X=1)}_{\% \text{ individuals with } X=1 \text{ in } P_T} \cdot \tau_{RD}^{P_T}(X=1) + \underbrace{p_T(X=0)}_{\% \text{ individuals with } X=0 \text{ in } P_T} \cdot \tau_{RD}^{P_T}(X=0), \quad (4)$$

where $\tau_{RD}^{P_S}(x)$ are local effects in the target population P_T . If we assume that the CATE on the source $\tau_{RD}^{P_S}(x)$ and target population $\tau_{RD}^{P_T}(x)$ are the same, we can swap them into the above equation, giving:

$$\text{Effect on target population } \tau_{RD}^{P_T} = \underbrace{p_T(X=1)}_{\% \text{ individuals with } X=1 \text{ in } P_T} \cdot \tau_{RD}^{P_S}(X=1) + \underbrace{p_T(X=0)}_{\% \text{ individuals with } X=0 \text{ in } P_T} \cdot \tau_{RD}^{P_S}(X=0). \quad (5)$$

Therefore, a natural procedure to generalize a collapsible causal measure to a target population is to replace the proportions $p_S(X=0)$ (resp. $p_S(X=1)$) in eq. 3 by their counterpart $p_T(X=0)$ (resp. $p_T(X=1)$) computed on the target population. This procedure can be found under various names: *standardization, re-weighting, recalibration* (Miettinen, 1972; Rothman and Greenland, 2000; Pearl and Bareinboim, 2014). We will call it *generalization*, as it follows the work initiated by Stuart et al. (2011). Stuart et al. (2011) explicitly tackles the generalization of a trial with a sample of a target population. We show below that procedure from eq. 5 is theoretically grounded, for collapsible causal measures.

Contribution 4: All causal measures are not equal when facing a population shift [Section 5.2] Current line of works usually advocate to adjust on all prognostic covariates being shifted between the two populations. Using Contribution 2 and 3, we will show that the Risk Difference is likely to be more easily generalizable than other causal measures, as it requires less covariates to adjust on (only the shifted treatment effect modulators, and not all shifted prognostic covariates). Other causal measures can be generalized using an extended set of variables via generalization of the conditional outcomes. In some specific settings, *e.g.* when the treatment effect is homogeneous, some measures can be easily generalized as the Risk Ratio in Table 1.

2.4 Related work: many different viewpoints on effect measures

The choice of measure, a long debate The question of which treatment-effect measure is most appropriate (RR, SR, RD, OR, NNT, log-OR, etc) is age-old (Sheps, 1958; Greenland, 1987; Laupacis et al., 1988; Cook and Sackett, 1995; Sackett et al., 1996; Davies et al., 1998; King and Zeng, 2002; Schwartz et al., 2006; Cummings, 2009). Health authorities advise to report both absolute and relative causal effect (Schulz et al., 2010, item 17b), but in practice public health publications mostly report relative risk (King et al., 2012). And yet, the question is still a heated debate: in the last 5 years, numerous publications have advocated different practices (Spiegelman and VanderWeele, 2017; Spiegelman et al., 2017; Lesko et al., 2018; Baker and Jackson, 2018; Feng et al., 2019; George et al., 2020; Doi et al., 2020, 2022; Xiao et al., 2021, 2022; Huitfeldt et al., 2021; Lapointe-Shaw et al., 2022, see Appendix F for details). Most of

these works focus on the interpretation of the metrics and simple properties such as symmetry (Cummings, 2009), heterogeneity of effects (Rothman, 2011; VanderWeele and Robins, 2007; Lesko et al., 2018), or collapsibility (Simpson, 1951; Whittemore, 1978; Miettinen and Cook, 1981; Greenland, 1987; Greenland et al., 1999; Cummings, 2009; Greenland and Pearl, 2011; Hernàn et al., 2011; Sjölander et al., 2016; Huitfeldt et al., 2019; Daniel et al., 2020; Liu et al., 2022; Didelez and Stensrud, 2022) –some works discuss the paradoxes induced by a lack of collapsibility without using this exact term, e.g. in oncology (Ding et al., 2016; Liu et al., 2022). We shed new light on this debate with a framing on generalization and non-parametric generative models of the outcome (Section 4).

Connecting to the generalization literature The problem of external validity is a growing concern in clinical research (Rothwell, 2005; Rothman et al., 2013; Berkowitz et al., 2018; Deeks, 2002), related to various methodological questions (Cook et al., 2002; Pearl and Bareinboim, 2011). We focus on external validity concerns due to shifted covariates between the trial’s population and the target population, following the line of work initiated in Imai et al. (2008) (see their definition of *sample* effect versus *population* effect), or Corollary 1 of Pearl and Bareinboim (2014). Generalization by standardization (eq. 5, *i.e.* re-weighting⁴ local effects) has been proposed before in epidemiology (Rothman and Greenland, 2000), and in an even older line of work in the demography literature (Yule, 1934). Note that eq. 5 is very close to procedure from eq. 3 which can be linked to post-stratification (Imbens, 2011; Miratrix et al., 2013). Post-stratification is used to lower variance on a randomized controlled trial and therefore has no explicit link with generalization, despite using a similar statistical procedure. Today, almost all statistical papers dealing with generalization focus on the estimation procedures that generalizes the risk difference τ_{RD} (Stuart et al., 2011; Tipton, 2013; O’Muircheartaigh and Hedges, 2013; Kern et al., 2016; Lesko et al., 2017; Nguyen et al., 2018; Gatsonis and Sally, 2017; Buchanan et al., 2018; Dahabreh et al., 2020; Ackerman et al., 2021) (reviewed in Degtiar and Rose (2023); Colnet et al. (2024)), seldom mentioning other measures. Other works focus on the generalization of the distribution of the treated outcome $\mathbb{E}[Y^{(1)}]$ (Pearl and Bareinboim, 2011, 2014; Cinelli and Pearl, 2020). A notable exception, Huitfeldt et al. (2018), details which choice of variables enables the standardization procedure for binary outcomes.

Building up on causal research By writing the outcomes as generated by a non-parametric process disentangling the baseline from the treatment effect (in the spirit of Robinson (1988); Nie and Wager (2020); Gao and Hastie (2021)), we extend the usual assumptions for generalization. In particular, Pearl and Bareinboim (2014) state that their assumptions for generalization are “*the worst case analysis where every variable may potentially be an effect-modifier*”. Our work proposes more optimistic situations, by introducing a notion of effect-modifier without parametric assumptions. This enables the description of situations where fewer covariates are required for the generalization of certain measures. Cinelli and Pearl (2020) have proposed similar ideas, assuming monotonicity of the effect (*i.e.* the effect being either harmful or beneficial for everyone) and the absence of shifted treatment effect modifiers, in order to generalize $\mathbb{E}[Y^{(1)}]$. More precisely they assume that what they call *probabilities of causation* $\mathbb{P}[Y^{(1)} = 0 \mid Y^{(0)} = 1]$ are invariant across populations. We relax this assumption to allow more general situations. Doing so, we also extend work from Huitfeldt et al. (2018, 2019), showing how those probabilities are linked with the causal measures of interest. Interestingly, all our derivations retrieves Sheps (1958) intuition and results when the outcome is binary (which was the only situation described by Sheps). Our work also proposes conclusions for a continuous outcome which was not treated by Sheps (1958); Cinelli and Pearl (2020); Huitfeldt et al. (2021).

⁴It can also be seen as a change of measure, where the Radon-Nikodym derivative fully characterizes the reweighting.

3 Causal metrics and their properties

This section uses notations introduced in Section 2, in particular the potential outcomes $Y^{(0)}$, $Y^{(1)}$ (which can be either binary or continuous), the binary treatment A , and the covariates X .

In this section, we ground formally concepts such as homogeneity and heterogeneity of treatment effect, but also collapsibility, and its link to generalization. Those concepts are already described in the literature, via numerous and slightly different definitions (see Appendix B). We unify existing definitions. For clarity, all definitions, assumptions, and lemmas that do not contain an explicit reference in the title are original.

Definition 1 (Causal effect measures – Pearl (2000)). *Assuming a certain joint distribution of potential outcomes $P(Y^{(0)}, Y^{(1)})$, which implies that a certain treatment A of interest is considered, we denote by τ any functional of the joint distribution of potential outcomes. More precisely,*

$$\begin{aligned} \mathcal{P}_{(Y^{(0)}, Y^{(1)})} &\rightarrow \mathbb{R} \\ \tau : P(Y^{(0)}, Y^{(1)}) &\mapsto \tau^P, \end{aligned} \tag{6}$$

where $\mathcal{P}_{(Y^{(0)}, Y^{(1)})}$ is the set of all joint distributions of $(Y^{(0)}, Y^{(1)})$.

This definition is also valid for any subpopulation: for any covariate X , the conditional causal effect measure $\tau^P(X)$ is defined as a functional of $P(Y^{(0)}, Y^{(1)} | X)$. This definition highlights the fact that a so-called treatment or causal effect naturally depends on *the population considered*. The notation τ^P highlights this dependency. Note also that this definition could admit many more causal measures than the ones presented in this work.

3.1 Treatment effect heterogeneity depends on the measure chosen

Homogeneity or heterogeneity is linked to how the effects change on population subgroups. If the effect amplitude or direction is different in some subgroups (not due to sampling noise as we only consider the true population’s values), the treatment effect is said to be heterogeneous. In the literature, one can find several informal definitions of heterogeneity of a treatment effect but formal definitions are scarce. From now on, we let \mathbb{X} be the covariate space.

Definition 2 (Treatment effect homogeneity). *A causal effect measure τ is said to be homogeneous with respect to the covariate space \mathbb{X} , if*

$$\forall x_1, x_2 \in \mathbb{X}, \quad \tau^P(x_1) = \tau^P(x_2) = \tau^P.$$

Definition 3 (Treatment effect heterogeneity - VanderWeele and Robins (2007)). *A causal effect measure τ is said to be heterogeneous with respect to any set of covariates X if there exist x_1, x_2 such that*

$$\tau^P(X = x_1) \neq \tau^P(X = x_2).$$

Heterogeneity and homogeneity are properties defined with respect to (i) covariates X and (ii) a measure. Claiming *heterogeneity or homogeneity of a treatment effect* should always be completed by the information about the considered covariates and the measure under study. For instance in the illustrative example from Table 1, the treatment effect on the Risk Difference scale is heterogeneous with respect to the baseline diastolic blood pressure level X , while the treatment effect on the Risk Ratio scale is homogeneous with respect to X . In Section 5.2, we will show that, under some proper assumptions, a homogeneous treatment effect is easily generalizable (Theorem 5).

3.2 Not all measures are collapsible

Intuition Collapsibility is intuitively linked to heterogeneity. Indeed, to investigate for heterogeneity, one looks up the treatment effect on subgroups of the population. Collapsibility is the opposite process, where local information is aggregated to obtain a global information (i.e. on a population). One might expect the global effect on a population to be an average of the subgroups effects, with weights corresponding to proportions of each subgroup in the target population of interest as in eq. 3. Counter-intuitively, this procedure is valid only for certain causal effect measures. For example, if the treatment effect is reported as an Odds Ratio, it is possible to find bewildering situations, such as that of the synthetic example detailed on Table 2. In this example, the Odds Ratio is measured on the overall population (Table 2 (a)) and on the two subpopulations if female ($X = 1$) or not ($X = 0$) (Table 2 (b)). Here, the drug’s effect (on the OR scale) is found almost equal on both males (0.166) and females (0.167); however the average effect on the overall population appears weaker (0.26). The Odds Ratio value in the overall population is not even *between* Odds Ratios of sub-populations. The situation mimics a randomized controlled trial conducted with exact population proportions and with X being a covariate, so the phenomenon observed is not an effect of confounding.

Table 2: Non-collapsibility of the odds ratio on a toy example: The tables below represent the exact proportion of an hypothetical population, considering two treatment level $A \in \{0, 1\}$ and a binary outcome. The proportion are as if a randomized controlled trial was conducted on this population. This population can be stratified in two strata: woman ($X = 1$) or not ($X = 0$). The odds ratio can be measured on (a) the overall population, or on (b) each of the sub-population, namely $X = 0$ or $X = 1$. Surprisingly, on each sub-population the odds ratios are similar, but on the overall population the odds ratio is almost two times bigger than on each sub-population. This example is largely inspired from Greenland (1987), but several similar examples can be found elsewhere, for example in Hernàn and Robins (2020) (see their Fine point 4.3) or in Greenland et al. (1999) (see their Table 1). Another didactic example is provided in Daniel et al. (2020) (see their Figure 1), with a geometrical argument.

(a) Overall population, $\tau_{OR} \approx 0.26$

	Y=0	Y=1
A=1	1005	95
A=0	1074	26

(b) $\tau_{OR|X=1} \approx 0.167$ and $\tau_{OR|X=0} \approx 0.166$

X=1	Y=0	Y=1	X=0	Y=0	Y=1
A=1	40	60	A=1	965	35
A=0	80	20	A=0	994	6

This apparent paradox is due to what is called the non-collapsibility⁵ of the Odds Ratio. The fact that the average effect on a population could not be written as a weighted sum of effects on sub-populations is somehow going against the “*implicit assumptions that drive our causal intuitions*” (Pearl (2000), page 180). Non-collapsibility can also be understood through the non-linearity of a function linking the baseline (control) and response functions, see C.3.3. On the contrary, an effect measure is said to be collapsible when the population effect measure can be expressed as a weighted average of the stratum-specific measures. Note that non-collapsibility and confounding are two different concepts, as explained in several papers e.g. in Greenland et al. (1999)⁶.

Formalizing the problem In various formal definitions found in the literature (see Section B), collapsibility relates to the possibility of writing the marginal effect as a weighted sum

⁵This definition and phenomenon has been observed long ago by Simpson. See also the Hernàn et al. (2011) for a discussion of Simpson’s original paper with modern statistical framework. Note that Pearl (2000) (page 176) mentions that collapsibility has been discussed earlier, for example by Pearson in 1899.

⁶“*the two concepts are distinct: confounding may occur with or without noncollapsibility and noncollapsibility may occur with or without confounding.*”

of conditional effects on each subgroups. Yet two definitions coexist, depending on whether weights are forced to be equal to the proportion of individuals in each subgroup or not. We outline various definitions and their links below.

Definition 4 (Direct collapsibility - adapted from [Greenland et al. \(1999\)](#); [Pearl \(2000\)](#); [Liu et al. \(2022\)](#); [Didelez and Stensrud \(2022\)](#)). *Let τ be a measure of effect (see Definition 1). The measure τ is said to be directly collapsible with respect to a set of covariates X if, for all joint distribution $P(Y^{(0)}, Y^{(1)}, X)$, we have*

$$\mathbb{E} [\tau^P(X)] = \tau^P.$$

This definition can be found written slightly differently in literature, see Definition 19 in Appendix B.2.

Lemma 1 (Direct collapsibility of the risk difference (RD) – ([Greenland et al., 1999](#))). *The Risk Difference τ_{RD} is directly collapsible.*

This result grounds eq. 3 in the illustrative example. In the literature, more flexible definitions of collapsibility can be found, keeping the intuition of the population effect being a weighted sum of effects on subpopulations, with certain constraints on the weights: weights must be positive and sum to one.

Definition 5 (Collapsibility - adapted from [Huitfeldt et al. \(2019\)](#)). *Let τ be a measure of effect and \mathbb{X} the covariate space. Let $\mathcal{P}_{(X, Y^{(0)})}$ be the set of all joint distributions of $(X, Y^{(0)})$. The measure τ is said to be collapsible with respect to the covariate space \mathbb{X} if there exists a positive weight function*

$$\begin{aligned} \mathbb{X} \times \mathcal{P}_{(X, Y^{(0)})} &\rightarrow \mathbb{R}_+ \\ w : (X, P(X, Y^{(0)})) &\mapsto w(X, P(X, Y^{(0)})), \end{aligned} \quad (7)$$

satisfying $\mathbb{E} [w(X, P(X, Y^{(0)}))] = 1$, such that, for all joint distributions $P(X, Y^{(0)}, Y^{(1)})$, we have

$$\mathbb{E} [w(X, P(X, Y^{(0)})) \tau^P(X)] = \tau^P.$$

Note that here weights depends on the density of X and the distribution of controls $P(X, Y^{(0)})$. The direct collapsibility is therefore a specific case of the more general version of collapsibility from Definition 5, where $w(X, P(X, Y^{(0)}))$ corresponds to 1. Allowing the weights to depend on the joint distribution of the covariates and the two potential outcomes would lead to all measures being collapsible. Besides, if one had access to the joint distribution of $(X, Y^{(0)}, Y^{(1)})$, one could generate and generalize any causal measure. We choose to consider weights that depend on $Y^{(0)}$ (instead of $Y^{(1)}$) as accessing the distribution of $Y^{(0)}$ (control cases) may be easier in practice.

Lemma 2 (Collapsibility of the Risk Ratio and survival ratio - extending [Ding et al. \(2016\)](#); [Huitfeldt et al. \(2019\)](#); [Didelez and Stensrud \(2022\)](#)). *The Risk Ratio and survival ratio are collapsible measures. In particular, for any set of covariates X , assume that, almost surely, $0 < \mathbb{E}[Y^{(0)}|X] < 1$. Then, the conditional Risk Ratio and conditional survival ratio exist and satisfy*

$$\mathbb{E} \left[\tau_{RR}^P(X) \frac{\mathbb{E} [Y^{(0)} | X]}{\mathbb{E} [Y^{(0)}]} \right] = \tau_{RR}^P \quad \text{and} \quad \mathbb{E} \left[\tau_{SR}^P(X) \frac{1 - \mathbb{E} [Y^{(0)} | X]}{1 - \mathbb{E} [Y^{(0)}]} \right] = \tau_{SR}^P.$$

Knowing the actual form of the weights will be very helpful when coming to generalization in Section 5.2. The proof of collapsibility for the Risk Ratio, the Survival Ratio and other causal measures are established in Appendix C.1. Note that results of Lemma 2 are already presented in Huitfeldt et al. (2019) or Ding et al. (2016) (see their Equation 2.3) but only for a binary outcome and categorical covariate⁷. Thus, Lemma 2 extends their results for any set of covariates X (including categorical and continuous variables) and any type of outcome Y (continuous or binary).

Lemma 3 (Non-collapsibility of the OR, log-OR, and NNT, based on Daniel et al. (2020)). *The odds ratio τ_{OR} , log odds ratio $\tau_{\log-OR}$, and Number Needed to Treat τ_{NNT} are non-collapsible measures.*

The proof is in Appendix C.1. While the non-collapsibility of the odds ratio and the log Odds Ratio have been reported multiple times (see, e.g., Daniel et al., 2020, and the example from Table 2), we have not found references stating results about the NNT.

When considering the OR, the marginal effect τ can be smaller or bigger than the range of local effects $\tau(x)$. Accordingly, Liu et al. (2022) introduces the term *logic* for such characteristic.

Definition 6 (Logic-respecting measure – Liu et al. (2022)). *A measure τ is said to be logic-respecting if, for any set of covariates X and any distribution $P(X, Y^{(0)}, Y^{(1)})$,*

$$\tau^P \in \left[\min_x(\tau^P(x)), \max_x(\tau^P(x)) \right].$$

Lemma 4 (All collapsible measures are logic-respecting, but not the opposite). *Several properties can be noted:*

- (i) *All collapsible measures are logic-respecting measures.*
- (ii) *The Number Needed to Treat is a logic-respecting measure.*
- (iii) *The OR and the log-OR are not logic-respecting measures.*

The proof is in Appendix C.3. While the NNT is not collapsible, this measure does not show the same paradoxical behavior as the OR (see Table 2). This is due to the fact that the NNT results from a monotonic transformation of the RD, which is collapsible (see Lemma 8 in Appendix C.2). The numerous mentions of paradoxes with the OR are probably more driven by its non logic-respecting property than by its non-collapsibility. This also probably explains why some definitions of collapsibility proposed in the literature do not explicitly separate the notions of collapsibility and logic-respecting as they do not detail how weights are defined (see for example Definitions 21 or 22 in Appendix). All properties of this section are summarized in Table 3.

4 Disentangling the treatment effect from the baseline

We now propose to reverse the thinking: rather than starting from a given metric, we propose to reason from generic non-parametric generative models (for continuous and binary outcomes). Such models allow us to disentangle covariates that affect only baseline level from those that

⁷Note that this result can be found under slightly different forms such as in Huitfeldt et al. (2018); Didelez and Stensrud (2022), with a categorical X and using Bayes formula, $\tau_{RR} = \sum_x \tau_{RR}(x) \mathbb{E}[X = x | Y^{(0)} = 1]$.

Table 3: Causal measures and their properties: highlighting the properties of collapsibility (Definition 5) and logic respecting (Definition 6). An exhaustive table is available in Appendix (see Table 5).

Measure	Collapsible	Logic-respecting
Risk Difference (RD)	Yes	Yes
Number Needed to Treat (NNT)	No	Yes
Risk Ratio (RR)	Yes	Yes
Survival Ratio (SR)	Yes	Yes
Odds Ratio (OR)	No	No

modulate treatment effects. This disentangling phenomenon will be used later on in Section 5 to determine which measures are easier to generalize.

4.1 One generative model per causal measure

In this section, we consider causal measures τ such that there exists a function $f : D_f \rightarrow \mathbb{R}$ defined on $D_f \subset \mathbb{R}^2$, verifying, for all distributions $(Y^{(0)}, Y^{(1)})|X$, and for all $x \in \mathbb{X}$ such that $(\mathbb{E}[Y^{(0)} | X = x], \mathbb{E}[Y^{(1)} | X = x]) \in D_f$,

$$\tau^P(x) = f(\mathbb{E}[Y^{(0)} | X = x], \mathbb{E}[Y^{(1)} | X = x]). \quad (8)$$

All causal measures presented in Section 2.2 satisfy eq. 8. For example, the function f associated to the risk difference is simply $f : (z, z') \mapsto z' - z$ with $D_f = \mathbb{R}^2$. If $(\mathbb{E}[Y^{(0)}], \mathbb{E}[Y^{(1)}]) \in D_f$, the average treatment effect for the measure defined in eq. 8 is simply given by

$$\tau^P = f(\mathbb{E}[Y^{(0)}], \mathbb{E}[Y^{(1)}]). \quad (9)$$

Assumption 1 (Injectivity). *Let τ be a causal measure defined in Equation eq. 8. Let, for all $z \in D_f^{(1)}$,*

$$g_z : \begin{array}{l} D_f^{(2)}(z) \rightarrow \mathbb{R} \\ z' \mapsto f(z, z'), \end{array} \quad (10)$$

where $D_f^{(1)} = \{z_1, \exists z' \in \mathbb{R} \text{ such that } (z_1, z') \in D_f\}$ and $D_f^{(2)}(z) = \{z', (z, z') \in D_f\}$. Assume that, for all $z \in D_f^{(1)}$, g_z is an injection.

Such an assumption, stating that g_z is an injection, is mild: if this was not the case, two different values of $\mathbb{E}[Y^{(1)}|X]$ would lead to the same CATE for a given baseline $\mathbb{E}[Y^{(0)}|X]$.

Using the binary nature of A , it is possible to decompose the response Y in two parts: baseline level and modification induced by the treatment. Such decomposition is generic and does not rely on any parametric assumptions.

Lemma 5. *Let τ be a causal measure defined in Equation eq. 8 satisfying Assumption 1. Then, for all distributions $(Y^{(0)}, Y^{(1)})|X$, there exist two unique functions $b, m : \mathbb{X} \rightarrow \mathbb{R}$ such that, for all $x \in \mathbb{X}$ such that*

$$(\mathbb{E}[Y^{(0)} | X = x], \mathbb{E}[Y^{(1)} | X = x]) \in D_f, \quad (11)$$

we have

$$\mathbb{E}[Y^{(0)}|X = x] = b(x) \quad \text{and} \quad \mathbb{E}[Y^{(1)}|X = x] = g_{b(x)}^{-1}(m(x)). \quad (12)$$

Under the model defined in eq. 12, for all x satisfying eq. 11,

$$\tau^P(x) = m(x). \quad (13)$$

The proof can be found in Appendix C.5.1. Lemma 5 shows that for any causal measure, there exists an appropriate generative model such that, under this model, the conditional causal measure captures the treatment effect $m(x)$. Applying Lemma 5 to the Risk Difference leads to the following Corollary.

Corollary 1. *Consider the Risk Difference. In the framework of Lemma 5, we have $b(X) = \mathbb{E}[Y^{(0)}|X]$. Besides, $g_z(z') = z' - z$ and $g_z^{-1}(z') = z' + z$, which leads to*

$$\mathbb{E}[Y^{(1)}|X] = m(X) + b(X). \quad (14)$$

Such a model can also be written as, for all $a \in \{0, 1\}$,

$$\mathbb{E}[Y^{(a)}|X] = b(X) + am(X). \quad (15)$$


Besides, we have $\tau_{RD}^P(X) = m(X)$,

$$\tau_{RD}^P = \mathbb{E}[m(X)], \quad \tau_{RR}^P = 1 + \frac{\mathbb{E}[m(X)]}{\mathbb{E}[b(X)]}, \quad \text{and} \quad \tau_{ERR}^P = \frac{\mathbb{E}[m(X)]}{\mathbb{E}[b(X)]}.$$

The formula in eq. 15 is related to the Robinson (Robinson, 1988) decomposition (see also Angrist and Pischke, 2008, for a completely linear model). This model allows to interpret the difference between the distributions of treated and control groups as the alteration $m(X)$ of a generative model $b(X)$ by the treatment. The function b corresponds to the **baseline**, and m to the **modifying function** due to treatment. Figure 1 gives the intuition backing Corollary 1.

Figure 1: Intuition behind eq. 15:

This illustration highlights that, for a given set of covariates X , one can assume that there exist two functions accounting for the expected outcome value for any individual with baseline characteristics X . Then, it is possible to denote $m(X)$ as the alteration or **modification** of the **baseline** $b(X) := \mathbb{E}[Y^{(0)} | X]$ response.



Corollary 1 also illustrates how the relative measures τ_{RR} and τ_{ERR} depend on both the effect $m(X)$ **and** the baseline $b(X)$. On the contrary, τ_{RD}^P and $\tau_{RD}^P(X)$ are independent of the baseline $b(X)$.

Based on Lemma 5, one can make explicit the generative model associated to any causal measure. In particular, the Conditional Odds Ratio equals the treatment effect in the logistic model (see Section D). Below, we detail the generative model associated to the Risk Ratio.

Corollary 2. *Consider the Risk Ratio. In the framework of Lemma 5, we have $b(X) = \mathbb{E}[Y^{(0)}|X]$. Besides, $g_z(z') = z'/z$ and $g_z^{-1}(z') = zz'$, which leads to*

$$\mathbb{E}[Y^{(1)}|X] = b(X)m(X). \quad (16)$$

Such a model can also be written as, for all $a \in \{0, 1\}$,

$$\mathbb{E}[Y^{(a)}|X] = b(X)(m(X))^a. \quad (17)$$

Consequently, we have

$$\tau_{RR}^P(X) = m(X) \quad \text{and} \quad \tau_{RR}^P = \frac{\mathbb{E}[Y^{(1)}]}{\mathbb{E}[Y^{(0)}]} = \frac{\mathbb{E}[b(X)m(X)]}{\mathbb{E}[b(X)]}. \quad (18)$$

Under the generative model associated with the Risk Ratio (as stated in Corollary 2), the conditional Risk Ratio captures the treatment effect, but the Risk Ratio computed on the overall population depends on the baseline: the Risk Ratio is unable to disentangle the treatment effect from the baseline both at a strata level and at the population level. Finally Appendix D proposes a comment about the logistic regression model which is usually used in applied statistics.

4.2 Only the Risk Difference can disentangle the treatment effect from the baseline

Lemma 5 seems to suggest that all causal measures are equivalent, in the sense that they can all capture the conditional treatment effect modification, provided a suitable generative model. While any CATE $\tau(x)$ is able to disentangle the treatment effect from the baseline provided a suitable generative model, it is not the case for the ATE. In fact, among all collapsible measures, only linear causal measures are able to disentangle the baseline from the treatment effect modification both at a conditional level (CATE) and for the overall population (ATE).

Theorem 1. *Let τ be a collapsible (see Definition 5) causal measure defined in Equation eq. 8 satisfying Assumption 1. Assume that for all distributions $P(X)$ of X , and for all functions $h : \mathbb{X} \rightarrow f(D_f)$, there exists $C_{P(X),h} \in \mathbb{R}$ such that, for all distributions $Y^{(0)}|X$ satisfying $\forall x \in \mathbb{X}, \mathbb{E}[Y^{(0)}|X = x] \in D_f^{(1)}$, there exists a distribution $Y^{(1)}|X$ such that*

- for all $x \in \mathbb{X}, \tau^P(x) = h(x)$
- $\tau^P = C_{P(X),h}$.

Then, there exist $a, b, c \in \mathbb{R}$ such that, for all distributions $P(X, Y^{(0)}, Y^{(1)})$,

$$\tau^P(X) = a\mathbb{E}[Y^{(1)}|X] + b\mathbb{E}[Y^{(0)}|X] + c. \quad (19)$$

The proof is postponed to Appendix C.5.2. Theorem 1 shows that up to renormalization, the Risk Difference is the only causal measure capable of separating the treatment effect from the baseline, both at a strata and population level. Indeed, the assumption inside Theorem 1 states that both the CATE and the ATE of the causal measure τ are independent of the baseline. Under this assumption, Theorem 1 establishes that τ is the Risk Difference (up to constant factors). Thus the Risk Difference is the only causal measure able to capture the treatment effect modification, regardless of the baseline value. This holds for *any* form of the treatment effect (the function h can be arbitrary chosen) independent of the baseline. While the assumption inside Theorem 1 may appear to be strong, it is valid in the generative models presented in Corollary 1, if the choice of the function m does not depend on the function b .

Case of bounded outcomes Let us consider a specific application in which the outcome and the potential outcomes are bounded. In this setting, the Risk Difference is not able to disentangle the treatment effect from all values of the baseline. More precisely, we assume that, for all $x \in \mathcal{X}$,

$$c_1(x) = \min(\mathbb{E}[Y^{(0)}|X = x], \mathbb{E}[Y^{(1)}|X = x]) > 0 \quad (20)$$

$$\text{and } c_2(x) = \max(\mathbb{E}[Y^{(0)}|X = x], \mathbb{E}[Y^{(1)}|X = x]) < \infty. \quad (21)$$

Since $\tau_{\text{RD}}^P(X) = \mathbb{E}[Y^{(1)}|X] - \mathbb{E}[Y^{(0)}|X]$, we must have

$$c_1(X) - \mathbb{E}[Y^{(0)}|X] \leq \tau_{\text{RD}}^P(X) \leq c_2(X) - \mathbb{E}[Y^{(0)}|X]. \quad (22)$$

Thus, assuming that $\tau_{\text{RD}}^P(X)$ is given, it may be possible to disentangle the treatment effect $\tau_{\text{RD}}^P(X)$ from the baseline distribution $Y^{(0)}|X$, but only for baseline distribution satisfying eq. 22. This condition is more stringent as the CATE is important (i.e., close to $c_1(x) - c_2(x)$ or $c_2(x) - c_1(x)$), which requires the baseline to be close to $c_1(x)$ or $c_2(x)$.

Definition 7. We say that $\mathcal{A} : x \mapsto \mathcal{A}(x) \subset \mathbb{R}$ is an admissible set of values for the potential outcomes if, for each $x \in \mathbb{X}$,

$$\mathbb{E}[Y^{(0)}|X = x], \mathbb{E}[Y^{(1)}|X = x] \in \mathcal{A}(x). \quad (23)$$

Given a causal measure τ , and a CATE $\tau(\cdot)$, we let $\mathcal{A}_{B,\tau(\cdot)}(x)$ be the admissible set of values for the baseline, defined as

$$\mathcal{A}_{B,\tau(\cdot)}(x) = \{u \in \mathcal{A}(x), \exists v \in \mathcal{A}(x) \text{ such that } f(u, v) = h(x)\}. \quad (24)$$

Theorem 2. Let \mathcal{A} be an admissible set of values for the potential outcomes and assume that there exist $\alpha_1 < \alpha_2$ such that, for all $x \in \mathbb{X}$, $(\alpha_1, \alpha_2) \subset \mathcal{A}(x)$. Let τ be a collapsible (see Definition 5) causal measure defined in Equation eq. 8 satisfying Assumption 1 and such that $\mathcal{A}(x) \times \mathcal{A}(x) \subset D_f$.

Assume that for all distributions $P(X)$ of X , and for all functions $h : \mathbb{X} \rightarrow f(D_f)$ such that $h(x) \in f(\mathcal{A}(x) \times \mathcal{A}(x))$, there exists $C_{P(X),h} \in \mathbb{R}$ such that, for all distributions $Y^{(0)}|X$ satisfying

$$\forall x \in \mathbb{X}, \mathbb{E}[Y^{(0)}|X = x] \in \mathcal{A}_{B,h}(x),$$

there exists a distribution $Y^{(1)}|X$ such that $\forall x \in \mathbb{X}, \mathbb{E}[Y^{(1)}|X = x] \in \mathcal{A}(x)$ and

- for all $x \in \mathbb{X}, \tau^P(x) = h(x)$
- $\tau^P = C_{P(X),h}$.

Then, there exist $a, b, c \in \mathbb{R}$ such that, for all distributions $P(X, Y^{(0)}, Y^{(1)})$ satisfying for all $x \in \mathbb{X}, \mathbb{E}[Y^{(0)}|X = x], \mathbb{E}[Y^{(1)}|X = x] \in \mathcal{A}(x)$, we have

$$\tau^P(X) = a\mathbb{E}[Y^{(1)}|X] + b\mathbb{E}[Y^{(0)}|X] + c. \quad (25)$$

The proof can be found in Appendix C.5.3. Theorem 2 is the equivalent of Theorem 1 when the potential outcomes are bounded from above and below. Theorem 2 states that the Risk Difference is the only causal measure capable of disentangling the treatment effect from the baseline, for any form of the treatment effect (function h) and any acceptable value of the baseline in $\mathcal{A}_{B,h}(x)$. In a binary setting, potential outcomes naturally belong to $[0, 1]$ and the expected potential outcomes turn into

$$\mathbb{E}[Y^{(0)}|X] = \mathbb{P}[Y^{(0)} = 1|X] \quad \text{and} \quad \mathbb{E}[Y^{(1)}|X] = \mathbb{P}[Y^{(1)} = 1|X]. \quad (26)$$

In this context, Theorem 2 proves that the only causal measure able to disentangle the treatment effect from the baseline at both a strata and global level for all admissible values of the baseline is the Risk Difference. However, in specific binary settings, other causal measures may allow us to retrieve information on the underlying causal process. This is the subject of the next section.

4.3 A specific binary outcome model: the Russian Roulette

4.3.1 Intuition of the entanglement model

We borrow the intuitive example of the Russian Roulette from [Huitfeldt \(2019\)](#), further used by [Cinelli and Pearl \(2020\)](#). When playing the Russian Roulette, everyone has the same probability of $1/6$ to die each time they play. We know this because of the intrinsic mechanism of the Russian Roulette. Now, assume that we have not access to this information. Consider a hypothetical randomized trial to estimate the effect of the Russian Roulette: a random set of individuals is forced to play Russian Roulette, and the others just wait. For logistic reasons, the experiment is done on a certain time frame, i.e. we collect the outcome 28 days after the “treatment” administration, mimicking a typical clinical outcome defined as mortality after 28 days of hospitalization. During this time frame, individuals can die from other reasons, such as diseases or poor health conditions. For an individual with characteristics x , denoting $b(x)$ his/her probability to die without the Russian Roulette, and counting a death as $Y = 1$ and survival $Y = 0$, one has:


$$\mathbb{P}[Y^{(a)} = 1 \mid X = x] = b(x) + a \underbrace{(1 - b(x))}_{\text{Entanglement}} \frac{1}{6}. \quad (27)$$

This equation simply states the fact that each individual $X = x$ has a certain probability to die $b(x)$ by default. When getting treatment, an individual can also die from Russian Roulette if affected in the treated group $a = 1$, but only if not dead otherwise. In this equation, one can explicitly observe that the effect (measured via the Risk Difference) is naturally *entangled* with the baseline. As a consequence, the treatment effect m in the generative model associated to the Risk Difference cannot be assumed to be independent of the baseline $b(x)$, as $m(x) = (1 - b(x))/6$. In particular, :

$$\tau_{\text{RD}}^P = \frac{1}{6} (1 - \mathbb{E}[b(x)]), \quad \text{and in particular} \quad \lim_{\mathbb{E}[b(x)] \rightarrow 1} \tau_{\text{RD}} = 0.$$

In this situation, the first assumption (independence between the CATE and the baseline) of [Theorem 2](#) is not satisfied. Thus [Theorem 2](#) does not apply. Indeed, both the CATE and the ATE of the Risk Difference depends on the baseline. This is illustrated in [Figure 2](#). In a population with a high baseline, the measured effect vanishes along the risk difference scale.

Figure 2: Illustration of the properties of the Risk Difference under the russian roulette example. With low baseline risk, the Risk Difference can capture the effect of the roulette $1/6$ whereas with high baseline the effects tend to 0.



In other words, when considering the RD, the effect of the treatment can only be observed on people that would not have died otherwise. This could seem a bit odd, as the Russian

Roulette example contains the idea of an *homogeneous* treatment effect, that should not vary over different populations. Still, one measure, the survival ratio, shows an interesting property,

$$\tau_{\text{SR}}^P = 1 - \frac{\mathbb{E}[(1 - b(X)) \frac{1}{6}]}{\mathbb{E}[(1 - b(X))]} = \frac{5}{6}.$$

The Survival Ratio thus captures the idea of homogeneity: no matter the baseline risk, the Russian Roulette acts in the same way for everyone, as noticed by [Huitfeldt \(2019\)](#). Appendix E gives more details about the origin of this example.

4.3.2 Formal analysis

Equation 27 only describes harmful situations while we may be interested in modelling positive or deleterious effects of the treatment. In addition, we want a model able to encode situations where there is heterogeneity of the treatment effect (e.g. Russian Roulette can have a higher impact on stressed out people because the prospect of playing would create cardiac arrests). Or on a more concrete example: the seat belts could be protective for taller individuals but less protective (or even deleterious) for smaller individuals because of the design.

Lemma 6 (Entanglement Model). *Considering a binary outcome Y , assume that*

$$\forall x \in \mathbb{X}, \forall a \in \{0, 1\}, \quad 0 < p_a(x) < 1, \quad \text{where } p_a(x) := \mathbb{P}[Y^{(a)} = 1 \mid X = x].$$

Introducing

$$m_g(x) := \mathbb{P}[Y^{(1)} = 0 \mid Y^{(0)} = 1, X = x] \quad \text{and} \quad m_b(x) := \mathbb{P}[Y^{(1)} = 1 \mid Y^{(0)} = 0, X = x],$$

allows to have

$$\mathbb{P}[Y^{(a)} = 1 \mid X = x] = b(x) + a((1 - b(x))m_b(x) - b(x)m_g(x)), \quad \text{where } b(x) := p_0(x).$$

Proof is available in Appendix C.5.4. Usually $Y = 1$ denotes death or deleterious events, therefore the subscripts b (resp. g) stands for *bad* (resp. *good*) events. m_b (resp. m_g) corresponds to the probability that a person who was previously not destined (resp. destined) to experience the outcome, does (resp. does not) experience the outcome in response to treatment. They represent the outcome switch depending on the position at baseline⁸. The expressions of classical causal measures are established in Lemma 9 (see Appendix C.5.5). Such expressions are difficult to interpret in the general case where both m_b and m_g are non-zero. In fact, in such a situation $m_b(X)$ and $m_g(X)$ are not identifiable ([Pearl, 2000](#); [Huitfeldt et al., 2018](#)). However, since we are mainly interested in the total effect, one could consider the generative model of the risk difference,

$$\mathbb{P}[Y^{(a)} = 1 \mid X = x] = b(x) + a\tau(x), \quad \text{where } \tau(x) := (1 - b(x))m_b(x) - b(x)m_g(x),$$

with the limitations described in Section 4.3.1. Thus, we consider the case of monotonous effects.

⁸Such parameters can be found to be close to the “*counterfactual outcome state transition*” (COST) in [Huitfeldt et al. \(2018\)](#). For example m_b would correspond to the quantity denoted by $1 - H$. Also note that the intrication model also allows to apprehend what has been done by [Cinelli and Pearl \(2020\)](#), where the quantity they introduce being $PS_{01} := \mathbb{P}[Y^{(1)} = 1 \mid Y^{(0)} = 0]$ corresponds to m_b . While their work mostly rely on the formalism of selection diagram, they define PS_{01} (and therefore m_b) as the probability of fatal treatment among those who would survive had they not been assigned to for treatment. And conversely, $PS_{10} := \mathbb{P}[Y^{(1)} = 0 \mid Y^{(0)} = 1]$ (corresponding to m_g) stands for the probability that the treatment is sufficient to save a person who would die if defined. As far as we understand, in both of these works these probabilities are not taken conditionally to X .

4.3.3 Notion of monotonous effect

We introduce the assumption of monotonous effects, where either $\forall x, m_b(x) = 0$ or $\forall x, m_g(x) = 0$ (Huitfeldt et al., 2018; Cinelli and Pearl, 2020), corresponding to scenarios where the treatment is only beneficial or deleterious⁹, but cannot be both. If the treatment is always beneficial (i.e. $\forall x, m_b(x) = 0$) then the probability $p_1(x)$ (see Lemma 6) is lower than the baseline. Respectively, if the treatment is always deleterious (i.e. $\forall x, m_g(x) = 0$) then the probability $p_1(x)$ is higher than the baseline. This can be summarized as follows,

$$\mathbb{P}[Y^{(a)} = 1 \mid X = x] = b(x) + \underbrace{a(1 - b(x))m_b(x)}_{\nearrow} - \underbrace{ab(x)m_g(x)}_{\searrow}, \quad (28)$$

where arrows indicate whether each term of the equation is increasing or decreasing the probability of occurrences. Equation eq. 28 highlights that the entanglement is not the same depending on the nature of the treatment (deleterious or not). A beneficial effect ($m_b(x) = 0$) is more visible on a high baseline population ($b(x)$ close to 1). On the opposite, a deleterious effect ($m_g(x) = 0$) is visible only on the population with low baseline ($1 - b(x)$ close to 1). In other words, an effect increasing the probability of occurrences acts only on individuals on which occurrences has not already happened yet.

Lemma 7 (Risk Ratio and Survival Ratio under a monotonous effect). *Ensuring conditions of Lemma 6,*

- Assuming that the treatment is beneficial (i.e. $\forall x, m_b(x) = 0$), then

$$\tau_{RR}^P(X) = 1 - m_g(X) \quad \text{and} \quad \tau_{RR}^P = 1 - \frac{\mathbb{E}[b(X)m_g(X)]}{\mathbb{E}[b(X)]}. \quad (29)$$

- Assuming that the treatment is harmful (i.e. $\forall x, m_g(x) = 0$), then

$$\tau_{SR}^P(X) = 1 - m_b(X) \quad \text{and} \quad \tau_{SR}^P = 1 - \frac{\mathbb{E}[(1 - b(X))m_b(X)]}{\mathbb{E}[1 - b(X)]}. \quad (30)$$

These results formalize what has been proposed several times in the literature, for example by Sheps (1958), and later by Huitfeldt et al. (2018, 2021), or with what has been called the *Generalised Relative Risk Reduction* (Baker and Jackson, 2018). In particular, Sheps finishes her paper with the following quote

“A beneficial or harmful effect may be estimated from the proportions of persons affected. The absolute measure does not provide a measure of this sort. The choice of an appropriate measure resolves itself largely into the choice of an appropriate base or denominator for a relative comparisons. [...] the appropriate denominator consists of the number of persons who could have been affected by the factor in question”.


This recommendation is consistent with Lemma 7. In other words, sign of the effect dictates on which labels the relative comparison should be made i.e., dividing by $\mathbb{P}[Y^{(0)} = 1]$ or $\mathbb{P}[Y^{(0)} = 0]$, to obtain a CATE disentangled from the baseline: SR should be used when the effect is harmful (like the Russian Roulette), while RR should be used when the effect is beneficial. While the CATE of SR (resp. RR) is interpretable, as it allows us to retrieve a deleterious (resp. beneficial) local effect, the corresponding ATE is not able to disentangle the baseline from the causal effect. This is consistent with the result of Theorem 2 that states that only the Risk Difference can disentangle baseline and treatment effects at both CATE and ATE levels.

⁹In particular, the Russian Roulette corresponds to a situation where $\forall x, m_g(x) = 0$ (Russian Roulette makes no good).

5 Generalization

As highlighted in Section 2, an RCT conducted in a population P_S allows for the estimation of a treatment effect τ^{P_S} on this population. What would the result be if the individuals in the trial were rather sampled from a population P_T with different covariates distribution? This question is linked to external validity, and more precisely to a sub-problem of external validity being *generalizability* or *transportability*. We say that findings from a trial sampled from P_S can be generalized to P_T when τ^{P_T} can be estimated without running a trial on P_T , but only using data from the RCT and baseline information on the target population P_T (the covariates X , and sometimes also the control outcome $Y^{(0)}$), as summarized on Figure 3.

Figure 3: Generalization in practice: We typically consider a situation where the treatment effect is estimated from a Randomized Controlled Trial (RCT) where individuals are sampled from a population P_S . When willing to extend these findings to P_T , we assume to have access to a representative sample of the patients of interest, with information on their covariates $P_T(X)$, and also maybe the outcome under no treatment $P_T(X, Y^{(0)})$.



We consider set-ups where control outcome is observed or not ↗

5.1 Two different strategies for generalizability

There exist two identification strategies, generalizing (i) the conditional outcomes or (ii) the local effect measure itself, leading to different assumptions required for generalizing. For both strategies, we consider the settings where information gathered on the source population covers at least the support of the target population.

Assumption 2 (Overlap or positivity). *The support of the target population is included in the source population: $\text{supp}(P_T) \subset \text{supp}(P_S)$.*

This assumption¹⁰ is the counterpart of the the so-called positivity or overlap assumption in observational studies. It means that all members of the target population have positive probability of being selected into the source population. In the specific case of generalization, such a common assumption is violated when the source population is a randomized controlled trial conducted on a restricted population (for e.g. because of strict eligibility criteria for safety reasons) compared to the target/whole population. Still, in practice, it is possible to restrict the support of the target population to the source population. This would allow generalizing an effect from the source population to the target population, answering the following question “what would the effect be on the target population if the same eligibility criteria were used?”.

The first approach aims at generalizing conditional expectations $\mathbb{E}_S [Y^{(a)} | X]$ of the potential outcomes to the target population. Such a strategy is valid only under the following assumption.

¹⁰Note that Assumption 2 can be phrased as “the measure P_T is absolutely continuous with respect to P_S ”.

Assumption 3 (Transportability or S-ignorability or Exchangeability between populations). For all $x \in \text{supp}(P_T) \cap \text{supp}(P_S)$, for all $a \in \{0, 1\}$,

$$\mathbb{E}_S [Y^{(a)} | X = x] = \mathbb{E}_T [Y^{(a)} | X = x].$$

This assumption¹¹ boils down to: X contains all covariates that are *both* shifted between the two populations P_S and P_T and prognostic of the outcome. Assumption 3 enables the identification of τ^{P_T} using information from $P_S(X, Y^{(0)}, Y^{(1)})$ and only the covariate distribution $P_T(X)$ in the target population, as shown in the following Proposition (see Appendix C.4 for the proof).

Proposition 1 (Generalizing conditional outcomes). Consider two distributions P_S and P_T satisfying Assumptions 2 and 3. Then, the conditional outcomes are generalizable:

$$\begin{aligned} \forall a \in \{0, 1\} \quad \mathbb{E}_T [Y^{(a)}] &= \mathbb{E}_T [\mathbb{E}_S [Y^{(a)} | X]] && \text{G-formula} \\ &= \mathbb{E}_S \left[\frac{p_T(X)}{p_S(X)} \mathbb{E}_S [Y^{(a)} | X] \right] \end{aligned}$$

where $\frac{p_T(X)}{p_S(X)}$ corresponds to the ratio of covariate densities in the source and target populations.

The first formula in Proposition 1 suggests a strategy to generalize the potential outcomes: first, one can compute of $\mu_{a,s}(x) = \mathbb{E}_S [Y^{(a)} | X = x]$ using the source distribution $P_S(X, Y^{(0)}, Y^{(1)})$, then one can compute $\mathbb{E}_T [\mu_{a,s}(X)]$ using the covariate target distribution $P_T(X)$. Any causal measure τ satisfying Equation eq.8 can be generalized on the target distribution using this strategy.

When the causal measure is collapsible, rather than using a conditional outcome model, the second approach relies on the local effects $\tau^{P_S}(x)$ to get the target population's effect τ^{P_T} , such as in Equation 5. Importantly, Assumption 3 can then be relaxed into a new, less restrictive, Assumption 4.

Assumption 4 (Transportability of the treatment effect). For all $x \in \text{supp}(P_T) \cap \text{supp}(P_S)$,

$$\tau^{P_S}(x) = \tau^{P_T}(x).$$

Here, the transportability assumption¹² can be phrased as: X contains all covariates that are *both* shifted between the two populations P_R and P_T and treatment effect modulators.

Proposition 2 (Generalizing local effects). Consider two distributions P_S and P_T and a collapsible causal measure τ satisfying Assumptions 2 and 4. Then, τ is generalizable to the target population via the formula

$$\begin{aligned} \tau^{P_T} &= \mathbb{E}_T [w(X, P_T(X, Y^{(0)})) \tau^{P_S}(X)] \\ &= \mathbb{E}_S \left[\frac{p_T(X)}{p_S(X)} w(X, P_T(X, Y^{(0)})) \tau^{P_S}(X) \right] && \text{Re-weighting.} \end{aligned}$$

where $\frac{p_T(X)}{p_S(X)}$ corresponds to the ratio of covariate densities in the source and target populations, and $w(X, P_T(X, Y^{(0)}))$ corresponds to the collapsibility weights (see Definition 5).

¹¹This assumption is also commonly found expressed as $Y^{(0)}, Y^{(1)} \perp\!\!\!\perp I | X$, where I is an indicator of the population membership (Stuart et al., 2011; Pearl, 2015; Lesko et al., 2017). Such assumptions can also be expressed using selection diagram (Pearl and Bareinboim, 2011).

¹²This assumption is also commonly found expressed as $Y^{(0)} - Y^{(1)} \perp\!\!\!\perp I | X$ when it comes to the generalization of the risk difference (I being an indicator of the population membership). Note that the transportability assumptions conveys the idea of some homogeneity assumption (close to the spirit of Definition 2). This is highlighted by Huitfeldt et al. (2018) who refer to Assumptions 3 and 4 as “different homogeneity conditions to operationalize standardization”.

The proof is postponed to Appendix C.4. The first formula in Proposition 2 leads to the following generalization strategy: the quantity $\tau^{P_S}(X) = \mathbb{E}_S[Y^{(1)} - Y^{(0)}|X]$ can be computed using the source distribution $P_S(X, Y^{(0)}, Y^{(1)})$ and both the collapsibility weights and the expectation in the first formula of Proposition 2 can be computed using the target distribution $P_T(X, Y^{(0)})$. Note that the second formula suggests the classical re-weighting estimation strategy also called IPSW (Inverse Propensity of Sampling Weighting, see Colnet et al. (2024) for a review on the Risk Difference).

The two above strategies rely on two different assumptions. However, it is very important to note that Assumption 4 is lighter than Assumption 3 as highlighted in Nguyen et al. (2018); Huitfeldt and Stensrud (2018); Colnet et al. (2022a). As a consequence, using local effects – Proposition 2 – as opposed to conditional-outcomes – Proposition 1 – may allow generalizing collapsible causal measure *with fewer covariates*, as detailed in the next section.

5.2 Are some measures easier to generalize than others?

Section 5.1 exposes two transportability assumptions depending on which conditional quantity from the source population is generalized: the conditional outcome (Assumption 3) or the local effect (Assumption 4). While Assumption 3 requires that all covariates being prognostic and shifted in the two populations have been observed, Assumption 4 involves all covariates modulating treatment effect and shifted. In this section, we analyze precisely which strategy can be used for a given causal measure, and what is the required set of covariates for such a strategy. We start by specifying which variables are shifted between the two populations.

Assumption 5 (Shifted covariates set). *We assume that only some components of X are shifted between the source and the target population. More precisely, we denote by $Sh \subset \{1, \dots, d\}$ the set of indices corresponding to the components of X that are shifted between the source and the target population, that is, for all integrable functions $f : \mathbb{X} \rightarrow \mathbb{R}$, for all $x \in \text{Supp}(P_T)$,*

$$\mathbb{E}_S[f(X)|X_{Sh} = x_{Sh}] = \mathbb{E}_T[f(X)|X_{Sh} = x_{Sh}],$$

and the complementary set of covariates X_{Sh^c} is independent of X_{Sh} .

To formalize which covariates are implied in local treatment effect, we introduce notations to distinguish covariates status, either intervening on the baseline level or modulating the effect.

Assumption 6 (Two types of covariates). *Let τ be a causal measure and let $b : \mathbb{X} \rightarrow \mathbb{R}$ and $m : \mathbb{X} \rightarrow \mathbb{R}$ be the function describing the associated model (see Lemma 5). For all $J \subset \{1, \dots, d\}$, we let X_J the subvector of X composed of components of X indexed by J . We assume that the function b depends only on X_B , a subset of covariates indexed by $B \subset \{1, \dots, d\}$. Similarly, we assume that the function m depends only on X_M , a subset of covariates indexed by $M \subset \{1, \dots, d\}$.*

The baseline b and the treatment effect m are assumed to depend on certain sets of variables (Assumption 6). Determining such sets is an active area of research (Hines et al., 2022; Bénard and Josse, 2023) and falls beyond the scope of this paper. Instead, we fix the sets X_B and X_M , and the set of shifted covariates between the source and target population, and analyze which covariates are required for generalization, depending on the considered strategy (generalizing potential outcomes or local effects)¹³

Generalizing conditional outcomes requires to have access to all shifted prognostic covariates.

¹³Note that the size of X_B , X_M and X_{Sh} completely depends on the data distribution and the causal measure: if the causal measure does not allow disentangling the treatment effect from the baseline at a strata level then $X_M = X_B$, whereas if all variables are shifted then $X_{Sh} = X$.

Theorem 3. Consider an injective causal measure (Assumption 1). For all distributions $P_S(X, Y^{(0)}, Y^{(1)})$ and $P_T(X, Y^{(0)}, Y^{(1)})$ satisfying Assumption 2 (overlap assumption) and Assumption 3, generalization of the conditional outcomes is possible if one has access to all shifted covariates involved in the baseline and the treatment effect, that is $X_{(B \cup M) \cap Sh}$.

The proof can be found in Appendix C.6.1. To illustrate what are the different covariate sets, we introduce the data generative model of the simulations (see Section 6), where we assume that six covariates are prognostic and that data are generated as

$$Y = b(X_1, X_2, X_3, X_4, X_5, X_6) + A m(X_1, X_2, X_5) + \varepsilon. \quad (31)$$

Doing so, $B = (1, 2, 3, 4, 5, 6)$, and $M = (1, 2, 5)$. In addition, the two populations are constructed such that X_1, \dots, X_4 are shifted covariates, but not X_5, X_6 . Figure 4 illustrates what shifted and non-shifted means. Theorem 3 states that generalization of the conditional outcomes is possible when observing X_1, \dots, X_4 .

Having access to all shifted prognostic covariates in the two data samples seems challenging (and maybe too optimistic). This situation could explain all the numerous recent research works about sensitivity analysis when necessary covariates are not observed or partially observed when generalizing (Nguyen et al., 2018; Nie et al., 2021; Colnet et al., 2022a). In such a context, generalizing local effects (instead of conditional outcomes) is a promising strategy, as it may require less covariates, as shown in Theorem 4 below.




Figure 4: $2 \in \text{Shift}$, and $6 \notin \text{Shift}$.

Theorem 4. Consider the Risk Difference τ_{RD} . For all distributions $P_S(X, Y^{(0)}, Y^{(1)})$ and $P_T(X, Y^{(0)}, Y^{(1)})$ satisfying Assumption 2 (overlap assumption) and Assumption 4, observing all shifted treatment effect modifiers $X_{M \cap Sh}$ is sufficient for generalizing τ_{RD} .

The proof can be found in Appendix C.6.2. Theorem 4 shows that the Risk Difference can be generalized via the local effect strategy with fewer covariates and under a weaker assumption compared to Theorem 3. Back to eq. 31, one would require only X_1 and X_2 to generalize the Risk Difference with the local effects strategy, as X_5 is not shifted.

There are two specific situations in which all collapsible causal measures can be generalized: in presence of a homogeneous effect or when the baseline and the treatment effect are independent.

Theorem 5. Consider a collapsible causal measure τ .

- (homogeneous treatment effect) For all distributions $P_S(X, Y^{(0)}, Y^{(1)})$ and $P_T(X, Y^{(0)}, Y^{(1)})$ satisfying Assumption 2 (overlap assumption), Assumption 4 and such that there exists $C \in \mathbb{R}$ satisfying, for all $x \in \text{Supp}(P_T)$, $\tau^{P_S}(x) = C$, we have

$$\tau^{P_T} = \tau^{P_S} = C. \quad (32)$$

- (independence between treatment effect and collapsibility weights) For all distributions $P_S(X, Y^{(0)}, Y^{(1)})$ and $P_T(X, Y^{(0)}, Y^{(1)})$ satisfying Assumption 2 (overlap assumption), Assumption 4 and such that $\tau(X)$ is independent of the collapsibility weights $w(X, P(X, Y^{(0)}))$ (Definition 5), we have,

$$\tau^{P_T} = \tau^{P_S} = \mathbb{E} [\tau^{P_S}(X)]. \quad (33)$$

6 Illustration through simulations

We use synthetic simulations to illustrate Theorems 3 and 4, that is different covariates sets are required to identify the target population effect depending on (i) the causal measure of interest and (ii) the generalization method. All implementations details, as well as the estimation strategies are provided in Appendix H. Other experiments studying the impact of missing covariates or misspecified models are also presented in Appendix H (see Figure 14 and Figure 15). The code to reproduce the simulations is available on [github](#) (see repository [BenedicteColnet/ratio-versus-difference](#)).




Figure 5: Results of the simulations for a continuous outcomes: where the generative model corresponds to eq. 31, and where $b(\cdot)$ and $m(\cdot)$ are linear functions (more details are given in Appendix, see eq. 161). Column 1 corresponds to generalizing conditional outcome (Proposition 1), column 2 corresponds to generalizing local effect (Proposition 2). For these two approaches we use different covariates set, with **shifted treatment effect modulators** (X_1, X_2), **shifted prognostic covariates** (X_1, X_2, X_3 , and X_4), and all **prognostic covariates** (X_1, X_2, X_3, X_4, X_4 and X_6). According to Theorems 3 and 4, only the Risk Difference can be generalized with a restricted covariates set. Simulations are performed with 1000 repetitions, a source sample size of 500 and target sample size of 1,000. Estimation is performed with plug-in g-formula modeling all responses with an OLS approach as detailed in Section H.2.1.

6.1 Continuous outcome

We propose a situation where the continuous outcome is generated from six prognostic covariates X_1, \dots, X_6 as detailed in eq. 31. More precisely, $B = \{1, 2, 3, 4, 5, 6\}$, and $M = \{1, 2, 5\}$, while only covariates X_1, X_2, X_3, X_4 are shifted between P_S and P_T . For this simulation, both $b(\cdot)$ and $m(\cdot)$ are linear functions of the covariates (see Section H.2.1), so that estimation with an OLS procedure is well-specified. Figure 5 presents results, where the **pink** dashed line represents the source causal effect and the **blue** dashed line represents the target causal effect.

As expected for the outcome generalization strategy (Theorem 3), all causal measure can be generalized using all prognostic and shifted covariates (orange boxplots). Note that adding all prognostic covariates (red boxplots) leads to more precision, in accordance with what is proposed in Colnet et al. (2022b) for the risk difference¹⁴. According to Theorem 4, the Risk Difference τ_{RD} can be generalized via the local effect strategy using less covariates, namely the shifted treatment effect modulators, X_1 and X_2 (yellow boxplot). We observe that all other causal measures require access to all shifted prognostic covariates in both strategies in order to retrieve the target effect.

6.2 Binary outcome

We enrich the example of the Russian Roulette assuming that the effect of the Russian Roulette itself is modulated by covariates. This gloomy example is, of course, completely fictitious and is used for better understanding. We adapt the generative model of eq. 27 into

$$\mathbb{P}[Y^{(a)} = 1 \mid X = x] = b(X_1, X_2, X_3) + a(1 - b(X_1, X_2, X_3)) m_b(X_2, X_3), \quad (34)$$

where $X_1 = \text{lifestyle}$, $X_2 = \text{stress}$, and $X_3 = \text{gender}$, a situation where individuals' baseline risk of death depends on their lifestyle, stress, and gender.




Figure 6: Simulation with binary outcome Y : for a monotonous and deleterious effect. Adjusting on **shifted prognostic covariates** (stress and lifestyle), or with all **prognostic covariates** (stress, lifestyle, and gender) enables generalization of all causal measures by generalization of the conditional outcome or re-weighting of local effect if possible (only for collapsible measures, namely RR, SR, and RD). On this simulation, estimation is done with IPSW estimator, source (resp. target) sample being of size $n = 5\,000$ (resp. $m = 20,000$), with 1000 repetitions.

¹⁴This is similar to adding an instrument or an outcome-related covariate in an adjustment set when estimating causal effect from a single observational data set (Brookhart et al., 2006).

We assume that the effect of the Russian Roulette can be modulated by stress (imagine individuals having a heart attack as soon as the gun is approaching their head) and gender (the executioner being more merciful when facing a women). We further assume that **gender** is the only covariate with no shift between the two populations. In particular, we suppose that P_s is composed of more people with a good lifestyle but are very stressed, while in P_T individuals have a poor lifestyle but a low stress. Details on the generative model are provided in Appendix (see Section H.3.1).

Results are shown in Figure 6. Note that on the simulation both the NNT and the OR cannot be generalized via the local effect strategy, as these measures are not collapsible. As expected for the outcome generalization strategy (Theorem 3), all causal measure can be generalized using all prognostic and shifted covariates (orange boxplots). Note that this appears to hold also for the local effect strategy.

7 Conclusion

The choice of a population-level measure of treatment effect has been much debated. Indeed, all causal measures do not share the same properties, which may lead to different interpretation of the treatment effect. In particular, we show that collapsibility is a very important property, as it allows computing the average treatment effect via a reweighting of local effects on substrata. Among such collapsible measures, only the Risk Difference is able to disentangle the treatment effect from the baseline at both a strata (CATE) and population (ATE) level (see Theorem 1). This generic result holds for both continuous and binary outcomes, but only for a restricted range of baseline functions in the case of bounded outcomes (see Theorem 2). Our analysis of the different properties of causal measures leads us to establish two different strategies for generalization, based on the potential outcomes (Proposition 1) or the local effect (Proposition 2). The first approach can be applied to any causal measure but requires a stronger assumption. The local effect strategy can be applied to collapsible causal measures only but requires a less stringent assumption, and potentially fewer covariates than the first approach. In particular, we show that all shifted prognostic variables are needed to generalize the potential outcomes (Theorem 3), while only shifted treatment effect modifiers are needed to generalize the Risk Difference via the local effect procedure (Theorem 4). Regardless of the outcome type (continuous or binary), the Risk Difference may require fewer variables than other causal measures to be generalized. Note that this is not always the case: if the treatment effect of the Risk Difference is entangled with the baseline (as in the Russian Roulette example), then generalizing the Risk Difference via local effect would require all shifted prognostic variables. Note that all other causal measures are able to separate the treatment effect from the baseline in very specific settings (e.g., homogeneous treatment effect), and are thus easily generalizable in these contexts (see Theorem 5).

Acknowledgments

First of all we would like to thank clinician François-Xavier AGERON who first raised our interest on generalizability and the choice of measure. We also would like to thank fruitful discussions with our clinicians collaborators, in particular with François-Camille GROLLEAU and Raphaël PORCHER. We thank Maxime FOSSET and Marine LE MORVAN who gave precious comments on the manuscript. Thank you also to Wouter VAN AMSTERDAM for careful proofreading. Finally, we would like to thank Anders HUITFIELDT: his research papers (and blog articles) have been precious sources of inspiration for our work.

Fundings

Authors are all funded by their respective employer (Inria or École polytechnique). This work/project was partially and publicly funded through ANR (the French National Research Agency) under the “*Investissements d’avenir*” program with the reference ANR-16-IDEX-0006. GV acknowledges funding from Intercept-T2D (HORIZON-HLTH-2022-STAYHLTH-02-01)

Data availability statement

The simulations that support the findings of this study are openly available on github at [BenedicteColnet/ratio-versus-difference](https://github.com/BenedicteColnet/ratio-versus-difference).

Conflict of interest

Authors state no conflict of interest.

References

- Ackerman, B., C. R. Lesko, J. Siddique, R. Susukida, and E. A. Stuart (2021). Generalizing randomized trial findings to a target population using complex survey population data. *Statistics in medicine* 40(5), 1101–1120.
- Altman, D. G. (1998). Confidence intervals for the number needed to treat. *Bmj* 317(7168), 1309–1312.
- Angrist, J. D. and J.-S. Pischke (2008, December). *Mostly Harmless Econometrics: An Empiricist’s Companion*. Princeton University Press.
- Baker, R. and D. Jackson (2018). A new measure of treatment effect for random-effects meta-analysis of comparative binary outcome data. *arXiv preprint arXiv:1806.03471*.
- Bénard, C. and J. Josse (2023). Variable importance for causal forests: breaking down the heterogeneity of treatment effects. *arXiv preprint arXiv:2308.03369*.
- Berkowitz, S. A., J. B. Sussman, D. E. Jonas, and S. Basu (2018). Generalizing intensive blood pressure treatment to adults with diabetes mellitus. *Journal of the American College of Cardiology* 72(11), 1214–1223. SPECIAL FOCUS ISSUE: BLOOD PRESSURE.
- Brookhart, M. A., S. Schneeweiss, K. J. Rothman, R. J. Glynn, J. Avorn, and T. Stürmer (2006). Variable selection for propensity score models. *American journal of epidemiology* 163(12), 1149–1156.
- Buchanan, A. L., M. G. Hudgens, S. R. Cole, K. R. Mollan, P. E. Sax, E. S. Daar, A. A. Adimora, J. J. Eron, and M. J. Mugavero (2018). Generalizing evidence from randomized trials using inverse probability of sampling weights. *Journal of the Royal Statistical Society: Series A (Statistics in Society)* 181, 1193–1209.
- Cinelli, C. and J. Pearl (2020). Generalizing experimental results by leveraging knowledge of mechanisms. *European Journal of Epidemiology*.
- Cole, P. and B. MacMahon (1971). Attributable risk percent in case-control studies. *British journal of preventive & social medicine* 25(4), 242.

- Colnet, B., J. Josse, G. Varoquaux, and E. Scornet (2022a). Causal effect on a target population: a sensitivity analysis to handle missing covariates. *Journal of Causal Inference* 10(1), 372–414.
- Colnet, B., J. Josse, G. Varoquaux, and E. Scornet (2022b). Reweighting the rct for generalization: finite sample analysis and variable selection. *arXiv preprint arXiv:2208.07614*.
- Colnet, B., I. Mayer, G. Chen, A. Dieng, R. Li, G. Varoquaux, J.-P. Vert, J. Josse, and S. Yang (2024). Causal inference methods for combining randomized trials and observational studies: a review. *Statistical science* 39(1), 165–191.
- Cook, R. J. and D. L. Sackett (1995). The number needed to treat: a clinically useful measure of treatment effect. *Bmj* 310(6977), 452–454.
- Cook, T. D., D. T. Campbell, and W. Shadish (2002). *Experimental and quasi-experimental designs for generalized causal inference*. Houghton Mifflin Boston, MA.
- Cornfield, J. et al. (1951). A method of estimating comparative rates from clinical data; applications to cancer of the lung, breast, and cervix. *Journal of the National Cancer Institute*, 1269–1275.
- Cummings, P. (2009, 05). The Relative Merits of Risk Ratios and Odds Ratios. *Archives of Pediatrics & Adolescent Medicine* 163(5), 438–445.
- Dahabreh, I. J., S. E. Robertson, J. A. Steingrimsson, E. A. Stuart, and M. A. Hernán (2020). Extending inferences from a randomized trial to a new target population. *Statistics in Medicine* 39(14), 1999–2014.
- Daniel, R., J. Zhang, and D. Farewell (2020, 12). Making apples from oranges: Comparing non-collapsible effect estimators and their standard errors after adjustment for different covariate sets. *Biometrical Journal* 63.
- Davies, H. T. O., I. K. Crombie, and M. Tavakoli (1998). When can odds ratios mislead? *Bmj* 316(7136), 989–991.
- Dawid, A. P. (2000). Causal inference without counterfactuals. *Journal of the American statistical Association* 95(450), 407–424.
- Deeks, J. (2002, June). Issues in the selection of a summary statistic in meta-analysis of clinical trials with binary outcomes. *Statistics in Medicine* 21(11), 1575–1600.
- Degtiar, I. and S. Rose (2023). A review of generalizability and transportability. *Annual Review of Statistics and Its Application* 10, 501–524.
- Didelez, V. and M. J. Stensrud (2022). On the logic of collapsibility for causal effect measures. *Biometrical Journal* 64(2), 235–242.
- Ding, Y., H.-M. Lin, and J. C. Hsu (2016). Subgroup mixable inference on treatment efficacy in mixture populations, with an application to time-to-event outcomes. *Statistics in medicine* 35(10), 1580–1594.
- Doi, S., L. Furuya-Kanamori, C. Xu, L. Lin, T. Chivese, and L. Thalib (2020, 11). Questionable utility of the relative risk in clinical research: A call for change to practice. *Journal of Clinical Epidemiology*.

- Doi, S. A., L. Furuya-Kanamori, C. Xu, T. Chivese, L. Lin, O. A. Musa, G. Hindy, L. Thalib, and F. E. Harrell Jr (2022). The odds ratio is “portable” across baseline risk but not the relative risk: Time to do away with the log link in binomial regression. *Journal of Clinical Epidemiology* 142, 288–293.
- Doi, S. A., L. Furuya-Kanamori, C. Xu, L. Lin, T. Chivese, and L. Thalib (2022). Controversy and debate: Questionable utility of the relative risk in clinical research: Paper 1: A call for change to practice. *Journal of Clinical Epidemiology* 142, 271–279.
- Edvinsson, L. (2021). Oral rimegepant for migraine prevention. *The Lancet* 397(10268), 4–5.
- Feng, C., B. Wang, and W. Hongyue (2019, 07). The relations among three popular indices of risks. *Statistics in Medicine* 38.
- Forrow, L., W. C. Taylor, and R. M. Arnold (1992). Absolutely relative: How research results are summarized can affect treatment decisions. *The American Journal of Medicine* 92(2), 121–124.
- Gao, Z. and T. Hastie (2021). Estimating heterogeneous treatment effects for general responses.
- Gatsonis, C. and M. C. Sally (2017). *Methods in Comparative Effectiveness Research*, pp. 177–199. Chapman & Hall.
- George, A., T. S. Stead, and L. Ganti (2020). What’s the risk: Differentiating risk ratios, odds ratios, and hazard ratios? *Cureus* 12.
- Greenland, S. (1987, 05). Interpretation and choice of effect measures in epidemiologic analyses. *American Journal of Epidemiology* 125(5), 761–768.
- Greenland, S. and J. Pearl (2011, 12). Adjustments and their consequences—collapsibility analysis using graphical models. *International Statistical Review / Revue Internationale de Statistique* 79.
- Greenland, S., J. M. Robbins, and J. Pearl (1999, 01). Confounding and collapsibility in causal inference. *Statistical Science* 14, 29–46.
- Guyatt, G., D. Rennie, M. O. Meade, and D. J. Cook (2015). *Users’ Guides to the Medical Literature : A Manual for Evidence-Based Clinical Practice*. New York: McGraw-Hill Education.
- Hernàn, M., D. Clayton, and N. Keiding (2011, 03). The simpson’s paradox unraveled. *International journal of epidemiology* 40, 780–5.
- Hernàn, M. and J. Robins (2020). *Causal Inference: What If*.
- Hines, O., K. Diaz-Ordaz, and S. Vansteelandt (2022). Variable importance measures for heterogeneous causal effects. *arXiv preprint arXiv:2204.06030*.
- Huitfeldt, A. (2019). Effect heterogeneity and external validity in medicine. *Available in: <https://www.lesswrong.com/posts/wwbrvumMWhDfeo652>*.
- Huitfeldt, A., M. P. Fox, E. J. Murray, A. Hróbjartsson, and R. M. Daniel (2021). Shall we count the living or the dead? *arXiv preprint arXiv:2106.06316*.

- Huitfeldt, A., A. Goldstein, and S. A. Swanson (2018). The choice of effect measure for binary outcomes: Introducing counterfactual outcome state transition parameters. *Epidemiologic methods* 7(1).
- Huitfeldt, A., M. Stensrud, and E. Suzuki (2019, 01). On the collapsibility of measures of effect in the counterfactual causal framework. *Emerging Themes in Epidemiology* 16.
- Huitfeldt, A. and M. J. Stensrud (2018). Re: generalizing study results: a potential outcomes perspective. *Epidemiology* 29(2), e13–e14.
- Huitfeldt, A., S. Swanson, M. Stensrud, and E. Suzuki (2019, 12). Effect heterogeneity and variable selection for standardizing causal effects to a target population. *European Journal of Epidemiology* 34.
- Imai, K., G. King, and E. A. Stuart (2008). Misunderstandings between experimentalists and observationalists about causal inference. *Journal of the royal statistical society: series A (statistics in society)* 171(2), 481–502.
- Imbens, G. W. (2011). Experimental design for unit and cluster randomid trials. *International Initiative for Impact Evaluation Paper*.
- Imbens, G. W. and D. B. Rubin (2015). *Causal Inference in Statistics, Social, and Biomedical Sciences*. Cambridge UK: Cambridge University Press.
- Jiménez, F. J., E. Guallar, and J. M. Martin-Moreno (1997). A graphical display useful for meta-analysis. *European Journal of Public Health* 7, 101–105.
- Kern, H. L., E. A. Stuart, J. Hill, and D. P. Green (2016). Assessing methods for generalizing experimental impact estimates to target populations. *Journal of research on educational effectiveness* 9(1), 103–127.
- King, G. and L. Zeng (2002). Estimating risk and rate levels, ratios and differences in case-control studies. *Statistics in medicine* 21(10), 1409–1427.
- King, N. B., S. Harper, and M. E. Young (2012). Use of relative and absolute effect measures in reporting health inequalities: structured review. *Bmj* 345.
- L’abbé, K. A., A. S. Detsky, and K. O’rourke (1987). Meta-analysis in clinical research. *Annals of internal medicine* 107 2, 224–33.
- Lapointe-Shaw, L., G. Babe, P. C. Austin, A. P. Costa, and A. Jones (2022, Nov.). Reporting risk: from math to meaning. *Canadian Journal of General Internal Medicine* 17(4), 59–66.
- Laupacis, A., D. L. Sackett, and R. S. Roberts (1988). An assessment of clinically useful measures of the consequences of treatment. *New England Journal of Medicine* 318(26), 1728–1733. PMID: 3374545.
- Lesko, C. R., A. L. Buchanan, D. Westreich, J. K. Edwards, M. G. Hudgens, and S. R. Cole (2017). Generalizing study results: a potential outcomes perspective. *Epidemiology (Cambridge, Mass.)* 28(4), 553.
- Lesko, C. R., N. C. Henderson, and R. Varadhan (2018). Considerations when assessing heterogeneity of treatment effect in patient-centered outcomes research. *Journal of clinical epidemiology* 100, 22–31.

- Liu, Y., B. Wang, H. Tian, and J. C. Hsu (2022). Rejoinder for discussions on correct and logical causal inference for binary and time-to-event outcomes in randomized controlled trials. *Biometrical Journal* 64(2), 246–255.
- Liu, Y., B. Wang, M. Yang, J. Hui, H. Xu, S. Kil, and J. C. Hsu (2022). Correct and logical causal inference for binary and time-to-event outcomes in randomized controlled trials. *Biometrical Journal* 64(2), 198–224.
- MacMahon, S., R. Peto, R. Collins, J. Godwin, J. Cutler, P. Sorlie, R. Abbott, J. Neaton, A. Dyer, and J. Stamler (1990). Blood pressure, stroke, and coronary heart disease: part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. *The Lancet* 335(8692), 765–774.
- Miettinen, O. S. (1972). Standardization of risk ratios. *American Journal of Epidemiology* 96(6), 383–388.
- Miettinen, O. S. and E. F. Cook (1981, 10). Counfounding: Essence and Detection. *American Journal of Epidemiology* 114(4), 593–603.
- Mills, A. (1999, 11). Clinical implications. Avoiding problems in clinical practice after the pill scare. *Human Reproduction Update* 5(6), 639–653.
- Miratrix, L. W., J. S. Sekhon, and B. Yu (2013). Adjusting treatment effect estimates by post-stratification in randomized experiments. *Journal of the Royal Statistical Society Series B* 75, 369–396.
- Moynihan, R., L. Bero, D. Ross-Degnan, D. Henry, K. Lee, J. Watkins, C. Mah, and S. B. Soumerai (2000). Coverage by the news media of the benefits and risks of medications. *New England journal of medicine* 342(22), 1645–1650.
- Naylor, C. D., E. Chen, and B. Strauss (1992). Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? *Annals of Internal Medicine* 117(11), 916–921.
- Neuhaus S, J. M. and N. P. Jewell (1993, 12). A geometric approach to assess bias due to omitted covariates in generalized linear models. *Biometrika* 80(4), 807–815.
- Nguyen, T., B. Ackerman, I. Schmid, S. Cole, and E. Stuart (2018, 12). Sensitivity analyses for effect modifiers not observed in the target population when generalizing treatment effects from a randomized controlled trial: Assumptions, models, effect scales, data scenarios, and implementation details. *PLOS ONE* 13, e0208795.
- Nie, X., G. Imbens, and S. Wager (2021). Covariate balancing sensitivity analysis for extrapolating randomized trials across locations. *arXiv preprint arXiv:2112.04723*.
- Nie, X. and S. Wager (2020, 09). Quasi-oracle estimation of heterogeneous treatment effects. *Biometrika* 108.
- Nuovo, J., J. Melnikow, and D. Chang (2002, 06). Reporting Number Needed to Treat and Absolute Risk Reduction in Randomized Controlled Trials. *JAMA* 287(21), 2813–2814.
- O’Muircheartaigh, C. and L. Hedges (2013, 11). Generalizing from unrepresentative experiments: A stratified propensity score approach. *Journal of the Royal Statistical Society: Series C (Applied Statistics)* 63.

- Pearl, J. (2000). *Causality: Models, Reasoning, and Inference*. Cambridge University Press.
- Pearl, J. (2015). Generalizing experimental findings. *Journal of Causal Inference* 3(2), 259–266.
- Pearl, J. and E. Bareinboim (2011). Transportability of causal and statistical relations: A formal approach. In *Proceedings of the Twenty-Fifth AAAI Conference on Artificial Intelligence, AAAI’11*, pp. 247–254. AAAI Press.
- Pearl, J. and E. Bareinboim (2014). External Validity: From Do-Calculus to Transportability Across Populations. *Statistical Science* 29(4), 579 – 595.
- Robinson, P. (1988). Root- n-consistent semiparametric regression. *Econometrica* 56(4), 931–54.
- Rothman, K. J. (2011). *Epidemiology: an introduction* (2 ed.). Oxford University Press.
- Rothman, K. J., J. E. Gallacher, and E. E. Hatch (2013, 08). Why representativeness should be avoided. *International Journal of Epidemiology* 42(4), 1012–1014.
- Rothman, K. J. and S. Greenland (2000). *Modern Epidemiology* (2 ed.). Lippincott Williams and Wilkins.
- Rothwell, P. M. (2005). External validity of randomised controlled trials: “to whom do the results of this trial apply?”. *The Lancet* 365, 82–93.
- Sackett, D. L., J. J. Deeks, and D. G. Altman (1996). Down with odds ratios! *Evidence Based Medicine* 1, 164 – 166.
- Schulz, K. F., D. G. Altman, D. Moher, and C. Group* (2010). Consort 2010 statement: updated guidelines for reporting parallel group randomized trials. *Annals of internal medicine* 152(11), 726–732.
- Schwartz, L. M., S. Woloshin, E. L. Dvorin, and H. G. Welch (2006, December). Ratio measures in leading medical journals: structured review of accessibility of underlying absolute risks. *BMJ (Clinical research ed.)* 333(7581), 1248.
- Sheps, M. C. (1958). Shall we count the living or the dead? *New England Journal of Medicine* 259(25), 1210–1214. PMID: 13622912.
- Simpson, E. H. (1951). The interpretation of interaction in contingency tables. *Journal of the Royal Statistical Society: Series B (Methodological)* 13(2), 238–241.
- Sjölander, A., E. Dahlqvist, and J. Zetterqvist (2016, May). A note on the noncollapsibility of rate differences and rate ratios. *Epidemiology (Cambridge, Mass.)* 27(3), 356—359.
- Spiegelman, D., P. Khudyakov, M. Wang, and T. Vanderweele (2017, 11). Evaluating public health interventions: 7. let the subject matter choose the effect measure: Ratio, difference, or something else entirely. *American journal of public health* 108, e1–e4.
- Spiegelman, D. and T. J. VanderWeele (2017). Evaluating public health interventions: 6. modeling ratios or differences? let the data tell us. *American Journal of Public Health* 107, 1087–1091.
- Splawa-Neyman, J., D. M. Dabrowska, and T. P. Speed (1990). On the Application of Probability Theory to Agricultural Experiments. Essay on Principles. Section 9. *Statistical Science* 5(4), 465 – 472.

- Stuart, E. A., S. R. Cole, C. P. Bradshaw, and P. J. Leaf (2011). The use of propensity scores to assess the generalizability of results from randomized trials. *Journal of the Royal Statistical Society: Series A (Statistics in Society)* 174, 369–386.
- Tipton, E. (2013). Improving generalizations from experiments using propensity score subclassification: Assumptions, properties, and contexts. *Journal of Educational and Behavioral Statistics* 38, 239–266.
- Turrini, M. and C. Bourgain (2021, August). Appraising screening, making risk in/visible. The medical debate over Non-Rare Thrombophilia (NRT) testing before prescribing the pill. *Sociology of Health and Illness* 43(7), 1627–1642.
- Vandenbroucke, J., T. Koster, F. Rosendaal, E. Briët, P. Reitsma, and R. Bertina (1994). Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor v leiden mutation. *The Lancet* 344(8935), 1453–1457. Originally published as Volume 2, Issue 8935.
- VanderWeele, T. J. and J. M. Robins (2007, September). Four types of effect modification: a classification based on directed acyclic graphs. *Epidemiology (Cambridge, Mass.)* 18(5), 561—568.
- Wager, S. and S. Athey (2018). Estimation and inference of heterogeneous treatment effects using random forests. *Journal of the American Statistical Association* 113(523), 1228–1242.
- Whittemore, A. S. (1978). Collapsibility of multidimensional contingency tables. *Journal of the Royal Statistical Society. Series B (Methodological)* 40(3), 328–340.
- Xiao, M., Y. Chen, S. Cole, R. MacLehose, D. Richardson, and H. Chu (2022). Is or “portable” in meta-analysis? time to consider bivariate generalized linear mixed model. *Journal of clinical epidemiology* 142, 280.
- Xiao, M., H. Chu, S. Cole, Y. Chen, R. MacLehose, D. Richardson, and S. Greenland (2021). Odds ratios are far from “portable”: A call to use realistic models for effect variation in meta-analysis.
- Yadlowsky, S., F. Pellegrini, F. Lionetto, S. Braune, and L. Tian (2021). Estimation and validation of ratio-based conditional average treatment effects using observational data. *Journal of the American Statistical Association* 116(533), 335–352.
- Yule, G. U. (1934). On some points relating to vital statistics, more especially statistics of occupational mortality. *Journal of the Royal Statistical Society* 97(1), 1–84.

Appendix

A Treatment effect measures

This section completes Section 2 (and more specially Section 2.2) by exposing the different treatment (or causal) effect measures.

A.1 About the definition of causal measures

Recall that all causal measures used in this paper or present in applied medical work can be defined as follows.

Definition 8 (Causal effect measures – Pearl (2000)). *Assuming a certain joint distribution of potential outcomes $P(Y^{(0)}, Y^{(1)})$, which implies that a certain treatment A of interest is considered, we denote by τ^P any functional of the joint distribution of potential outcomes. More precisely,*

$$\mathcal{P} \rightarrow \mathbb{R} \tag{35}$$

$$P(Y^{(0)}, Y^{(1)}) \mapsto \tau^P \tag{36}$$

This definition is also valid for any subpopulation, as for any covariate X , $\tau^P(X)$ is defined as a functional of $P(Y^{(0)}, Y^{(1)} | X)$. This definition is the one used in this article.

Why do we say that those measures are causal? Note that the same definition could have been made on the distribution $P(A, Y)$, comparing expectation on two distributions: $P(Y | A = 1)$ and $P(Y | A = 0)$. For example, within the statistical community, the odds ratio is often known as the strength of the association between two events, $A = 1$ and $A = 0$ and therefore defined as:

$$OR := \frac{P(Y = 1 | A = 1)}{P(Y = 0 | A = 1)} \cdot \frac{P(Y = 0 | A = 0)}{P(Y = 1 | A = 0)}.$$

In such a situation, the OR measure would be an associational measure and not a causal measure, except if there is no confounding in the distribution considered (for e.g. in the case of a Randomized Controlled Trial). To avoid discussion about confounding, in this paper we never consider distribution such as $Y | A, X$ or $Y | A$. We rather consider $Y^{(a)} | X$. For any new reader discovering the potential outcomes framework, we refer to the first chapters of Imbens and Rubin (2015) for a clear and complete exposition of this notations inherited from Neyman. Note that Didelez and Stensrud (2022) make the same distinction when discussing collapsibility questions.


A.2 Common treatment effect measures

As highlighted by Definition 1, many measures could be proposed. Here we detail common measures found in applied works and propose an illustration for the case of binary outcomes (Figure 7). Most of the time, the distinction is made on whether or not the measure is an absolute or a relative effect.


A.2.1 Absolute measures

Definition 9 (Risk Difference (RD)). *The risk difference is a causal effect measure defined as the difference of the expectations (also called risks),*


$$\tau_{RD} = \mathbb{E}[Y^{(1)}] - \mathbb{E}[Y^{(0)}].$$




(a) Risk Difference (RD)




(b) Number Needed to Treat (NNT)




(c) Risk Ratio (RR)



(d) Survival Ratio (SR)




(e) Odds Ratio (OR)



(f) Log Odds Ratio (log-OR)

Figure 7: Plots of the ranges of the different metrics as a function of the proportion of events in control group, namely $\mathbb{E}[Y^{(0)}]$ (x-axis), and of the proportion of events in treated group, namely $\mathbb{E}[Y^{(1)}]$ (y-axis). See Subfigure 8a. As both the colors and the different scale illustrate, the ranges of the effect considerably differ with the metric chosen. Similar plots can be found under the name "L'Abbé plots" (L'abbé et al., 1987; Jiménez et al., 1997; Deeks, 2002) in research works related to meta-analysis.



(a) Legend

RD is also named Absolute Risk Reduction (ARR), Absolute Effect (AE), Absolute Difference (AD), or Excess Risk (ER).

Definition 10 (Number Needed to Treat (NNT)). *The number needed to treat (NNT) is a causal effect measure defined as the average number of individuals or observations who need to be treated to prevent one additional outcome,*

$$\tau_{NNT} = \frac{1}{\mathbb{E}[Y^{(1)} = 1] - \mathbb{E}[Y^{(0)} = 1]}$$

The Number Needed to Treat (NNT) has been proposed as a measure rather recently ([Laupacis et al., 1988](#)). A harmful treatment is usually called the Number Needed to Harm (NNH) and made positive.

A.2.2 Relative measures

Definition 11 (Risk Ratio). *The Risk Ratio is a causal effect measure defined as the ratio of the expectations,*

$$\tau_{RR} = \frac{\mathbb{E}[Y^{(1)}]}{\mathbb{E}[Y^{(0)}]}$$

The Risk Ratio (RR) is also named Relative Risk (RR), Relative Response (RR), or Incidence Proportion Ratio (IPR)

Definition 12 (Survival Ratio). *The survival ratio is a causal effect measure defined as the Risk Ratio were labels are swapped,*

$$\tau_{SR} = \frac{1 - \mathbb{E}[Y^{(1)}]}{1 - \mathbb{E}[Y^{(0)}]}$$

It is possible to introduce a measure that captures both the Risk Difference, but normalized by the baseline.

Definition 13 (Excess relative risk (ERR)).

$$\tau_{ERR} = \frac{\mathbb{E}[Y^{(1)}] - \mathbb{E}[Y^{(0)}]}{\mathbb{E}[Y^{(0)}]}$$

The Excess relative risk (ERR) has been proposed by [Cole and MacMahon \(1971\)](#). Note that,

$$\tau_{ERR} = \tau_{RR} - 1.$$

Definition 14 (Relative Susceptibility (RS)).

$$\tau_{RS} := \frac{\mathbb{E}[Y^{(1)}] - \mathbb{E}[Y^{(0)}]}{1 - \mathbb{E}[Y^{(0)}]}.$$

Note that,

$$\tau_{RS} = 1 - \tau_{SR}.$$

Finally, another measure is often used based on odds. Odds are a way of representing probability in particular for betting. For example a throw with a die will produce a one with odds 1:5. The odds is the ratio of the probability that the event occurs to the probability it does not.

Definition 15 (Odds Ratio (OR)). *The odds ratio is a causal effect measure defined as the ratio of the odds of the treated and control groups,*

$$\tau_{OR} := \frac{\mathbb{P}[Y^{(1)} = 1]}{1 - \mathbb{P}[Y^{(1)} = 1]} \left(\frac{\mathbb{P}[Y^{(0)} = 1]}{1 - \mathbb{P}[Y^{(0)} = 1]} \right)^{-1}.$$

Odds Ratio (OR) is sometimes named Marginal Causal Odds Ratio (MCOR). This is by opposition to a conditional Odds Ratio, being defined as,

$$\tau_{OR}(X) := \frac{\mathbb{E}[Y^{(1)} = 1 \mid X = x]}{1 - \mathbb{E}[Y^{(1)} = 1 \mid X = x]} \left(\frac{\mathbb{E}[Y^{(0)} = 1 \mid X = x]}{1 - \mathbb{E}[Y^{(0)} = 1 \mid X = x]} \right)^{-1},$$

often used due to its homogeneity when considering a logistic generative model of the outcome (see Section C.1.3 for a detailed proof). The OR is known to approximate the RR at low baseline (see for example the illustrative example of Table 1).

Proof. $\mathbb{P}[Y^{(1)} = 1] \leq \mathbb{P}[Y^{(0)} = 1] \ll 1 \implies \tau_{OR} = \frac{\mathbb{P}[Y^{(1)}=1]}{1-\mathbb{P}[Y^{(1)}=1]} \cdot \frac{1-\mathbb{P}[Y^{(0)}=1]}{\mathbb{P}[Y^{(0)}=1]} \approx \frac{\mathbb{P}[Y^{(1)}=1]}{1} \cdot \frac{1}{\mathbb{P}[Y^{(0)}=1]} = \tau_{RR}$. \square

These derivations can be found as late as in the 50's in case-control studies about lung cancer (Cornfield et al., 1951). Also note that,

$$\tau_{OR} = \tau_{RR} \cdot \tau_{SR}^{-1}.$$

Proof.

$$\begin{aligned} \tau_{OR} &= \frac{\mathbb{P}[Y^{(1)} = 1]}{1 - \mathbb{P}[Y^{(1)} = 1]} \left(\frac{\mathbb{P}[Y^{(0)} = 1]}{1 - \mathbb{P}[Y^{(0)} = 1]} \right)^{-1} \\ &= \frac{\mathbb{P}[Y^{(1)} = 1]}{\mathbb{P}[Y^{(1)} = 0]} \left(\frac{\mathbb{P}[Y^{(0)} = 1]}{\mathbb{P}[Y^{(0)} = 0]} \right)^{-1} \\ &= \frac{\mathbb{P}[Y^{(1)} = 1]}{\mathbb{P}[Y^{(1)} = 0]} \frac{\mathbb{P}[Y^{(0)} = 0]}{\mathbb{P}[Y^{(0)} = 1]} \\ &= \frac{\mathbb{P}[Y^{(1)} = 1]}{\mathbb{P}[Y^{(0)} = 1]} \frac{\mathbb{P}[Y^{(0)} = 0]}{\mathbb{P}[Y^{(1)} = 0]} \\ &= \tau_{RR} \cdot \tau_{SR}^{-1} \end{aligned}$$

\square

One can observe on Figure 7 (see subplots Figures 7e and 7f) the range on which the OR varies depends on the direction of the effect. Therefore, the OR is often presented encapsulated in a logarithm.

Definition 16 (Log Odds Ratio (log-OR)).

$$\tau_{log-OR} := \log \left(\frac{\mathbb{P}[Y^{(1)} = 1]}{\mathbb{P}[Y^{(1)} = 0]} \right) - \log \left(\frac{\mathbb{P}[Y^{(0)} = 1]}{\mathbb{P}[Y^{(0)} = 0]} \right)$$

B Definitions found in the literature

This section completes Section 3 with formalization of homogeneity of effects, heterogeneity of effects, and collapsibility we have found in the literature. Doing so, we highlight that definitions can be more or less formal, and therefore can lead to different apprehension of phenomenons, in particular collapsibility.

B.1 Effect modification

This section supports definitions proposed in Section 3.1.

Note that effect modification or heterogeneity is mentioned in many places, but not always clearly defined. This is highlighted by the following quote:

We searched the National Library of Medicine Books, National Library of Medicine Catalog, Current Index to Statistics database, ISI web of science, and websites of 25 major regulatory agencies and organizations for papers and guidelines on study design, analysis and interpretation of treatment effect heterogeneity. Because there is not standard terminology for this topic, a structured search strategy was not sensitive nor specific and we found many resources through “snowball” searching, that is, reviewing citations in, and citations of, key methodological and policy papers. – (Lesko et al., 2018)

B.1.1 Definitions of heterogeneity of effect or effect modification found in the literature

Definition 17 (Rothman (2011), page 51). *Suppose we divide our cohort into two or more distinct categories, or strata. In each stratum, we can construct an effect measure of our choosing. These stratum-specific effect measures may or may not equal one another. Rarely would we have any reason to suppose that they do equal one another. If indeed they are not equal, we say that the effect measure is heterogeneous or modified across strata. If they are equal we say that the measure is homogeneous, constant, or uniform across strata. A major point about effect-measure modification is that, if effects are present, it will usually be the case that only one or none of the effect measures will be uniform across strata.*

Definition 18 (VanderWeele and Robins (2007)). *We say that a variable Q is a treatment effect modifier for the causal risk difference of A on Y if Q is not affected by A and if there exist two levels of A , a_0 and a_1 , such that $\mathbb{E}[Y^{(a_1)} | Q = q] - \mathbb{E}[Y^{(a_0)} | Q = q]$ is not constant in q .*

B.1.2 Effect heterogeneity depends on the chosen scale: an illustration

A treatment effect heterogeneity depends on the causal measure τ chosen (the scale). This idea is well-known in epidemiology (Rothman, 2011; Lesko et al., 2018). To be convinced by such phenomenon, the drawing in Figure 9 illustrates what could be two data generative models leading to two different homogeneity and heterogeneity patterns.




Figure 9: Heterogeneity of a treatment effect depends on the scale: Illustrative schematics where the data generative model on the left leads to a constant treatment effect on the absolute scale (RD) when conditioning on X , while on the data generative model on the right leads to an homogeneous treatment effect on the relative scale (RR). In both of the situations, homogeneity of treatment effect of one scale (RR or RD) leads to heterogeneity on the other scale. Note that a similar schematic is presented in Rothman (2011) (see their Figure 11–1, p. 199)

B.2 Different definitions of collapsibility in the literature

This section supports definitions proposed in Section 3.2.

B.2.1 Unformal definitions

We have found many unformal definitions in the literature, such as:

In a single study with a non-confounding stratification variable, if the stratum-specific effects are homogenous, then they are expected to be the same as the crude effect, a desirable property known as collapsibility of an effect measure. – (Xiao et al., 2022)

RR but, not OR, have a mathematical property called collapsibility; this means the size of the Risk Ratio will not change if adjustment is made for a variable that is not a confounder. – (Cummings, 2009)

and

Collapsibility means that in the absence of confounding, a weighted average of stratum-specific ratios (e.g., using Mantel-Haenszel methods) will equal the ratio from a single 2 by 2 table of the pooled (collapsed) counts from the stratum-specific tables. This means that a crude (unadjusted) ratio will not change if we adjust for a variable that is not a confounder. – (Cummings, 2009)

B.2.2 Formal definitions

Definition 19 (Strict collapsibility Greenland et al. (1999)). *We say a measure of association between $Y^{(0)}$ and $Y^{(1)}$ is strictly collapsible accross X if it is constant accross the strata (subtables) and this constant value equals the value obtained from the marginal table.*

Similar definition as Definition 19 have been proposed in Liu et al. (2022); Didelez and Stensrud (2022).

Definition 20 (Pearl (2000)). Let $\tau (P (Y^{(0)}, Y^{(1)}))$ be any functional that measures the association between $Y^{(0)}$ and $Y^{(1)}$ in the joint distribution $P (Y^{(0)}, Y^{(1)})$. We say that τ is collapsible on a variable V if

$$\mathbb{E} [\tau (P (Y^{(0)}, Y^{(1)} | V))] = \tau (P (Y^{(0)}, Y^{(1)}))$$

Note that in his book, Judea Pearl rather present the definition of collapsibility with respect two any two covariates, not necessarily potential outcomes. Indeed, collapsibility is a statistical concept at first. As in this work we are explicitly concerned with causal metrics, this definition has been written here with potential outcomes.

Definition 21 (Huitfeldt et al. (2019)). Let $\tau (P (Y^{(0)}, Y^{(1)}))$ be any function of the parameters $Y^{(0)}$ and $Y^{(1)}$ in the joint distribution $P (Y^{(0)}, Y^{(1)})$. We say that τ is collapsible on a variable V with weights w_v if,

$$\frac{\sum_v w_v \tau (P (Y^{(0)}, Y^{(1)} | V = v))}{\sum_v w_v} = \tau (P (Y^{(0)}, Y^{(1)}))$$

Definition 22 (Didelez and Stensrud (2022)). Let $\tau = \tau (P (Y^{(0)}, Y^{(1)}))$ be a measure of association between $Y^{(0)}$ and $Y^{(1)}$; that is, τ is a functional of the joint distribution $P (Y^{(0)}, Y^{(1)})$. Let $\tau_x = \tau (Y, A | X = x)$ be a measure of conditional association between Y and A given $X = x$; that is, τ_x is a functional of the conditional distribution $P (Y, A | X = x)$. The measure τ is called collapsible over X , if τ is a weighted average of τ_x for $x \in \mathbb{X}$. Strict collapsibility demands that $\tau = \tau_x$.

C Proofs

In this section we detail all the derivations needed to understand the results of this article.

C.1 Collapsibility

Note that not all proofs are novel work. Collapsibility results have been reported multiple times and in multiple ways as explained in the main paper. For clarity we still recall them. We indicate when the proofs are not novel or when similar proofs exist elsewhere. When we indicate nothing, this means that we have not found those results in other published work.

C.1.1 Proof of Lemma 1

N.B: The proof for the direct collapsibility of the RD is not a novel contribution.

Proof.

$$\begin{aligned} \tau_{\text{RD}}^P &= \mathbb{E} [Y^{(1)} - Y^{(0)}] && \text{By definition} \\ &= \mathbb{E} [\mathbb{E} [Y^{(1)} - Y^{(0)} | X]] && \text{Law of total expectation} \\ &= \mathbb{E} [\tau_{\text{RD}}^P (X)]. \end{aligned}$$

□

Remark To observe the phenomenon as weighting, one can also write this last quantity as an integral.

$$\begin{aligned}\mathbb{E} [\mathbb{E} [Y^{(1)} - Y^{(0)} | X]] &= \int_{\mathbf{X}} \mathbb{E} [Y^{(1)} - Y^{(0)} | X] f(x) dx && \text{Re-writing} \\ &= \int_{\mathbf{X}} \tau_{\text{RD}}^P(x) f(x) dx.\end{aligned}$$

Here, one can observe that weights are the density of x in the population. Most of the time (Pearl and Bareinboim, 2011; Huitfeldt et al., 2018; Didelez and Stensrud, 2022) express such quantity on categorical covariates X , therefore using a sum.

C.1.2 Proof of Lemma 2

N.B: The proof for the collapsibility of the RR and SR are extensions of Huitfeldt et al. (2019).

General comment In this subsection we detail the proof for collapsibility of the RR, and SR. Before detailing the proof, we want to highlight why the RR (and SR) is not directly collapsible.

$$\begin{aligned}\tau_{\text{RR}}^P &= \frac{\mathbb{E} [Y^{(1)}]}{\mathbb{E} [Y^{(0)}]} \\ &= \frac{\mathbb{E} [\mathbb{E} [Y^{(1)} | X]]}{\mathbb{E} [\mathbb{E} [Y^{(0)} | X]]} \\ &\neq \mathbb{E} \left[\frac{\mathbb{E} [Y^{(1)} | X]}{\mathbb{E} [Y^{(0)} | X]} \right],\end{aligned}$$

in all generality. For example, assuming that $\mathbb{E} [Y^{(0)} | X]$ and $\mathbb{E} [Y^{(1)} | X]$ are independent, we have

$$\mathbb{E} \left[\frac{\mathbb{E} [Y^{(1)} | X]}{\mathbb{E} [Y^{(0)} | X]} \right] = \mathbb{E}[Y^{(1)}] \mathbb{E} \left[\frac{1}{\mathbb{E} [Y^{(0)} | X]} \right] > \frac{\mathbb{E}[Y^{(1)}]}{\mathbb{E}[Y^{(0)}]} = \tau_{\text{RR}}^P,$$

by Jensen inequality, assuming additionally that $\mathbb{E} [Y^{(0)} | X] > 0$.

Risk Ratio (RR)

Proof.

$$\begin{aligned}\tau_{\text{RR}}^P &= \frac{\mathbb{E} [Y^{(1)}]}{\mathbb{E} [Y^{(0)}]} && \text{By definition of the RR} \\ &= \frac{\mathbb{E} [\mathbb{E} [Y^{(1)} | X]]}{\mathbb{E} [Y^{(0)}]} && \text{Law of total expectation used on } \mathbb{E} [Y^{(1)}] \\ &= \frac{\mathbb{E} \left[\frac{\mathbb{E} [Y^{(1)} | X]}{\mathbb{E} [Y^{(0)} | X]} \mathbb{E} [Y^{(0)} | X] \right]}{\mathbb{E} [Y^{(0)}]} && \mathbb{E} [Y^{(0)} | X] \neq 0 \text{ almost surely} \\ &= \mathbb{E} \left[\frac{\mathbb{E} [Y^{(1)} | X] \mathbb{E} [Y^{(0)} | X]}{\mathbb{E} [Y^{(0)} | X] \mathbb{E} [Y^{(0)}]} \right] && \mathbb{E} [Y^{(0)}] \text{ is a constant} \\ &= \mathbb{E} \left[\tau_{\text{RR}}^P(X) \frac{\mathbb{E} [Y^{(0)} | X]}{\mathbb{E} [Y^{(0)}]} \right]. && \frac{\mathbb{E} [Y^{(1)} | X]}{\mathbb{E} [Y^{(0)} | X]} := \tau_{\text{RR}}^P(X)\end{aligned}$$

□

Survival Ratio (SR)

Proof.

$$\begin{aligned}
\tau_{\text{SR}}^P &= \frac{1 - \mathbb{E}[Y^{(1)}]}{1 - \mathbb{E}[Y^{(0)}]} && \text{By definition of the SR} \\
&= \frac{1 - \mathbb{E}[\mathbb{E}[Y^{(1)} | X]]}{1 - \mathbb{E}[Y^{(0)}]} && \text{Law of total expectation} \\
&= \frac{\mathbb{E}\left[\frac{1 - \mathbb{E}[Y^{(1)} | X]}{1 - \mathbb{E}[Y^{(0)} | X]} (1 - \mathbb{E}[Y^{(0)} | X])\right]}{1 - \mathbb{E}[Y^{(0)}]} && 1 - \mathbb{E}[Y^{(0)} | X] \neq 0 \text{ almost surely} \\
&= \mathbb{E}\left[\tau_{\text{SR}}^P(X) \frac{1 - \mathbb{E}[Y^{(0)} | X]}{1 - \mathbb{E}[Y^{(0)}]}\right] && 1 - \mathbb{E}[Y^{(0)}] \text{ is a constant}
\end{aligned}$$

□

The Excess Risk Ratio (ERR) (resp. Risk Susceptibility) collapsibility are proven using the same derivations than RR (resp. SR).

Excess Risk Ratio (ERR)

Proof.

$$\begin{aligned}
\tau_{\text{ERR}}^P &= \frac{\mathbb{E}[Y^{(1)} - Y^{(0)}]}{\mathbb{E}[Y^{(0)}]} \\
&= \frac{\mathbb{E}[\mathbb{E}[Y^{(1)} - Y^{(0)} | X]]}{\mathbb{E}[Y^{(0)}]} \\
&= \mathbb{E}\left[\frac{\mathbb{E}[Y^{(1)} - Y^{(0)} | X]}{\mathbb{E}[Y^{(0)}]}\right] \\
&= \mathbb{E}\left[\frac{\mathbb{E}[Y^{(1)} - Y^{(0)} | X]}{\mathbb{E}[Y^{(0)}]} \frac{\mathbb{E}[Y^{(0)} | X]}{\mathbb{E}[Y^{(0)} | X]}\right] \\
&= \mathbb{E}\left[\tau_{\text{ERR}}^P(X) \frac{\mathbb{E}[Y^{(0)} | X]}{\mathbb{E}[Y^{(0)}]}\right]
\end{aligned}$$

□

Risk Susceptibility (RS)

Proof.

$$\begin{aligned}
\tau_{\text{RS}}^P &= \frac{\mathbb{E}[Y^{(1)} - Y^{(0)}]}{1 - \mathbb{E}[Y^{(0)}]} \\
&= \frac{\mathbb{E}[\mathbb{E}[Y^{(1)} - Y^{(0)} | X]]}{1 - \mathbb{E}[Y^{(0)}]} \\
&= \mathbb{E}\left[\frac{\mathbb{E}[Y^{(1)} - Y^{(0)} | X]}{1 - \mathbb{E}[Y^{(0)}]}\right] \\
&= \mathbb{E}\left[\frac{\mathbb{E}[Y^{(1)} - Y^{(0)} | X]}{1 - \mathbb{E}[Y^{(0)}]} \frac{1 - \mathbb{E}[Y^{(0)} | X]}{1 - \mathbb{E}[Y^{(0)} | X]}\right] \\
&= \mathbb{E}\left[\tau_{\text{RS}}^P(X) \frac{1 - \mathbb{E}[Y^{(0)} | X]}{1 - \mathbb{E}[Y^{(0)}]}\right]
\end{aligned}$$

□

C.1.3 Proof of Lemma 3: Non-collapsibility of the OR, log-OR, and NNT

Odds Ratio (OR). According to the first point of Lemma 4, all collapsible measure are logic-respecting. However, according to the third point of Lemma 4, OR is not logic-respecting. Therefore OR is not collapsible.

Log Odds Ratio (log-OR). The same reasoning as above holds for the log Odds Ratio.

Number Needed to Treat (NNT).

Proof. Recall that

$$\tau_{\text{NNT}}^P = \frac{1}{\mathbb{E}[Y^{(1)}] - \mathbb{E}[Y^{(0)}]} \quad \text{and} \quad \tau_{\text{NNT}}^P(X) = \frac{1}{\mathbb{E}[Y^{(1)}|X] - \mathbb{E}[Y^{(0)}|X]}. \quad (37)$$

Assume that the NNT causal measure is collapsible, that is there exist weights $w(X, P(X, Y^{(0)}))$ such that for all distributions $P(X, Y^{(0)}, Y^{(1)})$ we have

$$\mathbb{E} [w(X, P(X, Y^{(0)})) \tau_{\text{NNT}}^P(X)] = \tau_{\text{NNT}}^P, \quad \text{with } w \geq 0, \text{ and } \mathbb{E} [w(X, P(X, Y^{(0)}))] = 1. \quad (38)$$

Note that

$$\tau_{\text{NNT}}^P = \frac{1}{\mathbb{E} \left[\frac{1}{\tau_{\text{NNT}}^P(X)} \right]}, \quad (39)$$

which, combined with the previous equation, leads to

$$\mathbb{E} [w(X, P(X, Y^{(0)})) \tau_{\text{NNT}}^P(X)] = \frac{1}{\mathbb{E} \left[\frac{1}{\tau_{\text{NNT}}^P(X)} \right]}. \quad (40)$$

Assuming that $\tau_{\text{NNT}}^P(X) \geq 0$, by Jensen inequality, we have

$$\mathbb{E} [w(X, P(X, Y^{(0)})) \tau_{\text{NNT}}^P(X)] \leq \mathbb{E} [\tau_{\text{NNT}}^P(X)] \quad (41)$$

$$\mathbb{E} [(w(X, P(X, Y^{(0)})) - 1) \tau_{\text{NNT}}^P(X)] \leq 0. \quad (42)$$

Fix $\varepsilon > 0$. Assume now that there exists a measurable set $B \subset \mathcal{X}$ with positive measure, such that for all $x \in B$, $w(x, P(x, Y^{(0)})) > 1 + \varepsilon$. By choosing the distribution of $Y^{(1)}$ such that $\mathbb{E}[Y^{(1)}|X]$ is arbitrary close to $\mathbb{E}[Y^{(0)}|X]$ on B , one has that $\tau_{\text{NNT}}^P(X)$ is arbitrary large, so that $(w(X, P(X, Y^{(0)})) - 1) \tau_{\text{NNT}}^P(X)$ is arbitrary large on B , which contradicts eq. 42. This proves that $w(X, P(X, Y^{(0)})) \leq 1$ almost surely. Since $\mathbb{E}[w(X, P(X, Y^{(0)}))] = 1$, this implies that almost surely $w(X, P(X, Y^{(0)})) = 1$. Thus, one should have

$$\mathbb{E} [\tau_{\text{NNT}}^P(X)] = \frac{1}{\mathbb{E} \left[\frac{1}{\tau_{\text{NNT}}^P(X)} \right]}, \quad (43)$$

which, according to Jensen inequality, holds only if $\tau_{\text{NNT}}^P(X)$ is constant. Thus the Number Needed to Treat satisfies the collapsibility equation eq. 38 only in the specific case of homogeneous treatment effect.

This proves that the NNT is not collapsible.

□

C.2 Proof of Lemma 8

Lemma 8. Let τ_1 be any collapsible causal measure defined by Equation eq. 8, that is

$$\tau_1^P(x) = f(\mathbb{E}[Y^{(0)} | X = x], \mathbb{E}[Y^{(1)} | X = x]), \quad (44)$$

and

$$\tau_1^P = f(\mathbb{E}[Y^{(0)}], \mathbb{E}[Y^{(1)}]), \quad (45)$$

Consider τ_2 another causal measure, such that, there exists h satisfying

$$\tau_2^P(x) = h(\tau_1(x)) \text{ and } \tau_2 = h(\tau_1). \quad (46)$$

If h is bijective and monotonic, then τ_2 is logic-respecting.

Proof of Lemma 8. Since τ_1 is collapsible, we know that, for all distributions of $(X, Y^{(0)}, Y^{(1)})$,

$$\tau_1^P = \mathbb{E}[\tau_1^P(X)w(X, P(X, Y^{(0)}))]. \quad (47)$$

Since $\tau_2 = h(\tau_1)$, we obtain

$$\tau_2^P = h(\mathbb{E}[h^{-1}(\tau_2^P(X))w(X, P(X, Y^{(0)}))]). \quad (48)$$

Assume that h is increasing, then h^{-1} is increasing and

$$h^{-1}\left(\min_x \tau_2^P(x)\right) \leq h^{-1}(\tau_2^P(X)) \leq h^{-1}\left(\max_x \tau_2^P(x)\right), \quad (49)$$

which implies, since h is increasing,

$$\min_x \tau_2^P(x) \leq h(\mathbb{E}[h^{-1}(\tau_2^P(X))w(X, P(X, Y^{(0)}))]) \leq \max_x \tau_2^P(x), \quad (50)$$

and thus,

$$\min_x \tau_2^P(x) \leq \tau_2^P \leq \max_x \tau_2^P(x). \quad (51)$$

Consequently, the causal measure τ_2 is logic-respecting. The same reasoning holds for a decreasing function h . □

C.3 Proof of Lemma 4 (about logic-respecting measures)

C.3.1 All collapsible measures are logic respecting

Proof. We recall from Definition 5 that a measure τ is said to be collapsible (directly or not), if there exist positive weights $w(X, P(X, Y^{(0)}))$ verifying $\mathbb{E}[w(X, P(X, Y^{(0)}))] = 1$, such that

$$\tau^P = \mathbb{E}[w(X, P(X, Y^{(0)}))\tau^P(X)].$$

Then,

$$\begin{aligned} \tau^P &\leq \mathbb{E}\left[w(X, P(X, Y^{(0)})) \max_x (\tau^P(X))\right] \\ \tau^P &\leq \mathbb{E}\left[w(X, P(X, Y^{(0)}))\right] \max_x (\tau^P(x)) \\ \tau^P &\leq \max_x (\tau^P(x)) \end{aligned}$$

using the properties of the weights. Similarly, one can show that,

$$\mathbb{E}\left[w(X, P(X, Y^{(0)})) \min_x (\tau^P(x))\right] \leq \tau^P.$$

This proves that τ is logic-respecting, according to Definition 6. □

C.3.2 Number Needed to Treat is a logic-respecting measure

Proof. First, note that,

$$\begin{aligned}\tau_{\text{NNT}}^P &= \frac{1}{\mathbb{E}[Y^{(1)} - Y^{(0)}]} \\ &= \frac{1}{\mathbb{E}[\mathbb{E}[Y^{(1)} - Y^{(0)} \mid X]]} && \text{Law of total expectation} \\ &= \mathbb{E}\left[\frac{1}{\tau_{\text{NNT}}^P(X)}\right]^{-1}. && \tau_{\text{NNT}}^P(X) := 1/\mathbb{E}[Y^{(1)} - Y^{(0)} \mid X]\end{aligned}$$

By definition, $\min_x (\tau_{\text{NNT}}^P(x)) \leq \tau_{\text{NNT}}^P(X)$ almost surely, such that taking the inverse and the expectation leads to

$$\mathbb{E}\left[\frac{1}{\tau_{\text{NNT}}^P(X)}\right] \leq \mathbb{E}\left[\frac{1}{\min_x (\tau_{\text{NNT}}^P(x))}\right] = \frac{1}{\min_x (\tau_{\text{NNT}}^P(x))},$$

which implies

$$\min_x (\tau_{\text{NNT}}^P(x)) \leq \tau_{\text{NNT}}^P.$$

The exact same reasoning leads to

$$\tau_{\text{NNT}}^P \leq \max_x (\tau_{\text{NNT}}^P(x)).$$

Consequently,

$$\min_x (\tau_{\text{NNT}}^P(x)) \leq \tau_{\text{NNT}}^P \leq \max_x (\tau_{\text{NNT}}^P(x)),$$

which concludes the proof. \square

C.3.3 OR and log-OR are not logic-respecting

Proving that the OR is not logic-respecting can be done with a counter-example as in Table 2. Previous works propose to understand non-collapsibility through the non-linearity of a function linking the baseline (control) and response functions. This link function is named the *characteristic collapsibility function* (CCF) and have been proposed by [Neuhaus S and Jewell \(1993\)](#) and is nicely recalled in [Daniel et al. \(2020\)](#) (see their Appendix 1A). This proof relies on Jensen inequality. The proof we recall here is largely inspired from these works, but written within the formalism of our paper.

Proof. Assume a generative model such as

$$\text{logit}(\mathbb{P}(Y^{(a)} = 1 \mid X, A = a)) = b(X) + a m, \quad (52)$$

where $b(X)$ can be any function of the vector X to \mathbb{R} , and where m is a non-null constant. Without loss of generality, one can further assume that $m > 0$. Under such model, one has a property on the conditional log-OR or OR, being that:

$$\tau_{\text{log-OR}}^P(X) = \log\left(\frac{\mathbb{P}(Y^{(1)} = 1 \mid X)}{1 - \mathbb{P}(Y^{(1)} = 1 \mid X)} \cdot \left(\frac{\mathbb{P}(Y^{(0)} = 1 \mid X)}{1 - \mathbb{P}(Y^{(0)} = 1 \mid X)}\right)^{-1}\right) = b(X) + m - b(X) = m, \quad (53)$$

or similarly that

$$\tau_{\text{OR}}^P(X) = e^{b(X)+m} \cdot e^{-b(X)} = e^m.$$

In other words, for any x the OR $\tau_{\text{OR}}^P(x)$ (resp. log-OR) is the same and equal to e^m (resp. m).

Now, we propose to go from this conditional causal measure to the marginal measure. When looking for the marginal OR, one can first estimate $\mathbb{P}(Y^{(1)} = 1)$ and $\mathbb{P}(Y^{(0)} = 1)$, and then compute the OR. To do so, we propose to rewrite $\mathbb{P}(Y^{(1)} = 1 | X)$ as a function of $\mathbb{P}(Y^{(0)} = 1 | X)$. From eq. 52 one has,

$$\text{logit}(\mathbb{P}(Y^{(0)} = 1 | X)) = b(X),$$

so that

$$\text{logit}(\mathbb{P}(Y^{(1)} = 1 | X)) = \text{logit}(\mathbb{P}(Y^{(0)} = 1 | X)) + m, \quad (54)$$

which is equivalent to

$$\mathbb{P}(Y^{(1)} = 1 | X) = \text{expit}(\text{logit}(\mathbb{P}(Y^{(0)} = 1 | X)) + m). \quad (55)$$

Letting, for all $z \in [0, 1]$,

$$f(z) = \text{expit}(\text{logit}(z) + m), \quad (56)$$

we have

$$\mathbb{P}(Y^{(1)} = 1 | X) = f(\mathbb{P}(Y^{(0)} = 1 | X)). \quad (57)$$

Note that the function f is concave for positive m (it is possible to derive it, but we propose an illustration on Figure 10 to help to be convinced). Then, using Jensen inequality, we obtain,

$$\begin{aligned} \mathbb{P}(Y^{(1)} = 1) &= \mathbb{E}[\mathbb{P}(Y^{(1)} = 1 | X)] \\ &= \mathbb{E}[f(\mathbb{P}(Y^{(0)} = 1 | X))] \\ &< f(\mathbb{E}[\mathbb{P}(Y^{(0)} = 1 | X)]) \\ &= \text{expit}(\text{logit}(\mathbb{E}[\mathbb{P}(Y^{(0)} = 1 | X)]) + m) \quad \text{Jensen and } m > 0 \\ &= \text{expit}(\text{logit}(\mathbb{P}(Y^{(0)} = 1)) + m), \end{aligned}$$

and because the logit is a monotonous function, then,

$$\text{logit}(\mathbb{P}(Y^{(1)} = 1)) < \text{logit}(\mathbb{P}(Y^{(0)} = 1)) + m,$$

so that

$$\text{logit}(\mathbb{P}(Y^{(1)} = 1)) - \text{logit}(\mathbb{P}(Y^{(0)} = 1)) = \tau_{\text{log-OR}}^P < m,$$

where $m = \tau_{\text{log-OR}}^P(x)$ (see eq. 53). This allows to conclude that there exist a data generative process for which the odds ratio at the population level can not be written as a positively weighted sum of conditional odds ratio.

Note that the example provided in Table 2 is for a negative m , showing constant effect on the two substrata and a higher effect on the marginal population. \square




Figure 10: Implementation of the formulae from eq. 57 for different values of m . This illustrates the concavity of the function linking $\mathbb{P}(Y^{(0)} = 1 | X)$ to $\mathbb{P}(Y^{(1)} = 1 | X)$ when assuming the generative model of eq. 52.

C.4 Proofs related to generalizability

C.4.1 Proof of Proposition 1

Proof. Consider $a \in \{0, 1\}$, then

$$\begin{aligned}
 \mathbb{E}_T [Y^{(a)}] &= \mathbb{E}_T [\mathbb{E}_T [Y^{(a)} | X]] && \text{Total expectation} \\
 &= \mathbb{E}_T [\mathbb{E}_S [Y^{(a)} | X]] && \text{Transportability – Assumptions 3} \\
 &= \mathbb{E}_S \left[\frac{p_T(X)}{p_S(X)} \mathbb{E}_S [Y^{(a)} | X] \right] && \text{Overlap – Assumptions 2}
 \end{aligned}$$

□

The last step can also be written as follow:

$$\begin{aligned}
 \mathbb{E}_T [\mathbb{E}_S [Y^{(a)} | X]] &= \int \mathbb{E}_S [Y^{(a)} | X = x] p_T(x) dx && \text{By definition} \\
 &= \int \mathbb{E}_S [Y^{(a)} | X = x] p_T(x) \frac{p_S(x)}{p_S(x)} dx && \text{Assumption 2: } \frac{p_T(x)}{p_S(x)} \text{ is defined} \\
 &= \int \mathbb{E}_S [Y^{(a)} | X = x] p_S(x) \frac{p_T(x)}{p_S(x)} dx && \text{Re-arrangement} \\
 &= \mathbb{E}_S \left[\frac{p_T(X)}{p_S(X)} \mathbb{E}_S [Y^{(a)} | X] \right]
 \end{aligned}$$

C.4.2 Proof of Proposition 2

Proof. If τ is collapsible, then there exists weights $w(X, P_T(X, Y^{(0)}))$ such that

$$\begin{aligned}
 \tau^{P_T} &= \mathbb{E}_T [w(X, P_T(X, Y^{(0)})) \tau^{P_T}(X)] && \text{Collapsibility} \\
 &= \mathbb{E}_T [w(X, P_T(X, Y^{(0)})) \tau^{P_S}(X)] && \text{Transportability – Assumption 4} \\
 &= \mathbb{E}_S \left[\frac{p_T(X)}{p_S(X)} w(X, P_T(X, Y^{(0)})) \tau^{P_S}(X) \right] && \text{Overlap – Assumption 2.}
 \end{aligned}$$

□

C.5 Proofs related to non-parametric generative models (Section 4)

Proofs of Corollary 1 and 2 are straightforward and left to the reader.

C.5.1 Proof of Lemma 5

By assumption, throughout the paper, $\mathbb{E}[Y^{(0)}|X] < \infty$ and $\mathbb{E}[Y^{(1)}|X] < \infty$. Thus, one can set

$$b(X) = \mathbb{E}[Y^{(0)}|X], \quad \text{and} \quad m(X) = g_{b(X)}(\mathbb{E}[Y^{(1)}|X]). \quad (58)$$

Since, for all $b \in \mathbb{R}$, the function g_b is a bijection on its domain, we have

$$\mathbb{E}[Y^{(1)}|X] = g_{b(X)}^{-1}(m(X)). \quad (59)$$

With these notations,

$$\tau^P(X) = f(\mathbb{E}[Y^{(0)}|X], \mathbb{E}[Y^{(1)}|X]) \quad (60)$$

$$= g_{b(X)}(\mathbb{E}[Y^{(1)}|X]) \quad (61)$$

$$= m(X). \quad (62)$$

C.5.2 Proof of Theorem 1

Recall that the conditional causal measure τ can be written as

$$\tau^P(x) = f(\mathbb{E}[Y^{(0)}|X=x], \mathbb{E}[Y^{(1)}|X=x]), \quad (63)$$

if $(\mathbb{E}[Y^{(0)}|X=x], \mathbb{E}[Y^{(1)}|X=x]) \in D_f$. Besides, if $(\mathbb{E}[Y^{(0)}], \mathbb{E}[Y^{(1)}]) \in D_f$,

$$\tau^P = f(\mathbb{E}[Y^{(0)}], \mathbb{E}[Y^{(1)}]). \quad (64)$$

As the causal measure τ is assumed to be collapsible, there exist non-negative weights $w(X, P(X, Y^{(0)}))$ verifying, for all distribution $(X, Y^{(0)}, Y^{(1)})$, $\mathbb{E}[w(X, P(X, Y^{(0)}))] = 1$ and

$$\tau^P = \mathbb{E}[w(X, P(X, Y^{(0)}))\tau^P(X)]. \quad (65)$$

By assumption, for all distributions $P(X)$ of X , and for all functions $h : \mathbb{X} \rightarrow f(D_f)$, there exists $C_{P(X),h} \in \mathbb{R}$ such that, for all distributions $Y^{(0)}|X$ satisfying $\forall x \in \mathbb{X}, \mathbb{E}[Y^{(0)}|X=x] \in D_f^{(1)}$, there exists a distribution $Y^{(1)}|X$ such that

- for all $x \in \mathbb{X}, \tau^P(x) = h(x)$
- $\tau^P = C_{P(X),h}$.

Thus, for all distributions $P(X)$ of X , and for all functions $h : \mathbb{X} \rightarrow f(D_f)$, there exists $C_{P(X),h} \in \mathbb{R}$ such that, for all distributions $Y^{(0)}|X$ satisfying $\forall x \in \mathbb{X}, \mathbb{E}[Y^{(0)}|X=x] \in D_f^{(1)}$,

$$C_{P(X),h} = \mathbb{E}[h(X)w(X, P(X, Y^{(0)}))]. \quad (66)$$

Note that the joint distribution $P(X, Y^{(0)})$ can be written as $P(Y^{(0)}|X)P(X)$. Since h can be arbitrary chosen, and since the left-hand term does not depend on the distribution $Y^{(0)}|X$, one must have

$$w(X, P(X, Y^{(0)})) = w(X, P(X)). \quad (67)$$

Therefore,

$$\tau^P = \mathbb{E} [\tau^P(X)w(X, P(X))], \quad (68)$$

For simplicity, we denote $w(X, P(X))$ by $w(X)$. Thus, for all distributions $(X, Y^{(0)}, Y^{(1)})$,

$$\tau^P = \mathbb{E} [\tau^P(X)w(X)], \quad (69)$$

which is equivalent to

$$f(\mathbb{E}[Y^{(0)}], \mathbb{E}[Y^{(1)}]) = \mathbb{E} [f(\mathbb{E}[Y^{(0)}|X], \mathbb{E}[Y^{(1)}|X]) w(X)]. \quad (70)$$

Now, assume that $\mathbb{E}[Y^{(0)}|X] = C$ (constant baseline), and let $h(X) = \mathbb{E}[Y^{(1)}|X]$. We have

$$f(C, \mathbb{E}[h(X)]) = \mathbb{E} [f(C, h(X)) w(X)]. \quad (71)$$

First case Assume that $f(C, C) = 0$. Let $B \subset \mathbb{X}$ a borelian. Set

$$h_B(x) = \begin{cases} 0 & \text{if } x \in B^c \\ C & \text{if } x \in B \end{cases} \quad (72)$$

We have

$$\mathbb{E}[h_B(X)] = C\mu_X(B), \quad (73)$$

and

$$\mathbb{E}[f(C, h_B(X)) w(X)] = \mathbb{E}[f(C, 0) \mathbf{1}_{X \in B^c} w(X)]. \quad (74)$$

Hence,

$$f(C, C\mu_X(B)) = f(C, 0)\mathbb{E}[w(X)\mathbf{1}_{X \in B^c}]. \quad (75)$$

Since $x \mapsto f(C, x)$ is an injection, $f(C, 0) \neq f(C, C) = 0$. Thus, for all borelian $B_1, B_2 \subset \mathbb{X}$ such that $\mu_X(B_1) = \mu_X(B_2)$,

$$\frac{1}{\mu_X(B_1)}\mathbb{E}[w(X)\mathbf{1}_{X \in B_1}] = \frac{1}{\mu_X(B_2)}\mathbb{E}[w(X)\mathbf{1}_{X \in B_2}]. \quad (76)$$

Let $x_1, x_2 \in \mathbb{X}$ and $(B_{1,n}), (B_{2,n})$ two sequences of decreasing open balls centered respectively at x_1 and x_2 such that, for all n , $\mu_X(B_{1,n}) = \mu_X(B_{2,n})$. Letting f the density of X , we have

$$\frac{1}{\mu_X(B_{1,n})}\mathbb{E}[w(X)\mathbf{1}_{X \in B_{1,n}}] = \frac{\mu(B_{1,n})}{\mu_X(B_{1,n})} \frac{1}{\mu(B_{1,n})} \int_{B_{1,n}} w(x)f(x)dx. \quad (77)$$

According to the Lebesgue density theorem, we have

$$\frac{\mu_X(B_{1,n})}{\mu(B_{1,n})} = \frac{1}{\mu(B_{1,n})} \int_{B_{1,n}} f(x)dx \rightarrow f(x_1), \quad (78)$$

and

$$\frac{1}{\mu(B_{1,n})} \int_{B_{1,n}} w(x)f(x)dx \rightarrow w(x_1)f(x_1). \quad (79)$$

Thus,

$$\frac{1}{\mu_X(B_{1,n})}\mathbb{E}[w(X)\mathbf{1}_{X \in B_{1,n}}] \rightarrow w(x_1) \quad (80)$$

and similarly,

$$\frac{1}{\mu_X(B_{2,n})}\mathbb{E}[w(X)\mathbf{1}_{X \in B_{2,n}}] \rightarrow w(x_2), \quad (81)$$

which implies, according to equation eq. 115, $w(x_1) = w(x_2)$. Since $\mathbb{E}[w(X)] = 1$, we obtain $w(x) = 1$ for all $x \in \mathbb{X}$.

Second case Assume that $f(C, 0) = 0$. For all Borelian $B \subset \mathbb{X}$,

$$h_B(x) = \begin{cases} 0 & \text{if } x \in B \\ 1 & \text{if } x \in B^c \end{cases} \quad (82)$$

We have

$$\mathbb{E}[h_B(X)] = \mu_X(B^c), \quad (83)$$

and

$$\mathbb{E}[f(C, h_B(X))w(X)] = \mathbb{E}[f(C, 1)\mathbb{1}_{X \in B^c}w(X)]. \quad (84)$$

Hence,

$$f(C, \mu_X(B^c)) = f(C, 1)\mathbb{E}[w(X)\mathbb{1}_{X \in B^c}], \quad (85)$$

and the same reasoning as above applies. Since for all x , $w(x) = 1$, according to Equation eq. 105, we have

$$f(\mathbb{E}[Y^{(0)}], \mathbb{E}[Y^{(1)}]) = \mathbb{E}[f(\mathbb{E}[Y^{(0)}|X], \mathbb{E}[Y^{(1)}|X])]. \quad (86)$$

Again, assume that $\mathbb{E}[Y^{(0)}|X] = C$ and set $h(X) = \mathbb{E}[Y^{(1)}|X]$. For any $a, b \in \mathbb{R}$, and any $p \in [0, 1]$, set

$$h_{a,b,p}(x) = \begin{cases} a & \text{with probability } p \\ b & \text{with probability } 1 - p \end{cases} \quad (87)$$

Hence,

$$f(C, ap + b(1 - p)) = f(C, a)p + f(C, b)(1 - p). \quad (88)$$

Thus, the function $x \mapsto f(C, x)$ is convex. By Jensen inequality, eq. 121 holds if and only if $x \mapsto f(C, x)$ is linear or $h(X)$ is degenerate. Since eq. 121 must hold for every distribution of $h(X)$, we deduce that, for all C , $x \mapsto f(C, x)$ is linear. The same reasoning can be applied by considering $x \mapsto f(x, C)$. Thus, $x \mapsto f(x, C)$ is also linear for all C and we obtain that there exist $a, b, c, d \in \mathbb{R}$ such that

$$f(\mathbb{E}[Y^{(0)}|X], \mathbb{E}[Y^{(1)}|X]) = a\mathbb{E}[Y^{(1)}|X]\mathbb{E}[Y^{(0)}|X] + b\mathbb{E}[Y^{(1)}|X] + c\mathbb{E}[Y^{(0)}|X] + d. \quad (89)$$

Considering $\mathbb{E}[Y^{(0)}|X] = \mathbb{E}[Y^{(1)}|X] = h(X)$, we have

$$f(\mathbb{E}[h(X)], \mathbb{E}[h(X)]) = a(\mathbb{E}[h(X)])^2 + (b + c)\mathbb{E}[h(X)] + d, \quad (90)$$

and

$$\mathbb{E}[f(h(X), h(X))] = a\mathbb{E}[h(X)^2] + (b + c)\mathbb{E}[h(X)] + d, \quad (91)$$

which leads to, according to Equation eq. 121,

$$a\mathbb{V}[h(X)] = 0 \quad (92)$$

Since this must hold for every distribution of $h(X)$, we deduce that $a = 0$. Finally, there exist $a, b, c \in \mathbb{R}$ such that

$$\tau^P(X) = f(\mathbb{E}[Y^{(0)}|X], \mathbb{E}[Y^{(1)}|X]) \quad (93)$$

$$= a\mathbb{E}[Y^{(1)}|X] + b\mathbb{E}[Y^{(0)}|X] + c. \quad (94)$$

C.5.3 Proof of Theorem 2

Recall that, by assumption, there exist α_1, α_2 such that for all $x \in \mathbb{X}$, $(\alpha_1, \alpha_2) \subset \mathcal{A}(x)$. Recall that the conditional causal measure τ can be written as

$$\tau^P(x) = f(\mathbb{E}[Y^{(0)}|X=x], \mathbb{E}[Y^{(1)}|X=x]), \quad (95)$$

if $(\mathbb{E}[Y^{(0)}|X=x], \mathbb{E}[Y^{(1)}|X=x]) \in D_f$. Besides, if $(\mathbb{E}[Y^{(0)}], \mathbb{E}[Y^{(1)}]) \in D_f$,

$$\tau^P = f(\mathbb{E}[Y^{(0)}], \mathbb{E}[Y^{(1)}]). \quad (96)$$

As the causal measure τ is assumed to be collapsible, there exist non-negative weights $w(X, P(X, Y^{(0)}))$ verifying, for all distribution $(X, Y^{(0)}, Y^{(1)})$, $\mathbb{E}[w(X, P(X, Y^{(0)}))] = 1$ and

$$\tau^P = \mathbb{E}[\tau^P(X)w(X, P(X, Y^{(0)}))]. \quad (97)$$

By assumption, for all distributions $P(X)$ of X , and for all functions $h : \mathbb{X} \rightarrow f(D_f)$ such that $h(x) \in f(\mathcal{A}(x) \times \mathcal{A}(x))$, there exists $C_{P(X), h} \in \mathbb{R}$ such that, for all distributions $Y^{(0)}|X$ satisfying

$$\forall x \in \mathbb{X}, \mathbb{E}[Y^{(0)}|X=x] \in \mathcal{A}_{B, h}(x),$$

there exists a distribution $Y^{(1)}|X$ such that $\forall x \in \mathbb{X}, \mathbb{E}[Y^{(1)}|X=x] \in \mathcal{A}(x)$ and

- for all $x \in \mathbb{X}, \tau^P(x) = h(x)$
- $\tau^P = C_{P(X), h}$.

Consequently, since τ is collapsible,

$$C_{P(X), h} = \mathbb{E}[h(X)w(X, P(X, Y^{(0)}))]. \quad (98)$$

Assume that one can find two distributions P_1 and P_2 of $Y^{(0)}|X$ such that $w(X, P(X), P_1)$ and $w(X, P(X), P_2)$ differ, that is there exists a ball $B \subset \mathbb{X}$ such that

$$\mathbb{E}[w(X, P(X), P_1)\mathbf{1}_{X \in B}] \neq \mathbb{E}[w(X, P(X), P_2)\mathbf{1}_{X \in B}]. \quad (99)$$

Let $h(x) = (f(\alpha_1, \alpha_2) - f(\alpha_1, \alpha_1))\mathbf{1}_{x \in B} + f(\alpha_1, \alpha_1) \in f(\mathcal{A}(x) \times \mathcal{A}(x))$, we have

$$\mathbb{E}[h(X)w(X, P(X), P_1)] = \mathbb{E}[h(X)w(X, P(X), P_2)] \quad (100)$$

$$\Leftrightarrow \mathbb{E}[(f(\alpha_1, \alpha_2) - f(\alpha_1, \alpha_1))\mathbf{1}_{x \in B}w(X, P(X), P_1)] \quad (101)$$

$$= \mathbb{E}[(f(\alpha_1, \alpha_2) - f(\alpha_1, \alpha_1))\mathbf{1}_{x \in B}w(X, P(X), P_2)] \quad (102)$$

$$\Leftrightarrow \mathbb{E}[\mathbf{1}_{x \in B}w(X, P(X), P_1)] = \mathbb{E}[\mathbf{1}_{x \in B}w(X, P(X), P_2)], \quad (103)$$

since $\mathbb{E}[w(X, P(X), P_1)] = \mathbb{E}[w(X, P(X), P_2)] = 1$ and by injectivity of $x \mapsto f(\alpha_1, x)$. Therefore, $w(X, P(X, Y^{(0)}))$ does not depend on the distribution $Y^{(0)}|X$ and one can write, for all distributions $(X, Y^{(0)}, Y^{(1)})$,

$$\tau^P = \mathbb{E}[\tau^P(X)w(X)], \quad (104)$$

where $w(X) = w(X, P(X))$. Thus,

$$f(\mathbb{E}[Y^{(0)}], \mathbb{E}[Y^{(1)}]) = \mathbb{E}[f(\mathbb{E}[Y^{(0)}|X], \mathbb{E}[Y^{(1)}|X])w(X)]. \quad (105)$$

Now, assume that $\mathbb{E}[Y^{(0)}|X] = \alpha_1$ (constant baseline), and let $h(X) = \mathbb{E}[Y^{(1)}|X]$. We have

$$f(\alpha_1, \mathbb{E}[h(X)]) = \mathbb{E}[f(\alpha_1, h(X))w(X)]. \quad (106)$$

Let $B \subset \mathbb{X}$ a borelian. Set

$$h_B(x) = \begin{cases} \alpha_1 & \text{if } x \in B \\ \alpha_2 & \text{if } x \in B^c \end{cases} \quad (107)$$

We have

$$\mathbb{E}[h_B(X)] = \alpha_1 \mu_X(B) + \alpha_2 \mu_X(B^c) \quad (108)$$

$$= \alpha_2 + (\alpha_1 - \alpha_2) \mu_X(B), \quad (109)$$

and

$$\mathbb{E}[f(\alpha_1, h_B(X)) w(X)] \quad (110)$$

$$= \mathbb{E}[f(\alpha_1, \alpha_1) \mathbb{1}_{X \in B} w(X)] + \mathbb{E}[f(\alpha_1, \alpha_2) \mathbb{1}_{X \in B^c} w(X)] \quad (111)$$

$$= f(\alpha_1, \alpha_2) + (f(\alpha_1, \alpha_1) - f(\alpha_1, \alpha_2)) \mathbb{E}[\mathbb{1}_{X \in B} w(X)]. \quad (112)$$

Hence,

$$f(\alpha_1, \alpha_2 + (\alpha_1 - \alpha_2) \mu_X(B)) = f(\alpha_1, \alpha_2) + (f(\alpha_1, \alpha_1) - f(\alpha_1, \alpha_2)) \mathbb{E}[\mathbb{1}_{X \in B} w(X)]. \quad (113)$$

Since $x \mapsto f(\alpha_1, x)$ is an injection, $f(\alpha_1, \alpha_1) \neq f(\alpha_1, \alpha_2)$. Thus, the right-hand side in

$$\mathbb{E}[\mathbb{1}_{X \in B} w(X)] = \frac{f(\alpha_1, \alpha_2 + (\alpha_1 - \alpha_2) \mu_X(B)) - f(\alpha_1, \alpha_2)}{f(\alpha_1, \alpha_1) - f(\alpha_1, \alpha_2)} \quad (114)$$

depends only on $\mu_X(B)$. Hence, for all borelian $B_1, B_2 \subset \mathbb{X}$ such that $\mu_X(B_1) = \mu_X(B_2)$,

$$\frac{1}{\mu_X(B_1)} \mathbb{E}[w(X) \mathbb{1}_{X \in B_1}] = \frac{1}{\mu_X(B_2)} \mathbb{E}[w(X) \mathbb{1}_{X \in B_2}]. \quad (115)$$

Let $x_1, x_2 \in \mathbb{X}$ and $(B_{1,n}), (B_{2,n})$ two sequences of decreasing open balls centered respectively at x_1 and x_2 such that, for all n , $\mu_X(B_{1,n}) = \mu_X(B_{2,n})$. Letting f the density of X , we have

$$\frac{1}{\mu_X(B_1)} \mathbb{E}[w(X) \mathbb{1}_{X \in B_1}] = \frac{\mu(B_{1,n})}{\mu_X(B_{1,n})} \frac{1}{\mu(B_{1,n})} \int_{B_{1,n}} w(x) f(x) dx. \quad (116)$$

According to the Lebesgue density theorem, we have

$$\frac{\mu_X(B_{1,n})}{\mu(B_{1,n})} = \frac{1}{\mu(B_{1,n})} \int_{B_{1,n}} f(x) dx \rightarrow f(x_1), \quad (117)$$

and

$$\frac{1}{\mu(B_{1,n})} \int_{B_{1,n}} w(x) f(x) dx \rightarrow w(x_1) f(x_1). \quad (118)$$

Thus,

$$\frac{1}{\mu_X(B_{1,n})} \mathbb{E}[w(X) \mathbb{1}_{X \in B_{1,n}}] \rightarrow w(x_1) \quad (119)$$

and similarly,

$$\frac{1}{\mu_X(B_{2,n})} \mathbb{E}[w(X) \mathbb{1}_{X \in B_{2,n}}] \rightarrow w(x_2), \quad (120)$$

which implies, according to equation eq. 115, $w(x_1) = w(x_2)$. Since $\mathbb{E}[w(X)] = 1$, we obtain $w(x) = 1$ for all $x \in \mathbb{X}$. Since for all x , $w(x) = 1$, according to Equation eq. 105, we have

$$f(\mathbb{E}[Y^{(0)}], \mathbb{E}[Y^{(1)}]) = \mathbb{E}[f(\mathbb{E}[Y^{(0)}|X], \mathbb{E}[Y^{(1)}|X])]. \quad (121)$$

Let $x \in \mathbb{X}$. Let $a, b \in \mathcal{A}(x)$. Set $\mathbb{E}[Y^{(0)}|X] = a$ and, for any $p \in [0, 1]$,

$$\mathbb{E}[Y^{(1)}|X = x] = \begin{cases} a & \text{with probability } p \\ b & \text{with probability } 1 - p \end{cases} \quad (122)$$

Hence,

$$f(a, ap + b(1 - p)) = f(a, a)p + f(a, b)(1 - p). \quad (123)$$

Thus, the function $z' \mapsto f(a, z')$ is convex. By Jensen inequality, eq. 121 holds if and only if $z' \mapsto f(a, z')$ is linear or $h(X)$ is degenerate. Since eq. 121 must hold for every distribution of $h(X)$, we deduce that, for all $u \in \mathcal{A}(x)$, $z' \mapsto f(u, z')$ is linear. The same reasoning can be applied by considering $z \mapsto f(z, u)$. Thus, $z \mapsto f(z, u)$ is also linear for all $u \in \mathcal{A}(x)$ and we obtain that there exist $\beta_1, \beta_2, \beta_3, \beta_4 \in \mathbb{R}$ such that

$$f(\mathbb{E}[Y^{(0)}|X], \mathbb{E}[Y^{(1)}|X]) = \beta_1 \mathbb{E}[Y^{(1)}|X] \mathbb{E}[Y^{(0)}|X] + \beta_2 \mathbb{E}[Y^{(1)}|X] + \beta_3 \mathbb{E}[Y^{(0)}|X] + \beta_4. \quad (124)$$

Considering $\mathbb{E}[Y^{(0)}|X] = \mathbb{E}[Y^{(1)}|X] = h(X)$, we have

$$f(\mathbb{E}[h(X)], \mathbb{E}[h(X)]) = \beta_1 (\mathbb{E}[h(X)])^2 + (\beta_2 + \beta_3) \mathbb{E}[h(X)] + \beta_4, \quad (125)$$

and

$$\mathbb{E}[f(h(X), h(X))] = \beta_1 \mathbb{E}[h(X)^2] + (\beta_2 + \beta_3) \mathbb{E}[h(X)] + \beta_4, \quad (126)$$

which leads to, according to Equation eq. 121,

$$\beta_1 \mathbb{V}[h(X)] = 0 \quad (127)$$

Since this must hold for every distribution of $h(X)$, we deduce that $\beta_1 = 0$. Finally, there exist $a, b, c \in \mathbb{R}$ such that

$$\tau^P(X) = f(\mathbb{E}[Y^{(0)}|X], \mathbb{E}[Y^{(1)}|X]) \quad (128)$$

$$= a \mathbb{E}[Y^{(1)}|X] + b \mathbb{E}[Y^{(0)}|X] + c. \quad (129)$$

C.5.4 Proof of Lemma 6 (binary outcomes)

Proof. Consider a binary outcome Y . We further assume that,

$$\forall x \in \mathbb{X}, \forall a \in \{0, 1\}, \quad 0 < p_a(x) < 1, \quad \text{where } p_a(x) := \mathbb{P}[Y^{(a)} = 1 | X = x],$$

which means that the outcome is non-deterministic. Using the law of total expectation, one has

$$\begin{aligned} p_1(x) &= \mathbb{P}[Y^{(1)} = 1 | X = x] \\ &= \mathbb{P}[Y^{(1)} = 1 | Y^{(0)} = 0, X = x] \mathbb{P}[Y^{(0)} = 0 | X = x] \\ &\quad + \mathbb{P}[Y^{(1)} = 1 | Y^{(0)} = 1, X = x] \mathbb{P}[Y^{(0)} = 1 | X = x] \\ &= \mathbb{P}[Y^{(1)} = 1 | Y^{(0)} = 0, X = x] (1 - p_0(x)) + \mathbb{P}[Y^{(1)} = 1 | Y^{(0)} = 1, X = x] p_0(x). \end{aligned}$$

Denoting

$$m_g(x) := \mathbb{P}[Y^{(1)} = 0 \mid Y^{(0)} = 1, X = x] \quad \text{and} \quad m_b(x) := \mathbb{P}[Y^{(1)} = 1 \mid Y^{(0)} = 0, X = x],$$

we finally obtain

$$\begin{aligned} p_1(x) &= m_b(x)(1 - p_0(x)) + (1 - m_g(x))p_0(x) \\ &= p_0(x) + m_b(x)(1 - p_0(x)) - p_0(x)m_g(x). \end{aligned}$$

Therefore, for all $a \in \{0, 1\}$,

$$p_a(x) = p_0(x) + a(m_b(x)(1 - p_0(x)) - p_0(x)m_g(x)).$$

□

Note that the rational of the proof can be captured with a probability tree. Below on Figure 11 illustrates the problem with the Russian roulette example.




Figure 11: Illustration of the Russian Roulette problem with a probability tree

C.5.5 Proof of Lemma 9

Lemma 9 (Expression of the causal measures). *Ensuring conditions of Lemma 6 leads to,*

$$\begin{aligned} \tau_{RD}^P &= \mathbb{E}[(1 - b(X)) m_b(X)] - \mathbb{E}[b(X) m_g(X)] \\ \tau_{NNT}^P &= \frac{1}{\mathbb{E}[(1 - b(X)) m_b(X)] - \mathbb{E}[b(X) m_g(X)]} \\ \tau_{RR}^P &= 1 + \frac{\mathbb{E}[(1 - b(X)) m_b(X)]}{\mathbb{E}[b(X)]} - \frac{\mathbb{E}[b(X) m_g(X)]}{\mathbb{E}[b(X)]} \\ \tau_{SR}^P &= 1 - \frac{\mathbb{E}[(1 - b(X)) m_b(X)]}{\mathbb{E}[1 - b(X)]} + \frac{\mathbb{E}[b(X) m_g(X)]}{\mathbb{E}[1 - b(X)]}, \\ \tau_{OR}^P &= \frac{\mathbb{E}[b(X)] + \mathbb{E}[(1 - b(X)) m_b(X)] - \mathbb{E}[b(X) m_g(X)]}{\mathbb{E}[1 - b(X)] - \mathbb{E}[(1 - b(X)) m_b(X)] + \mathbb{E}[b(X) m_g(X)]} \frac{\mathbb{E}[1 - b(X)]}{\mathbb{E}[b(X)]}. \end{aligned}$$

Proof. Consider a binary outcome Y . Under the assumptions of Lemma 6, there exist probabilities $b(x)$, $m_g(x)$, and $m_b(x)$ such that

$$\mathbb{P}[Y^{(a)} = 1 \mid X = x] = b(x) + a((1 - b(x)) m_b(x) - b(x) m_g(x)).$$

Using such a decomposition, one has

$$\begin{aligned}
\tau_{\text{RD}}^P &= \mathbb{E}[b(X) + ((1 - b(X)) m_b(X) - b(X) m_g(X))] - \mathbb{E}[b(X)] \\
&= \mathbb{E}[(1 - b(X)) m_b(X)] - \mathbb{E}[b(X) m_g(X)], \\
\tau_{\text{NNT}}^P &= \frac{1}{\mathbb{E}[(1 - b(X)) m_b(X)] - \mathbb{E}[b(X) m_g(X)]}, \\
\tau_{\text{RR}}^P &= \frac{\mathbb{E}[b(X) + ((1 - b(X)) m_b(X) - b(X) m_g(X))]}{\mathbb{E}[b(X)]} \\
&= 1 + \frac{\mathbb{E}[(1 - b(X)) m_b(X)]}{\mathbb{E}[b(X)]} - \frac{\mathbb{E}[b(X) m_g(X)]}{\mathbb{E}[b(X)]}, \\
\tau_{\text{SR}}^P &= \frac{1 - \mathbb{E}[b(X) + ((1 - b(X)) m_b(X) - b(X) m_g(X))]}{1 - \mathbb{E}[b(X)]} \\
&= \frac{\mathbb{E}[1 - b(X) - ((1 - b(X)) m_b(X) + b(X) m_g(X))]}{\mathbb{E}[1 - b(X)]} \\
&= 1 - \frac{\mathbb{E}[(1 - b(X)) m_b(X)]}{\mathbb{E}[1 - b(X)]} + \frac{\mathbb{E}[b(X) m_g(X)]}{\mathbb{E}[1 - b(X)]}, \\
\tau_{\text{OR}}^P &= \frac{\mathbb{P}[Y^{(1)} = 1]}{\mathbb{P}[Y^{(1)} = 0]} \left(\frac{\mathbb{P}[Y^{(0)} = 1]}{\mathbb{P}[Y^{(0)} = 0]} \right)^{-1} \\
&= \frac{\mathbb{E}[b(X) + ((1 - b(X)) m_b(X) - b(X) m_g(X))]}{1 - \mathbb{E}[b(X) + ((1 - b(X)) m_b(X) - b(X) m_g(X))]} \left(\frac{\mathbb{E}[b(X)]}{1 - \mathbb{E}[b(X)]} \right)^{-1} \\
&= \frac{\mathbb{E}[b(X) + ((1 - b(X)) m_b(X) - b(X) m_g(X))]}{\mathbb{E}[1 - b(X) - ((1 - b(X)) m_b(X) + b(X) m_g(X))]} \frac{\mathbb{E}[1 - b(X)]}{\mathbb{E}[b(X)]} \\
&= \frac{\mathbb{E}[b(X)] + \mathbb{E}[(1 - b(X)) m_b(X)] - \mathbb{E}[b(X) m_g(X)]}{\mathbb{E}[1 - b(X)] - \mathbb{E}[(1 - b(X)) m_b(X)] + \mathbb{E}[b(X) m_g(X)]} \frac{\mathbb{E}[1 - b(X)]}{\mathbb{E}[b(X)]} \\
&= \left(1 + \frac{\mathbb{E}[(1 - b(X)) m_b(X)]}{\mathbb{E}[b(X)]} - \frac{\mathbb{E}[b(X) m_g(X)]}{\mathbb{E}[b(X)]} \right) \\
&\quad \cdot \left(1 - \frac{\mathbb{E}[(1 - b(X)) m_b(X)]}{\mathbb{E}[1 - b(X)]} + \frac{\mathbb{E}[b(X) m_g(X)]}{\mathbb{E}[1 - b(X)]} \right)^{-1}.
\end{aligned}$$

□

C.6 Proofs of Section 5.2

C.6.1 Proof of Theorem 3

Proof. Let τ be a causal measure defined as

$$\tau^P = f(\mathbb{E}[Y^{(0)}], \mathbb{E}[Y^{(1)}]). \quad (130)$$

Let $P_s(X, Y^{(0)}, Y^{(1)})$ and $P_T(X, Y^{(0)}, Y^{(1)})$ satisfying Assumption 2 (overlap assumption) and Assumption 3. By Lemma 5, on the source population, for all $x \in \text{supp}(P_s)$, we have

$$\mathbb{E}_s[Y^{(0)}|X = x] = b(x) \quad \text{and} \quad \mathbb{E}_s[Y^{(1)}|X = x] = g_{b(x)}^{-1}(m(x)), \quad (131)$$

where $g_z : z' \mapsto f(z, z')$. According to Assumption 3, for all $x \in \text{supp}(P_T) \cap \text{supp}(P_s) = \text{supp}(P_T)$ (by Assumption 2),

$$\mathbb{E}_T[Y^{(0)}|X = x] = \mathbb{E}_s[Y^{(0)}|X = x] \quad (132)$$

$$\text{and } \mathbb{E}_T[Y^{(1)}|X = x] = \mathbb{E}_s[Y^{(1)}|X = x]. \quad (133)$$

Thus,

$$\mathbb{E}_T[Y^{(0)}|X] = b(X) \quad \text{and} \quad \mathbb{E}_T[Y^{(1)}|X] = g_{b(X)}^{-1}(m(X)). \quad (134)$$

We are interested in estimating the average treatment effect on the target population, that is

$$\tau^{P_T} = f(\mathbb{E}_T[Y^{(0)}], \mathbb{E}_T[Y^{(1)}]). \quad (135)$$

According to Definitions 6 and 5, we have

$$\mathbb{E}_T[Y^{(0)}] = \mathbb{E}_T[b(X)] \quad (136)$$

$$= \mathbb{E}_T[\mathbb{E}_T[b(X) | X_{Sh}]] \quad (137)$$

$$= \mathbb{E}_T[\mathbb{E}_S[b(X) | X_{Sh}]] \quad (138)$$

$$= \mathbb{E}_T[\mathbb{E}_S[b(X) | X_{B \cap Sh}]], \quad (139)$$

where the third line comes from Assumption 2 and the definition of X_{Sh} . Similarly,

$$\mathbb{E}_T[Y^{(1)}] = \mathbb{E}_T[g_{b(X)}^{-1}(m(X))] \quad (140)$$

$$= \mathbb{E}_T[\mathbb{E}^T[g_{b(X)}^{-1}(m(X)) | X_{Sh}]] \quad (141)$$

$$= \mathbb{E}_T[\mathbb{E}_S[g_{b(X)}^{-1}(m(X)) | X_{Sh}]] \quad (142)$$

$$= \mathbb{E}_T[\mathbb{E}_S[g_{b(X)}^{-1}(m(X)) | X_{(M \cup B) \cap Sh}]]. \quad (143)$$

Consequently, one can generalize τ to the target population by using the formula

$$\tau^{P_T} = f\left(\mathbb{E}_T[\mathbb{E}_S[b(X) | X_{B \cap Sh}], \mathbb{E}_T[\mathbb{E}_S[g_{b(X)}^{-1}(m(X)) | X_{(M \cup B) \cap Sh}]]\right). \quad (144)$$

□

C.6.2 Proof of Theorem 4

Proof. Consider the Risk Difference τ_{RD} . Let $P_S(X, Y^{(0)}, Y^{(1)})$ and $P_T(X, Y^{(0)}, Y^{(1)})$ satisfying Assumption 2 (overlap assumption) and Assumption 4. Since τ_{RD} satisfies Assumption 1, Corollary 1 can be applied on the source population, that is, for all $x \in \text{supp}(P_S)$, we have

$$\mathbb{E}_S[Y^{(0)}|X = x] = b(x) \quad \text{and} \quad \mathbb{E}_S[Y^{(1)}|X = x] = b(x) + m(x). \quad (145)$$

Thus, for all $x \in \text{supp}(P_S)$,

$$m(x) = \mathbb{E}_S[Y^{(1)} - Y^{(0)}|X = x]. \quad (146)$$

According to Assumption 4, for all $x \in \text{supp}(P_T) \cap \text{supp}(P_S) = \text{supp}(P_T)$ (Assumption 2),

$$m(x) = \mathbb{E}_T[Y^{(1)} - Y^{(0)}|X = x]. \quad (147)$$

Since τ_{RD} is directly collapsible, we have

$$\tau_{RD}^{P_T} = \mathbb{E}_T[m(X)] \quad (148)$$

$$= \mathbb{E}_T[\mathbb{E}_T[m(X) | X_{M \cap Sh}]], \quad (149)$$

where

$$\begin{aligned}
\mathbb{E}_{\mathbf{T}} [m(X) \mid X_{M \cap \text{Sh}}] &= \mathbb{E}_{\mathbf{T}} [m(X) \mid X_{\text{Sh}}] && \text{Definition 6} \\
&= \mathbb{E}_{\mathbf{S}} [m(X) \mid X_{\text{Sh}}] && \text{Definition 5} \\
&= \mathbb{E}_{\mathbf{S}} [m(X) \mid X_{M \cap \text{Sh}}] && \text{Definition 6} \\
&= \tau_{\text{RD}}^{P_{\mathbf{S}}}(X_{M \cap \text{Sh}}).
\end{aligned}$$

Consequently,

$$\tau_{\text{RD}}^{P_{\mathbf{T}}} = \mathbb{E}_{\mathbf{T}} [\tau_{\text{RD}}^{P_{\mathbf{S}}}(X_{M \cap \text{Sh}})], \quad (150)$$

and τ_{RD} is generalizable with covariates $X_{M \cap \text{Sh}}$. □

C.6.3 Proof of Theorem 5

The proof is straightforward by recalling that any collapsible causal measure satisfies Definition 5.

D Comments on logistic regression

A common practice in applied statistics is to adopt a logistic regression model (or any model encapsulating a function taking values in \mathbb{R}), for example assuming that the following logistic model holds:

$$\log \left(\frac{\mathbb{P}(Y^{(a)} = 1 \mid X)}{\mathbb{P}(Y^{(a)} = 0 \mid X)} \right) = \beta_0 + \langle \boldsymbol{\beta}, \mathbf{X} \rangle + A m, \quad (151)$$

where $\beta_0, \boldsymbol{\beta}$ and m are the coefficients of a linear model (see for example [Daniel et al. \(2020\)](#)). When the generative model from Equation 151 holds, some nice properties arise. Notably, one can show that this implies constant conditional odds ratio $\tau_{\log\text{-OR}}(x) = m$ and $\tau_{\text{OR}}(x) = e^m$. The derivations are detailed below:

$$\begin{aligned}
\tau_{\text{OR}}(X) &:= \frac{\mathbb{P}(Y^{(1)} = 1 \mid X)}{\mathbb{P}(Y^{(1)} = 0 \mid X)} \cdot \left(\frac{\mathbb{P}(Y^{(0)} = 1 \mid X)}{\mathbb{P}(Y^{(0)} = 0 \mid X)} \right)^{-1} \\
&= e^{\beta_0 + \langle \boldsymbol{\beta}, \mathbf{X} \rangle + m} \cdot e^{-\beta_0 - \langle \boldsymbol{\beta}, \mathbf{X} \rangle} \\
&= e^m.
\end{aligned}$$

Beyond eq. 151 it is possible to encapsulate non-parametric functions in the logit. Such decomposition is present in the literature ([Gao and Hastie, 2021](#)) (and see Section D, and in particular Lemma 11 for details).

Lemma 10 (Logit generative model for a binary outcome). *Considering a binary outcome Y , assume that*

$$\forall x \in \mathbb{X}, \forall a \in \{0, 1\}, \quad 0 < p_a(x) < 1, \quad \text{where } p_a(x) = \mathbb{P}(Y^{(a)} = 1 \mid X = x).$$

Then, there exist two functions $b, m : \mathcal{X} \rightarrow \mathbb{R}$ such that

$$\ln \left(\frac{\mathbb{P}(Y^{(a)} = 1 \mid X)}{\mathbb{P}(Y^{(a)} = 0 \mid X)} \right) = b(X) + a m(X).$$

Proof. Consider $a \in \{0, 1\}$, and assume that there exists a function $p_a : \mathbb{R}^d \rightarrow]0, 1[$ such that,

$$\mathbb{P}(Y^{(a)} = 1 \mid X) = p_a(X).$$

Because p_a takes values in $]0, 1[$ the odds can be considered, so that,

$$\ln \left(\frac{\mathbb{P}(Y^{(a)} = 1 \mid X)}{\mathbb{P}(Y^{(a)} = 0 \mid X)} \right) = \ln \left(\frac{p_a(X)}{1 - p_a(X)} \right).$$

Denoting,

$$b(X) := \ln \left(\frac{p_0(X)}{1 - p_0(X)} \right),$$

and

$$m(X) := \ln \left(\frac{p_1(X)}{1 - p_1(X)} \right) - \ln \left(\frac{p_0(X)}{1 - p_0(X)} \right) = \ln \left(\frac{p_1(X)}{1 - p_1(X)} \frac{1 - p_0(X)}{p_0(X)} \right),$$

one can write the log-odds as

$$\ln \left(\frac{\mathbb{P}(Y^{(a)} = 1 \mid X)}{\mathbb{P}(Y^{(a)} = 0 \mid X)} \right) = b(X) + A m(X).$$

Note that another link function could have been chosen, which impacts how $b(x)$ and $m(x)$ are defined. \square

Lemma 11 (Conditional log odds ratio). *Ensuring conditions of Lemma 10 leads to,*

$$\mathbb{E}[\tau_{\log\text{-OR}}(X)] := \mathbb{E} \left[\ln \left(\frac{\mathbb{P}(Y^{(1)} = 1 \mid X)}{\mathbb{P}(Y^{(1)} = 0 \mid X)} \left(\frac{\mathbb{P}(Y^{(0)} = 1 \mid X)}{\mathbb{P}(Y^{(0)} = 0 \mid X)} \right)^{-1} \right) \right] = \mathbb{E}[m(X)].$$

This result is apparently satisfying, where $\mathbb{E}[\tau_{\log\text{-OR}}(X)]$ somehow only grasps the modification function. Still, note that due to non-collapsibility of the odds ratio, this does not imply that $\tau_{\log\text{-OR}} = \tau$ (i.e. $\tau_{\text{OR}} = e^\tau$) because $\mathbb{E}[\tau_{\log\text{-OR}}(X)] \neq \tau_{\log\text{-OR}}$ (except if treatment effect is null or if the outcome does not depend on X , that is $b(X)$ and $m(X)$ are both scalars). As an intermediary conclusion, the working model from Lemma 10 leads to complex expression of causal measures, except for $\mathbb{E}[\tau_{\log\text{-OR}}(X)]$, but with the default that this measure shows bad property of non-collapsibility.

For example, a working model such that $m(x) = m$ is a constant don't lead to any measures to be constant.

Lemma 12. *Ensuring conditions of Lemma 10 leads to,*

$$\tau_{RD} = \mathbb{E} \left[\frac{e^{b(X)+m(X)}}{1 + e^{b(X)+m(X)}} \right] - \mathbb{E} \left[\frac{e^{b(X)}}{1 + e^{b(X)}} \right] \quad (152)$$

$$\tau_{ERR} = \mathbb{E} \left[\frac{e^{b(X)+m(X)}}{1 + e^{b(X)+m(X)}} \right] \left(\mathbb{E} \left[\frac{e^{b(X)}}{1 + e^{b(X)}} \right] \right)^{-1} - 1 \quad (153)$$

$$\tau_{NNT} = \left(\mathbb{E} \left[\frac{e^{b(X)+m(X)}}{1 + e^{b(X)+m(X)}} \right] - \mathbb{E} \left[\frac{e^{b(X)}}{1 + e^{b(X)}} \right] \right)^{-1} \quad (154)$$

$$\tau_{RR} = \mathbb{E} \left[\frac{e^{b(X)+m(X)}}{1 + e^{b(X)+m(X)}} \right] \left(\mathbb{E} \left[\frac{e^{b(X)}}{1 + e^{b(X)}} \right] \right)^{-1} \quad (155)$$

$$\tau_{SR} = \mathbb{E} \left[(1 + e^{b(X)+m(X)})^{-1} \right] \left(\mathbb{E} \left[(1 + e^{b(X)})^{-1} \right] \right)^{-1} \quad (156)$$

$$\tau_{OR} = \frac{\mathbb{E} \left[\frac{e^{b(X)+m(X)}}{1 + e^{b(X)+m(X)}} \right] \mathbb{E} \left[\frac{1}{1 + e^{b(X)}} \right]}{\mathbb{E} \left[\frac{1}{1 + e^{b(X)+m(X)}} \right] \mathbb{E} \left[\frac{e^{b(X)}}{1 + e^{b(X)}} \right]}. \quad (157)$$

All expressions from Lemma 12 now involve both $b(\cdot)$ and $m(x)$. All other metrics show complex relation between the two functions.

Finally, note that the logistic model is unable to easily describe accurately the Russian Roulette thought being simple. Note that

$$\log \left(\frac{\mathbb{P}(Y^{(a)} = 1 | X = x)}{\mathbb{P}(Y^{(a)} = 0 | X = x)} \right) = \log \left(\frac{b(x)}{1 - b(x)} \right) + A \log \left(\frac{\left(\frac{1}{6} + b(x)\right)}{1 - \left(\frac{1}{6} + b(x)\right)(1 - b(x))} \cdot \frac{1 - b(x)}{b(x)} \right),$$

is the equivalent to Equation 27.

E More details about the Russian Roulette example

We provide more details on how the Russian Roulette is stated in Cinelli and Pearl (2020). Note that the first reference we have found of this problem is in Huitfeldt (2019). This section is just meant to recall how the problem was initially introduced by Huitfeldt (2019).

Suppose the city of Los Angeles decides to run a randomized control trial. Running the experiment, the mayor of Los Angeles discovers that “Russian Roulette” is harmful: among those assigned to play Russian Roulette, 17.5% of the people died, as compared to only 1% among those who were not assigned to play the game (people can die due to other causes during the trial, for example, prior poor health conditions). This example is a good toy example as the mechanism is well-known, with a chance of one over six to die when playing. Even if it seems counter-intuitive, we consider the treatment as being forced to play to the russian roulette (we consider the player plays only one time). We denote by Π the population from Los Angeles. In that case, we can already note that the RR is 17.5 and the ATE is 0.165 (outcome being Y equals to 1 if death before the end of the period). With this notation $E[Y^{(0)}|pop = \Pi] = 0.01$ and $E[Y^{(1)}|pop = \Pi] = 0.175$

After hearing the news about the Los Angeles experiment, the mayor of New York City (a dictator, and we propose to denote the population of New York City by Π^*) wonders what the overall mortality rate would be if the city forced everyone to play Russian Roulette. Currently, the practice of Russian Roulette is forbidden in New York, and its mortality rate is at 5% (4% higher than LA, being $E[Y^{(0)}|pop = \Pi^*] = 0.05$). The mayor thus asks the city’s statistician to decide whether and how one could use the data from from Los Angeles to predict the mortality rate in New York, once the new policy is implemented. But in fact, knowing the mechanism of the russian roulette we can already compute the value of interest being $E[Y^{(1)}|pop = \Pi^*]$. Results are presented in Table 4. Here we used the fact that mortality is a consequence of two “independent” processes (the game of Russian Roulette and prior health conditions of the individual), and while the first factor remains unaltered across cities, the second intensifies by a known amount (5% vs 1%). Moreover, we can safely assume that the two processes interact disjunctively, namely, that death occurs if and only if at least one of the two processes takes effect. We can also - within the two cities - compute the associated RR, ATE and survival ratio (SR). We can observe they are not the same, but only the survival ratio comparing how many people dies with treatment on how many people would have died without treatment, transport the *mechanism* of the Russian Roulette (note that $\frac{5}{6} \sim 0.83$).

F Different points of view

This section gathers quotes from research papers or books. The aim is to illustrate how diverse opinions are.

Population	Los Angeles (Π)	New York city (Π^*)
$E[Y^{(0)}]$	0.01	0.05
$E[Y^{(1)}]$	$\frac{1}{6}0.99 + 0.01 = 0.175$	$\frac{1}{6}0.95 + 0.05 = 0.208$
RR	17.5	4.16
ATE	0.165	0.158
SR	0.83	0.83

Table 4: Summary of the different values. Note that none of the transport equation is applied, everything is computed within each population taking into account a distinct mechanism between the two reasons to die. SR corresponds to the survival ratio.

General remarks about the choice of measure

Physicians, consumers, and third-party payers may be more enthusiastic about long-term preventive treatments when benefits are stated as relative, rather than absolute, reductions in the risk of adverse events. Medical-journal editors have said that reporting only relative reductions in risk is usually inadequate in scientific articles and have urged the news media to consider the importance of discussing both absolute and relative risks. For example, a story reporting that in patients with myocardial infarction, a new drug reduces the mortality rate at two years from 10 percent to 7 percent may help patients weigh both the 3 percent absolute and the 30 percent relative reduction in risk against the costs of the drug and its side effects. – (Moynihan et al., 2000)

In general, giving only the absolute or only the relative benefits does not tell the full story; it is more informative if both researchers and the media make data available in both absolute and relative terms. – (Moynihan et al., 2000)

The promotion of a measure often reflects personal preferences – those who are keen to promote the use of research in practice emphasize issues of interpretability of Risk Ratios and risk differences, those who are keen to ensure mathematical rules are always obeyed emphasize the limitations and inadequacies of the same measures. – (Deeks, 2002)

Failing to report NNT may influence the interpretation of study results. For example reporting RR alone may lead a reader to believe that a treatment effect is larger than it really is. – (Nuovo et al., 2002)

As *evidence-based practitioners*, we must decide which measure of association deserves our focus. Does it matter? The answer is yes. The same results, when presented in different ways, may lead to different treatment decisions. – (Guyatt et al., 2015)

You must, however, distinguish between the RR and the RD. The reason is that the RR is generally far larger than the RD, and presentations of results in the form of RR (or RRR) can convey a misleading message. – (focusing on binary outcome) (Guyatt et al., 2015)

Standard measures of effect, including the Risk Ratio, the odds ratio, and the risk difference, are associated with a number of well-described shortcomings, and no consensus exists about the conditions under which investigators should choose one effect measure over another. – (Huitfeldt et al., 2018)

Additive treatment effect heterogeneity is also most informative for guiding public health policy that aims to maximize the benefit or minimize the harm of an exposure by targeting subgroups. The relative scale (Risk Ratios or odds ratios) can tend to overstate treatment benefits or harms. – (Lesko et al., 2018)

The way to express and measure risk may appear to be a pure technicality. In fact, it is a crucial element of the risk-benefit balance that underlies the dominant medical discourse on contraception. Its influence on the perception and communication of risk is decisive, especially among people without a solid statistical education, like most patients and doctors who prescribe the pill (mostly generalists and gynaecologists). The dispute over *Non-rare thrombophilia* (NRT) screening sets an important difference between the absolute risk, the number of events occurring per time unit and the relative risk, which is the ratio between two absolute risks. Practically, whereas the relative risk may sound alarming, the absolute risk looks more reassuring. – (Turrini and Bourgain, 2021)

We believe if an efficacy measure is

- well defined,
- understandable by human,
- desired by patients and clinicians,
- proven to be logic-respecting¹⁵,
- readily implementable computationally,

them it is worthy of consideration. – (Liu et al., 2022)

The odds ratio as a complex measure to interpret

Odds ratios and parameters of multivariate models will often be useful in serving as or in constructing the estimates, but should not be treated as the end product of a statistical analysis of epidemiologic data or as summaries of effect in themselves. – (Greenland, 1987)

The concept of the odds ratio is now well-established in epidemiology, largely because it serves as a link between results obtainable from follow-up studies and those obtainable from case-control studies. [...] This ubiquity, along with certain technical considerations, has led some authors to treat the odds ratio as perhaps a “universal” measure of epidemiologic effect, in that they would estimate odds ratios in follow-up studies as well as case-control studies; others have expressed reservations about the utility of the odds ratio as something other than an estimate of an incidence ratio. I believe that such controversy as exists regarding the use of the odds ratio arises from its inherent disadvantages compared with the other measures for biological inference, and its inherent advantages for statistical inference. – (Greenland, 1987)

There is a problem with odds: unlike risks, they are difficult to understand. – (Davies et al., 1998)

¹⁵see Definition 6.

Another measure often used to summarise effects of treatment is the odds ratio. This is defined as the odds of an event in the active treatment group divided by the odds of an event in the control group. Though this measure has several statistical advantages and is used extensively in epidemiology, we will not pursue it here as it is not helpful in clinical decision making. – (Cook and Sackett, 1995)

In logit and other multiplicative intercept models (but not generally), OR also has the attractive feature of being invariant with respect to the values at which control variables are held constant. The disadvantage of OR is understanding what it means, and when OR is not the quantity of interest then its ‘advantages’ are not sufficient to recommend its use. Some statisticians seem comfortable with OR as their ultimate quantity of interest, but this is not common. Even more unusual is to find anyone who feels more comfortable with OR than the other quantities defined above; we have found no author who claims to be more comfortable communicating with the general public using an odds ratio. – (King and Zeng, 2002)

The OR lacks any interpretation as an average. – (Cummings, 2009)

As is well established, the odds ratio is not a parameter of interest in public health research. – (Spiegelman and VanderWeele, 2017)

Because of the exaggeration present, it is important to avoid representing ORs as RRs, and similarly, it is important to recognize that a reported OR rarely provides a good approximation of relative risks but rather simply provides a measure of correlation. – (George et al., 2020)

We agree with Liu et al. (2020) that (causal) odds ratios and hazard ratios are problematic as causal contrasts. The non-collapsibility of these parameters is a mathematical property which makes their interpretation awkward, and this is amplified for hazard by their conditioning on survival. Thus they are also unsuitable measures for transportability between different populations (Martinussen & Vansteelandt, 2013). It is particularly concerning that meta-analyses pool odds ratios or hazard ratios from different studies each possibly using different variables for adjustment where the issue of non-collapsibility is typically ignored. – (Didelez and Stensrud, 2022)

ORs are notoriously difficult to interpret. When people hear “odds” they think of “risks” and this leads to the common misinterpretation of the OR as a RR by scientists and the public, which is a serious concern. For example, an OR of 2 is not generally a doubling of risk (if the risk in the control group is 20% and the OR is 2, then the risk in the treated group is 33.3% not 40%). In contrast, the RD and RR offer clearer interpretations. – (Xiao et al., 2022)

The admitted mathematical niceties of the OR are not reason enough to accept such a confusing state of affairs. Of course, when the outcome is rare, the OR approximates the RR and is, therefore, approximately collapsible.– (Xiao et al., 2022)

Because of the interpretability issues and lack of collapsibility, we urge researchers to avoid ORs when either the RD or RR is available. – (Xiao et al., 2022)

Odds ratios provoke similar discomfort—only 19% of learners and 25% of speakers at an annual meeting of the Canadian Society of Internal Medicine (CSIM) understood odds ratios well enough to explain them to others. – (Lapointe-Shaw et al., 2022)

The OR is a better metric to use than RR

The results demonstrate the need to a) end the primary use of the RR in clinical trials and meta-analyses as its direct interpretation is not meaningful; b) replace the RR by the OR; and c) only use the post-intervention risk recalculated from the OR for any expected level of baseline risk in absolute terms for purposes of interpretation such as the number needed to treat. – (Doi et al., 2020)

We can no longer accept the commonly argued for view that the relative risk is easier to understand. Once we realize that the RR depends more on prevalence than the exposure-outcome association, its interpretation becomes much more difficult to comprehend than the odds ratio. It is well known that, for common events, large values of the Risk Ratio are impossible and this should have rung the alarm bells much earlier regarding whether the RR is more a measure of prevalence than a measure of effect. However this was not the main focus of the derivation outlined previously and the latter was aimed at demonstrating why the OR is a true measure of effect against which the RR can be compared. – (Doi et al., 2020)

Our response to this is that, although this is certainly a problem, there is an even bigger problem – *the RR is not a portable measure of effect*. By "portable" we mean a numerical value that is not dependent on baseline risk and not transportability in causal inference. — (Doi et al., 2022)

Relative versus absolute measures

In reviewing the different ways that benefit and harm can be expressed, we conclude that the RD is superior to the RR because it incorporates both the baseline risk and the magnitude of the risk reduction. – (Laupacis et al., 1988)

For clinical decision making, however, it is more meaningful to use the measure "number needed to treat." This measure is calculated on the inverse of the absolute risk reduction. It has the advantage that it conveys both statistical and clinical significance to the doctor. Furthermore, it can be used to extrapolate published findings to a patient at an arbitrary specified baseline risk when the relative risk reduction associated with treatment is constant for all levels of risk. – (Cook and Sackett, 1995)

Medical journals need to be conscious that they will contribute to scaremongering newspaper headlines if they do not request authors to quantify Adverse Drug Reactions (ADR) into best estimates of absolute numbers. – (Mills, 1999)

As a relative measure of effect, the RR is most directly estimated by the multiplicative model when it fits the data. The risk difference is an absolute measure of effect, most directly estimated by the additive model when it fits the data. – (Spiegelman and VanderWeele, 2017)

About portability or generalizability of causal effects

The numbers needed to treat method still presents a problem when applying the results of a published randomised trial in patients at one baseline risk to a particular patient at a different risk. – (Cook and Sackett, 1995)

Some authors prefer odds ratios because they believe a constant (homogeneous) odds ratio may be more plausible than a constant Risk Ratio when outcomes are common. – (Cummings, 2009)

All of this assumes a constant RR across risk groups; fortunately, a more or less constant RR is usually the case, and we suggest you make that assumption unless there is evidence that suggests it is incorrect. – (Guyatt et al., 2015)

Although further and more formal quantitative work evaluating the relative degree of heterogeneity for Risk Ratio versus risk differences may be important, the previously mentioned considerations do seem to provide some indication that, for whatever reason, Risk Ratio modification is uncommon. – (Spiegelman and VanderWeele, 2017)

It is commonly believed that the Risk Ratio is a more homogeneous effect measure than the risk difference, but recent methodological discussion has questioned the evidence for the conventional wisdom. – (Huitfeldt et al., 2018)

In the real world of clinical medicine, doctors are usually given information about the effects of a drug on the Risk Ratio scale (the probability of the outcome if treated, divided by the probability of the outcome if untreated). With information on the Risk Ratio, a doctor may make a prediction for what will happen to the patient if treated, by multiplying the Risk Ratio and patient’s risk if untreated (which is predicted informally based on observable markers for the patient’s condition). – (Huitfeldt, 2019)

In this article we will show that the RR is not a measure of the magnitude of the intervention-outcome association alone because it has a stronger relationship with prevalence and therefore is not generalizable beyond the baseline risk of the population in which it is computed. – (Doi et al., 2020)

It is possible that no effect measure is “portable” in a meta-analysis. In cases where portability of the effect measure is challenging to satisfy, we suggest presenting the conditional effect based on the baseline risk using a bivariate generalized linear mixed model. The bivariate generalized linear mixed model can be used to account for correlation between the effect measure and baseline disease risk. Furthermore, in addition to the overall (or marginal) effect, we recommend that investigators also report the effects conditioning on the baseline risk. – (Xiao et al., 2022)

Despite some concerns, the RR has been widely used because it is considered a measure with “portability” across varying outcome prevalence, especially when the outcome is rare. – (Doi et al., 2022)

G Comments and answers to related articles

As highlighted by the length of the references or even by Section F: the literature on the choice of causal measures is prolific. In this Section, we propose comments or answers to previous articles in order to show how our contributions either complete what was said or shed lights on a different apprehension of the problem.

G.1 Comments of Cummings (2009)

Cummings (2009) propose a review of how the OR and the RR differ. In particular, they review typical arguments for pro and cons, while providing examples. In this section, we want to comment how the entanglement model (Lemma 6) allows to formalize many of their arguments and examples.

Some authors prefer odds ratios because they believe a constant (homogeneous) odds ratio may be more plausible than a constant Risk Ratio when outcomes are common. Risk range from 0 to 1. Risk Ratios greater than 1 have an upper limit constrained by the risk when not exposed. For example the risk when not exposed is 0.5, the Risk Ratio when exposed cannot exceed $2 : 5 \cdot 2 = 1$. In a population with an average Risk Ratio of 2 for outcome Y among those exposed to X, assuming that the risk for Y if not exposed to X varies from .1 to .9, the average Risk Ratio must be less than 2 for those with risks greater than 0.5 when not exposed. Because the average Risk Ratio for the entire population is 2, the average Risk Ratio must be more than 2 for those with risks less than .5 when not exposed. Therefore, a Risk Ratio of 2 cannot be constant (homogeneous) for all individuals in a population if risk when not exposed is sometimes greater than .5. More generally, if the average Risk Ratio is greater than 1 in a population, the individual Risk Ratios cannot be constant (homogeneous) for all persons if any of them have risks when not exposed that exceed $1/\text{average Risk Ratio}$.

The authors claim that if $\tau_{RR} > 1$, then


- The RR has an upper limit linked to the risk of the unexposed ($p_0(x) = b(x)$),
- Or, the RR cannot be constant on every individuals if their risk is above a certain threshold being equal to $1/\text{average Risk Ratio}$.

The entanglement model perfectly describes such a situation, and we propose to illustrate why. As authors consider that $\tau_{RR} > 1$, then we use Lemma 6 with $\forall x, m_g(x) = 0$. More specifically, the authors mention that for $\tau_{RR} > 1$ (that we rather model as $\forall x, m_g(x) = 0$), it is not possible to have a constant RR on each subgroup. We recall that,

$$\forall x, \tau_{RR}(x) = 1 + \frac{1 - b(x)}{b(x)} m_b(x) \quad (158)$$


If $\tau_{RR}(x)$ is assumed constant, one can plot the probability $m_b(x)$ as a function of $b(x)$ and observe that indeed this quantity is bounded and/or that $m_b(x)$ can not exist for all baseline $b(x)$. We illustrate this equation on Figure 12.

Figure 12: Illustration of the impossibility of having a constant $\tau_{RR}(x) > 1$ if allowing all ranges for baseline risks $p_0(x)$: This plot illustrates eq. 158 for several constant values of $\tau_{RR}(x)$ (from 1.2 to 4), showing how the baseline risk $p_0(x)$ implies different values of $m_b(x)$. If the baseline risk is too high, then there is no plausible $m_b(x)$ (the upper limit is highlighted with the dashed red line). The dark vertical dashed line illustrate the precise example of Cummings (2009) with $\tau_{RR}(x) = 2$.



We want to add that, as the treatment effect is assumed to increase the occurrence of the event, then a better measure to use (at least if willing to maximise the chance to have a constant value for each individuals as claimed by the author) is the survival ratio. In particular, the Figure 12 can be adapted when considering a constant SR (see Figure 13). One can observe that all ranges of the baseline risks are allowed.

Figure 13: Illustration of the possibility to have a constant $\tau_{SR}(x) < 1$ when allowing all ranges for baseline risks $p_0(x)$: This plot illustrates how several constant values of $\tau_{SR}(x)$ (from 0.2 to 0.9) is allowed for any baseline values $p(x)$. Note that this implies a constant $m_b(x)$.



Then, authors add the following comment.

Odds range from 0 to infinity. Odds ratios greater than 1 have no upper limit, regardless of the outcome odds for persons not exposed. If we multiply any unexposed outcome odds by an exposure odds ratio greater than 1 and convert the resulting odds when exposed to a risk, that risk will fall between 0 and 1. Thus, it is always hypothetically possible for an odds ratio to be constant for all individuals in a population.

We agree that it is always hypothetically possible for an odds ratio to be constant for all individuals (this corresponds to Lemma 11, and $m(x) = m$ in the logistic working models). But note that this does not mean that the odds ratio at the individual level is then the same for the population level due to non-collapsibility.

Possibility of Constancy for Risk Ratios Less Than 1. For both risk and odds, the lower limit is 0. For any level of risk or odds under no exposure, multiplication by a risk or odds ratio less than 1 will produce a risk or odds given exposure that is possible: 0 to 1 for risks and 0 to infinity for odds. Thus, a constant

risk or odds ratio is possible for ratios less than 1. If the Risk Ratio comparing exposed persons with those not exposed is greater than 1, the ratio can be inverted to be less than 1 by comparing persons not exposed with those exposed. Therefore, a constant Risk Ratio less than 1 is hypothetically possible. This argument has been used to rebut the criticism of the Risk Ratio in the previous argument.

To us, this argument is a consequence of Lemma 7 accounting for the fact that a RR less than 1 is comparable to $m_b(x) = 0$.

G.2 Comment on Appendix 3 of Huitfeldt et al. (2018)

Many of our insights can be found in Huitfeldt et al. (2018) (and in particular in their Appendix). What we want to highlight is that our notations and framework enable another view of the problem. First, we quote the authors.

For illustration, we will consider an example concerning the effect of treatment with antibiotics (A), on mortality (Y). We will suppose that response to treatment is fully determined by bacterial susceptibility to that antibiotic (X). In the following, we will suppose that attribute X has the same prevalence in populations s and t (for example because the two populations share the same bacterial gene pool) and that treatment with A has no effect in the absence of X . Further, suppose that this attribute is independent of the baseline risk of the outcome (for example, old people at high risk of death may have the same strains of the bacteria as young people at low risk).

Within the entanglement model, and denoting $X = 0$ the absence of the mutation, this means that:

- “attribute X has the same prevalence in populations s and t ” which corresponds to Definition 5;
- “treatment with A has no effect in the absence of X ” $m_b(X = 0) = m_g(X = 0) = 0$,
- “Further, suppose that this attribute is independent of the baseline risk of the outcome” Here, we think that this assumption could be easily transposed in our intrication model, clearly decomposing X_B and X_M .

G.3 Comment on the research work from Cinelli & Pearl

The way Cinelli and Pearl (2020) deals with the problem is to encode the assumption of the problem with selection diagrams. In particular selection diagrams are an extension of DAGs with selection nodes, those nodes are used by the analyst to indicate which local mechanisms are suspected to differ between two environments (in the Russian roulette example, the prevalence risk is suspected to differ between Los Angeles and New York, but not the mechanism).

A first difference to our work is that authors rather want to predict in a target population $\mathbb{E}_T [Y^{(1)}]$ from $\mathbb{E}_T [Y^{(0)}]$ and PS_{01} and PS_{10} detailed below, while we focus on causal effects τ . Another difference is that authors mostly reason marginally, while in our work we link subpopulations with larger populations relying on collapsibility.

Cinelli and Pearl introduce the following quantities:

$$PS_{01} := \mathbb{P} [Y^{(1)} = 1 \mid Y^{(0)} = 0], \quad \text{and} \quad PS_{10} := \mathbb{P} [Y^{(1)} = 0 \mid Y^{(0)} = 1].$$

Those quantity corresponds to $\mathbb{E}[m_b(X)]$ and $\mathbb{E}[m_g(X)]$ defined in Lemma 6. In their work, Cinelli and Pearl (2020) assumes that $\mathbb{E}_T[m_b(X)] = \mathbb{E}_S[m_b(X)]$ and $\mathbb{E}_T[m_g(X)] = \mathbb{E}_S[m_g(X)]$. Therefore, their equation,

$$\mathbb{P}^{\Pi^*}[Y^{(1)} = 1] = (1 - \text{PS}_{10})\mathbb{P}^{\Pi^*}[Y^{(0)} = 1] + \text{PS}_{01}(1 - \mathbb{P}^{\Pi^*}[Y^{(0)} = 1]),$$

is completely equivalent to the entanglement model. Note that they do consider that $\mathbb{P}^{\Pi^*}[Y^{(0)} = 1]$ (which corresponds to $\mathbb{E}_T[b(x)]$) varies when marginalized in another population. The entanglement model rather highlight the dependencies to covariates (i.e. characteristics), while their equation rather models the fact that only the baseline risk is necessary to be known if

$$Y^{(1)} \perp\!\!\!\perp I \mid Y^{(0)},$$

where I is the indicator of population's membership and if effect is monotonous (and they denote $Y^{(1)} \leq Y^{(0)}$ or conversely depending on the direction assumed).

In our work, such assumption is equivalent with assuming monotonicity (either $m_b(x) = 0$ or $m_g(x) = 0$) and that all treatment effect modifiers are not shifted. Authors then propose to soften their assumptions deriving bounds on the target quantity $\mathbb{P}^{\Pi^*}[Y^{(1)} = 1]$. Our work rather keeps on targeting causal measure themselves, and assume that we have access to the shifted covariates of X_M . We think this could be stated as,

$$Y^{(1)} \perp\!\!\!\perp I \mid Y^{(0)}, X_M,$$

along with the monotonicity assumption. Linking selection diagrams assumptions with results from Theorems 1 and 2 is an open work.

H Details about the simulations

H.1 Comments on estimation

In this paper, we have been focusing on identification rather than estimation. In this simulation, we illustrate the two approaches that can be taken when transforming identification formula (see Propositions 1 and 2) into estimation: Plug-in g-formula or Inverse Propensity Sampling Weighting (IPSW). Existing consistency results of these approaches for the Risk Difference are reviewed in Colnet et al. (2024). We assume that the data sampled from P_S is a randomized trial \mathcal{R} of size n and the data sampled from P_T is a cohort \mathcal{T} of size m which contains covariates information X and possibly $Y^{(0)}$.

H.1.1 Plug-in formula

When considering *generalization of the conditional outcome*, the plug-in g-formula consists in estimating the two surface responses $\mathbb{E}[Y^{(a)} \mid X]$ using the RCT data from P_T . We denote by $\hat{\mu}_{a,n}(X)$ the estimates (n is added to indicate that estimation is performed on the trial). Any approach can be proposed, for e.g. OLS or non-parametric learners. These models are then used on the target sample to estimate the averaged expected responses,

$$\hat{\mathbb{E}}_T[Y^{(a)}] = \frac{1}{m} \sum_{i \in \mathcal{T}} \hat{\mu}_{a,n}(X), \quad (159)$$

where m denotes the target sample size. Doing so this estimate depends on the two sample sizes, n and m . Finally, $\hat{\mathbb{E}}_T[Y^{(0)}]$ and $\hat{\mathbb{E}}_T[Y^{(1)}]$ are then used to estimate any causal measures on the target population: RD, RR, OR, and so on. Consistency of procedure eq. 159 has been

proven for any consistent estimator $\hat{\mu}_a$ of $\mathbb{E}[Y^{(a)} | X]$ in Colnet et al. (2022a).

Generalizing local effects using a plug-in formula suggests to estimate the local treatment effect (or CATE) $\hat{\tau}_n(x)$ using \mathcal{S} . This can be done using the previously introduced $\hat{\mu}_a(X)$ too (this is called T-learner), and then making a difference or a ratio of the two depending on the causal measure someone wants to generalize. Then, one has to estimate $\hat{g}_m(X, P(X, Y^{(0)}))$ using \mathcal{T} , for exemple using a linear model (or any other model). Finally, one can obtain the target treatment effect with

$$\hat{\tau} = \frac{1}{m} \sum_{i \in \mathcal{T}} \hat{g}_m(X_i, P(X_i, Y_i^{(0)})) \hat{\tau}_n(X_i), \quad (160)$$

where m denotes the target sample size. Note that eq. 160 relies on the estimation of $\tau(X)$ directly. While the estimation of the conditional risk difference is well described in the literature (Wager and Athey, 2018; Nie and Wager, 2020) (to name a few), estimation of conditional ratios is way less described. We have found only one recent work dealing with such questions (Yadlowsky et al., 2021). Consistency of such procedure for another metric than the Risk Difference is an open research question.

H.1.2 Inverse Propensity Sampling Weighting (IPSW)

IPSW uses the ratio of densities to re-weight individual observation in the trial. Denoting $r(X) := \frac{p_{\mathcal{T}}(X)}{p_{\mathcal{S}}(X)}$ the density ratio, one has first to learn this ratio $\hat{r}_{n,m}(X)$ using both data set \mathcal{S} and \mathcal{T} . One can *generalize conditional outcomes* doing:

$$\hat{\mathbb{E}}_{\mathcal{T}}[Y^{(a)}] = \frac{1}{n} \sum_{i \in \mathcal{S}} \hat{r}_{n,m}(X_i) A_i Y_i.$$

Those estimates ($\hat{\mathbb{E}}_{\mathcal{T}}[Y^{(0)}]$ and $\hat{\mathbb{E}}_{\mathcal{T}}[Y^{(a1)}]$) are then used to estimate any causal measures on the target population.

Now, considering *generalizing local effects* using a re-weighting approach rather suggest to also estimate $\hat{g}_m(X, P(X, Y^{(0)}))$ using \mathcal{T} (for example using a linear model). Then, for e.g when considering the Risk Difference, this consists in doing

$$\hat{\tau}_{\text{RD}} = \frac{1}{n} \sum_{i \in \mathcal{S}} \hat{r}(X_i) (A_i Y_i - (1 - A_i) Y_i),$$

or when considering the Risk Ratio, a procedure could be

$$\ln(\hat{\tau}_{\text{RR}}) = \frac{1}{n} \sum_{i \in \mathcal{S}} \hat{r}(X_i) (\ln(A_i Y_i) - \ln((1 - A_i) Y_i)) \hat{w}_m(X_i, P(X_i, Y_i^{(0)})).$$

We use these weighting approaches for the simulation with a binary outcomes. As the purpose is not estimation, we propose a simulation with categorical covariates only, in particular to propose an estimation of $\hat{r}_{n,m}(X)$ as in Colnet et al. (2022b). $\hat{w}_m(X, P(X, Y^{(0)}))$ is estimating by computing the empirical mean of $\mathbb{E}[Y^{(0)} | X]$ in each category.

H.2 Continuous outcomes

H.2.1 Data generative process

We assume that the outcome is generated linearly from six covariates in the two populations $Y(a) = 0.05X_1 + 0.04X_2 + 2X_3 + X_4 + 2X_5 - 2X_6 + a \cdot (1.5X_1 + 2X_2 + X_5) + \epsilon$ with $\epsilon \sim \mathcal{N}(0, 2)$. (161)

The two data samples are directly sampled from two different baseline distributions. Covariates X_1, X_2, X_3 are generated from

$$\mathcal{N} \left(\begin{bmatrix} 6 \\ 5 \\ 8 \end{bmatrix}, \begin{bmatrix} 1 & 0 & 0.5 \\ 0 & 1 & 0.2 \\ 0.5 & 0.2 & 1 \end{bmatrix} \right)$$

in P_S , and in

$$\mathcal{N} \left(\begin{bmatrix} 15 \\ 7 \\ 10 \end{bmatrix}, \begin{bmatrix} 1 & 0 & 0.5 \\ 0 & 1 & 0.2 \\ 0.5 & 0.2 & 1 \end{bmatrix} \right)$$

for P_T . X_4 is such that $X_4 \sim \mathcal{B}(1, 0.8)$ in P_S and $X_4 \sim \mathcal{B}(1, 0.3)$ in P_T . Then, X_5 and X_6 are non-shifted covariates, where $X_5 \sim \mathcal{B}(1, 0.8)$ and $X_6 \sim \mathcal{N}(4, 1)$ in both populations.

Within the trial sample of size n we generate the treatment according to a Bernoulli distribution with probability equals to 0.5.

Estimation For this simulation we applied a plug-in g-formula approach, using Ordinary Least Squares (OLS) to estimate $\hat{\mu}_{a,n}$ and $\hat{g}_m(X, P(X, Y^{(0)}))$. $\hat{\tau}_n$ is estimated combining $\hat{\mu}_{a,n}$ as a difference or ratio or else (T-learner). More precisely, in this simulation the different steps when generalizing the conditional outcomes are the following :

- Fit an OLS estimator on the subset of treated individuals ($A = 1$) in the trial sample to obtain $\hat{\mu}_{1,n}(X)$,
- Fit an OLS estimator on the subset of control individuals ($A = 0$) in the trial sample to obtain $\hat{\mu}_{0,n}(X)$,
- Estimate the expected outcome if treated and control on the target population using the following formulae

$$\hat{\mathbb{E}}_T [Y^{(a)}] = \frac{1}{m} \sum_{i \in \mathcal{T}} \hat{\mu}_{a,n}(X),$$

- Use the two previous quantities to estimate
 - The risk difference $\hat{\tau}_{RD} = \hat{\mathbb{E}}_T [Y^{(1)}] - \hat{\mathbb{E}}_T [Y^{(0)}]$,
 - The Risk Ratio $\hat{\tau}_{RR} = \hat{\mathbb{E}}_T [Y^{(1)}] / \hat{\mathbb{E}}_T [Y^{(0)}]$,
 - The excess Risk Ratio $\hat{\tau}_{ERR} = \left(\hat{\mathbb{E}}_T [Y^{(1)}] - \hat{\mathbb{E}}_T [Y^{(0)}] \right) / \hat{\mathbb{E}}_T [Y^{(0)}]$.

To generalize the local effects, we perform the following list of steps :

- Rely on the first two steps performed to generalize the conditional outcomes, namely fit an OLS estimator on the trial sample to obtain $\hat{\mu}_{1,n}(X)$ and $\hat{\mu}_{0,n}(X)$,
- The risk difference is estimated with the following formula¹⁶

$$\hat{\tau}_{RD} = \frac{1}{m} \sum_{i \in \mathcal{T}} \hat{\mu}_{1,n}(X) - \hat{\mu}_{0,n}(X),$$

¹⁶Note that by linearity we retrieve that for the risk difference and for a continuous outcome, generalizing conditional outcomes or local effects is strictly equivalent.

- The Risk Ratio is obtained by
 - Fitting an OLS estimator on the target sample to obtain $\hat{\mu}_{0,m}(X)$,
 - To finally compute

$$\hat{\tau}_{\text{RR}} = \frac{1}{m} \sum_{i \in \mathcal{T}} \frac{\hat{\mu}_{1,n}(X_i)}{\hat{\mu}_{0,n}(X_i)} \underbrace{\frac{\hat{\mu}_{0,m}(X_i)}{\frac{1}{m} \sum_{j \in \mathcal{T}} \hat{\mu}_{0,m}(X_j)}}_{\text{weights estimated on } \mathcal{T}}.$$

What if a shifted treatment effect modifier is missing? This situation leads to a biased estimate (Nguyen et al., 2018; Colnet et al., 2022a). To illustrate such situation we replicated simulations presented in Figure 5 but without covariate X_1 . Results are presented on Figure 14




Figure 14: Results of the simulations for a continuous outcomes without observing X_1 : where the generative model corresponds to eq. 31. Column 1 corresponds to generalizing conditional outcome, column 2 corresponds to generalizing local effect with the proper collapsibility weights. For these two approaches we use different covariates set, with X_2 , $X_{2...4}$, and $X_{2...6}$. According to Theorem 3 and 4, the target treatment effect can not be identified when a shifted treatment effect modifier is unobserved. Simulations are performed following the exact same procedure than Figure 5, with 1000 repetitions, a source sample size of 500 and target sample size of 1,000.

What if misspecification occurs? This situation leads to a biased estimate. To illustrate such situation we introduced a different generative model for the outcome such that eq. 161 becomes

$$Y(a) = 0.05X_1^2 + 0.04X_2 + 2X_3 + X_4 + 2X_5 - 2X_6 + a \cdot (1.5X_1^2 + 2X_2 + X_5) + \epsilon \text{ with } \epsilon \sim \mathcal{N}(0, 2). \quad (162)$$

Then, and using a simple OLS estimator without squared terms such as described in Section H.2.1 and presented in Figure 5, leads to a biased estimate in all situations (generalizing local effects or conditional outcomes, and with any of the covariates subsets). Results are presented on Figure 15.




Figure 15: Results of the simulations for a continuous outcomes with misspecification: where the generative model corresponds to eq. 162 rather than eq. 161. Column 1 corresponds to generalizing conditional outcome, column 2 corresponds to generalizing local effect with the proper collapsibility weights. For these two approaches we use different covariates set, with X_2 , $X_{2...4}$, and $X_{2...6}$. According to Theorem 3 and 4, the target treatment effect can not be identified when a shifted treatment effect modifier is unobserved. Simulations are performed following the exact same procedure than Figure 5, with 1000 repetitions, a source sample size of 500 and target sample size of 1,000. Estimation is performed with plug-in g-formula modeling all responses with an OLS approach as detailed in Section H.2.1.

H.3 Binary outcomes

H.3.1 Data generative process

For this simulation the covariates are categorical to ease the estimation strategy, and as the purpose of this work is not on estimation. The data generative model is build on top of eq. 27, and adapted to give,

$$\mathbb{P}[Y^{(a)} = 1 \mid X = x] = b(X_1, X_2, X_3) + a(1 - b(X_1, X_2, X_3))m_b(X_2, X_3),$$

where $X_1 = \text{lifestyle}$, $X_2 = \text{stress}$, and $X_3 = \text{gender}$.

Each of the three covariates are sampled following a Bernoulli distribution. In P_s , one has $X_1 \sim \mathcal{B}(1, 0.4)$, $X_2 \sim \mathcal{B}(1, 0.8)$, and $X_3 \sim \mathcal{B}(1, 0.5)$. In P_T , one has $X_1 \sim \mathcal{B}(1, 0.6)$, $X_2 \sim \mathcal{B}(1, 0.2)$, and $X_3 \sim \mathcal{B}(1, 0.5)$.

The outcome is defined such as,

$$b(X) = \text{ifelse}(X_1 = 1, 0.2, 0.05) \cdot \text{ifelse}(X_2 = 1, 2, 1) \cdot \text{ifelse}(X_3 = 1, 0.5, 1),$$

where `ifelse` corresponds to the function with the same name in `R`. And,

$$m_b(X) = \text{ifelse}(X_2 = 1, 1/4, \text{ifelse}(X_3 = 1, 1/10, 1/6)).$$

Within the trial sample of size n we generate the treatment according to a Bernoulli distribution with probability equals to 0.5.

H.3.2 Estimation

First we estimate $\mu_a(\cdot)$ on the trial sample. As covariates are categorical this corresponds to computing average values of Y in each bin, namely

$$\forall x \in \mathcal{X}, \hat{\mu}_{1,n}(x) := \frac{\sum_{i \in \mathcal{S}; X_i=x} Y_i A_i}{\sum_{i \in \mathcal{S}} \mathbb{1}_{A_i=1} \mathbb{1}_{X_i=x}} \quad \text{and} \quad \hat{\mu}_{0,n}(x) := \frac{\sum_{i \in \mathcal{S}; X_i=x} Y_i (1 - A_i)}{\sum_{i \in \mathcal{S}} \mathbb{1}_{A_i=0} \mathbb{1}_{X_i=x}}.$$

This allows to estimate $\hat{\mathbb{E}}_{\mathcal{T}} [Y^{(0)}]$ and $\hat{\mathbb{E}}_{\mathcal{T}} [Y^{(1)}]$ with

$$\hat{\mathbb{E}}_{\mathcal{T}} [Y^{(1)}] = \frac{\sum_{i \in \mathcal{T}} \hat{\mu}_{1,n}(X_i)}{m} \quad \text{and} \quad \hat{\mathbb{E}}_{\mathcal{T}} [Y^{(0)}] = \frac{\sum_{i \in \mathcal{T}} \hat{\mu}_{0,n}(X_i)}{m}.$$

Then, these two quantities are used to estimate :

- The risk difference $\hat{\tau}_{\text{RD}} = \hat{\mathbb{E}}_{\mathcal{T}} [Y^{(1)}] - \hat{\mathbb{E}}_{\mathcal{T}} [Y^{(0)}]$,
- The number needed to treat $\hat{\tau}_{\text{NNT}} = \tau_{\text{RD}}^{-1}$,
- The Risk Ratio $\hat{\tau}_{\text{RR}} = \hat{\mathbb{E}}_{\mathcal{T}} [Y^{(1)}] / \hat{\mathbb{E}}_{\mathcal{T}} [Y^{(0)}]$,
- The survival ratio $\hat{\tau}_{\text{SR}} = \left(1 - \hat{\mathbb{E}}_{\mathcal{T}} [Y^{(1)}]\right) / \left(1 - \hat{\mathbb{E}}_{\mathcal{T}} [Y^{(0)}]\right)$,
- The odds ratio $\hat{\tau}_{\text{OR}} = \left(\hat{\mathbb{E}}_{\mathcal{T}} [Y^{(1)}] / \left(1 - \hat{\mathbb{E}}_{\mathcal{T}} [Y^{(1)}]\right)\right) \cdot \left(\hat{\mathbb{E}}_{\mathcal{T}} [Y^{(0)}] / \left(1 - \hat{\mathbb{E}}_{\mathcal{T}} [Y^{(0)}]\right)\right)^{-1}$.

This procedure corresponds to the generalization of the outcome.

On the other hand, for each categories in the trial sample, each causal measure τ is estimated on each strata to obtain $\tau(x)$, using the fitted outcome models $\hat{\mu}_{1,n}(\cdot)$ and $\hat{\mu}_{0,n}(\cdot)$. This corresponds to local effects. For example for the Risk Ratio, one has :

$$\forall x \in \mathcal{X}, \hat{\tau}_{\text{RR},n}(x) := \frac{\hat{\mu}_{1,n}(X_i)}{\hat{\mu}_{0,n}(X_i)}.$$

Then collapsibility weights are estimated as followed :

1. Estimate the outcome model on the target population

$$\hat{\mu}_{0,m}(x) := \frac{\sum_{i \in \mathcal{T}; X_i=x} Y_i}{\sum_{i \in \mathcal{S}} \mathbb{1}_{X_i=x}}.$$

2. So that

$$\hat{w}_{\mathcal{T},m}(x) := \frac{\hat{\mu}_{0,m}(x)}{\frac{\sum_{i \in \mathcal{T}} Y_i}{m}}.$$

Finally and for each causal measure τ , the target effect is obtained computing :

$$\hat{\tau}_{\mathcal{T},n,m} := \frac{1}{m} \sum_{i \in \mathcal{T}} \hat{w}_{\mathcal{T},m}(X_i) \hat{\tau}_n(X_i).$$

Name	Outcome type	Definition	Collapsibility	Logic respecting	Invariant to encoding	Covariate set for generalization
Risk Difference (RD)	Continuous	$\tau_{RD} := \mathbb{E}[Y^{(1)}] - \mathbb{E}[Y^{(0)}]$	Directly collapsible	Logic-respecting	Not applicable	$X_{M \cap Sh}$
Risk Ratio (RR)	Continuous	$\tau_{RR} := \mathbb{E}[Y^{(1)}] / \mathbb{E}[Y^{(0)}]$	Collapsible	Logic-respecting	Not applicable	$X_{(M \cup B) \cap Sh}$
Excess Risk Ratio (ERR)	Continuous	$\tau_{ERR} := \tau_{RD} / \mathbb{E}[Y^{(0)}] = \tau_{RR} - 1$	Collapsible	Logic-respecting	Not applicable	$X_{(M \cup B) \cap Sh}$
Risk Difference (RD)	Binary	$\tau_{RD} := \mathbb{P}[Y^{(1)} = 1] - \mathbb{P}[Y^{(0)} = 1]$	Directly collapsible	Logic-respecting	Multiplied by -1	$X_{(M \cup B) \cap Sh}$
Number Needed to Treat (NNT)	Binary	$\tau_{RD} := 1 / (\mathbb{P}[Y^{(1)} = 1] - \mathbb{P}[Y^{(0)} = 1])$	Not collapsible	Logic-respecting	Multiplied by -1	$X_{(M \cup B) \cap Sh}$
Risk Ratio (RR)	Binary	$\tau_{RR} := \mathbb{P}[Y^{(1)} = 1] / \mathbb{P}[Y^{(0)} = 1]$	Collapsible	Logic-respecting	$= \tau_{SR}$	If $m_b(x) = 0$, $X_{M \cap Sh}$
Survival Ratio (SR)	Binary	$\tau_{SR} := \mathbb{P}[Y^{(1)} = 0] / \mathbb{P}[Y^{(0)} = 0]$	Collapsible	Logic-respecting	$= \tau_{RR}$	If $m_g(x) = 0$, $X_{M \cap Sh}$
Excess Risk Ratio (ERR)	Binary	$\tau_{ERR} := \tau_{RD} / \mathbb{P}[Y^{(0)} = 1] = \tau_{RR} - 1$	Collapsible	Logic-respecting	$= \tau_{SR} - 1$	If $m_b(x) = 0$, $X_{M \cap Sh}$
Relative Susceptibility (RS)	Binary	$\tau_{RS} := \tau_{RD} / \mathbb{P}[Y^{(0)} = 0] = 1 - \tau_{SR}$	Collapsible	Logic-respecting	$= 1 - \tau_{RR}$	If $m_g(x) = 0$, $X_{M \cap Sh}$
Odds Ratio (OR)	Binary	$\tau_{OR} := \frac{\mathbb{P}[Y^{(1)}=1]}{\mathbb{P}[Y^{(1)}=0]} \left(\frac{\mathbb{P}[Y^{(0)}=1]}{\mathbb{P}[Y^{(0)}=0]} \right)^{-1} = \tau_{RR} \cdot \tau_{SR}^{-1}$	Not collapsible	Not logic-respecting	Reciprocal	$X_{(M \cup B) \cap Sh}$
Log Odds Ratio (log-OR)	Binary	$\tau_{\log-OR} := \log \left(\frac{\mathbb{P}[Y^{(1)}=1]}{\mathbb{P}[Y^{(1)}=0]} \right) - \log \left(\frac{\mathbb{P}[Y^{(0)}=1]}{\mathbb{P}[Y^{(0)}=0]} \right)$	Not collapsible	Not logic-respecting	Multiplied by -1	$X_{(M \cup B) \cap Sh}$

Table 5: Typical causal measures reported in clinical practice: The upper part of the Table mentions the three typical measures found when the outcome is ordinal or continuous, and the lower part mentions measures for binary outcomes. For each measure we provide the explicit formulae, and properties such as collapsibility (see Definitions 4 and 5), invariance to encoding (also called symmetry in the literature), and whether the covariate set for generalization by standardization is extended or not. All these properties are defined in this article, and proved for each of the measures.